[
    {
        "content": "Nov 10 Valeant Pharmaceuticals International Inc :",
        "date": "11102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant completes sale of Obagi Medical products business to Haitong International Zhongua Finance Acquisition Fund I  L.P. "
    },
    {
        "content": "* Valeant announces pricing of private offering of add-on secured notes",
        "date": "11142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces pricing of private offering of add-on secured notes "
    },
    {
        "content": "Nov 9 Valeant Pharmaceuticals International Inc :",
        "date": "11092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals amends existing credit agreement "
    },
    {
        "content": "* Valeant announces launch of private offering of add-on secured notes",
        "date": "11132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces launch of private offering of add-on secured notes "
    },
    {
        "content": "* Bausch + Lomb and Nicox announce FDA approval of Vyzulta\u2122 (latanoprostene Bunod Ophthalmic Solution)  0.024%",
        "date": "11022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta "
    },
    {
        "content": "TORONTO  Nov 7 Canada's main stock index added to its record highs on Tuesday  boosted by a jump in the shares of Valeant Pharmaceuticals International Inc after the company's quarterly profit beat estimates  while energy shares also climbed.",
        "date": "11072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX adds to record highs as Valeant  energy climb "
    },
    {
        "content": "Nov 6 Valeant Pharmaceuticals International Inc said on Monday it will sell its female libido-pill business Sprout Pharmaceuticals back to its former owners  two years after buying the company for about $1 billion.",
        "date": "11062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell female libido pill business back to former owners "
    },
    {
        "content": "* Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-118  novel plaque psoriasis treatment",
        "date": "11022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ortho Dermatologics announces FDA filing acceptance for IDP-118  novel plaque psoriasis treatment "
    },
    {
        "content": "Nov 2 Valeant Pharmaceuticals International Inc :",
        "date": "11022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ortho Dermatologics reports U.S. FDA filing acceptance for idp-118  novel plaque psoriasis treatment "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business  sending its shares up more than 15 percent.",
        "date": "11072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant profit beats forecasts on Bausch & Lomb strength "
    },
    {
        "content": "Nov 7 Valeant Pharmaceuticals International Inc reported a better-than-expected quarterly profit on strength in its Bausch and Lomb eye care business  sending its shares up more than 15 percent.",
        "date": "11072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant profit beats forecasts on Bausch & Lomb strength "
    },
    {
        "content": "* Valeant agrees to sell Sprout Pharmaceuticals subsidiary to former shareholders of Sprout Pharmaceuticals",
        "date": "11062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant agrees to sell Sprout Pharmaceuticals unit to former shareholders of Sprout Pharmaceuticals "
    },
    {
        "content": "Nov 1 Valeant Pharmaceuticals International Inc :",
        "date": "11012017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant  Pershing Square Capital Management  others amend litigation management agreement\u200b "
    },
    {
        "content": "* Q3 revenue $2.219 billion versus I/B/E/S view $2.15 billion",
        "date": "11072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces Q3 revenue of $2.22 billion "
    },
    {
        "content": "Nov 7 Canada's Valeant Pharmaceuticals International Inc  reported a 10.5 percent fall in quarterly revenue on Tuesday  hurt by declining sales in its branded drugs division.",
        "date": "11072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant's revenue falls 10.5 pct "
    },
    {
        "content": "Oct 31 Valeant Pharmaceuticals International Inc -",
        "date": "10312017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant will reduce debt by additional $125 mln  will exceed $5 bln debt reduction commitment "
    },
    {
        "content": "* PDL Biopharma - \u200dValeant to pay a one-time  lump-sum payment of $13.0 million as part of settlement",
        "date": "10302017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-PDL Biopharma announces settlement agreement with Valeant "
    },
    {
        "content": "* Ortho Dermatologics announces two-year findings from pivotal phase 3 study of Siliq\u2122 (brodalumab) injection data demonstrating long-term efficacy profile",
        "date": "10122017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Ortho Dermatologics  unit of Valeant  announces two-year findings from pivotal phase 3 study of Siliq injection data demonstrating long-term efficacy profile "
    },
    {
        "content": "* Valeant announces pricing of private offering of senior secured notes",
        "date": "10022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces pricing of private offering of senior secured notes "
    },
    {
        "content": "* Valeant and one of its subsidiaries commence cash tender offers for up to $1 000 000 000 outstanding principal amount",
        "date": "10022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant commences cash tender offers for up to $1 bln outstanding principal amount "
    },
    {
        "content": "* Valeant announces launch of private offering of senior secured notes",
        "date": "10022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces launch of private offering of senior secured notes "
    },
    {
        "content": "Sept 29 Valeant Pharmaceuticals International Inc:",
        "date": "09292017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals completes sale of Inova Pharmaceuticals "
    },
    {
        "content": "* Valeant pharmaceuticals provides update on canadian regulatory filing about future financing plans",
        "date": "09282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals provides update on Canadian regulatory filing about future financing plans "
    },
    {
        "content": "* Ortho dermatologics submits new drug application to the u.s. Food and drug administration for psoriasis treatment idp-118",
        "date": "09052017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Ortho Dermatologics submits NDA to U.S. FDA for psoriasis treatment IDP-118 "
    },
    {
        "content": "* Valeant director Richard Deschutter reports purchase of 10 000 shares of co's common stock on Aug. 21 - SEC filing Source text for Eikon: Further company coverage:",
        "date": "08222017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant director Richard Deschutter reports purchase of 10 000 shares of co's common stock "
    },
    {
        "content": "Aug 10 Valeant Pharmaceuticals International Inc -",
        "date": "08102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Hedge fund Paulson & Co trims stake in Valeant "
    },
    {
        "content": "* Valeant receives FDA confirmation of voluntary action indicated (VAI) inspection classification for tampa facility",
        "date": "08162017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant receives FDA confirmation of inspection for Tampa facility "
    },
    {
        "content": "* Paulson & Co dissolves share stake in Pfizer- SEC filing \u200d\u200b",
        "date": "08142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Paulson & Co dissolves share stake in Pfizer  ups in Valeant\u00a0\u200d\u200b "
    },
    {
        "content": "Aug 10 Valeant Pharmaceuticals International Inc investor John Paulson trimmed his stake in the Canadian drugmaker but said he remains fully supportive of the company's leadership.",
        "date": "08092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Hedge fund Paulson & Co trims stake in Valeant "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc said on Tuesday it expects to repay more than $5 billion in debt earlier than it had targeted  news that pushed its shares up 9 percent.",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant says it will exceed debt repayment target  shares surge "
    },
    {
        "content": "* Paulson & Co Inc reports 6 percent stake in Valeant as of Aug 9 - SEC filing",
        "date": "08092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Paulson & Co reports 6 pct stake in Valeant  as of Aug 9 "
    },
    {
        "content": "* Says subsidiaries in australia are under audit by the australian tax office for various years beginning in 2010\u200d\u200b",
        "date": "08092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says subsidiaries in Australia are under audit by tax office "
    },
    {
        "content": "Aug 8 Canada's Valeant Pharmaceuticals International Inc  said on Tuesday it expects to repay more than $5 billion in debt earlier than it had targeted  news that pushed its shares up 9 percent.",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant says it will exceed debt repayment target  shares surge "
    },
    {
        "content": "TORONTO  Aug 8 Canada's main stock index was modestly higher on Tuesday as positive earnings results and a deal in the gaming sector helped offset declines in BlackBerry Ltd and other tech shares.",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX up on Valeant  Ritchie results; BlackBerry falls on sell rating "
    },
    {
        "content": "TORONTO  Aug 8 Canada's main stock index opened modestly higher on Tuesday  as better-than-expected quarterly results from Valeant Pharmaceuticals International Inc helped offset declines in tech stocks.",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX opens higher; Valeant jumps "
    },
    {
        "content": "* Valeant - \u200dexpects to exceed $5 billion debt reduction commitment early\u200b",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant posts Q2 loss per share $0.11 "
    },
    {
        "content": "Aug 8 Canada's Valeant Pharmaceuticals International Inc  reported a 7.8 percent fall in quarterly revenue  hurt by declines in volume and pricing of its generic and neurology products.",
        "date": "08082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant revenue falls 8 pct "
    },
    {
        "content": "* Tabula Rasa Healthcare announces second quarter 2017 results",
        "date": "08072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Tabula Rasa Healthcare reports Q2 loss per share of $0.09 "
    },
    {
        "content": "* Valeant Pharmaceuticals receives complete response letter from the FDA for Latanoprostene Bunod Ophthalmic Solution  0.024 pct NDA",
        "date": "08072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals receives complete response letter for Latanoprostene Bunod Ophthalmic Solution "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    said on Monday it would sell its Obagi Medical Products business for $190 million in cash  as part of the Canadian drugmaker's efforts to cut down its debt.",
        "date": "07172017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant to sell Obagi Medical Products business for $190 million "
    },
    {
        "content": "July 17 Valeant Pharmaceuticals International Inc  said on Monday it would sell its Obagi Medical Products business for $190 million in cash  as part of the Canadian drugmaker's efforts to cut down its debt.",
        "date": "07172017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell Obagi Medical Products business for $190 mln "
    },
    {
        "content": "* Says \u200dValeant will use proceeds from sale to permanently repay term loan debt under its senior secured credit facility\u200b",
        "date": "07172017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant agrees to sell Obagi Medical Products business "
    },
    {
        "content": "July 13 Valeant Pharmaceuticals International Inc",
        "date": "07132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces redemption of about $500 mln senior notes "
    },
    {
        "content": "* Valeant pays down $811 million of senior secured term loans",
        "date": "07102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant pays down $811 million of senior secured term loans "
    },
    {
        "content": "July 6 Valeant Pharmaceuticals International Inc :",
        "date": "07062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says Bausch + Lomb unit introduces Aqualox lenses to Japan "
    },
    {
        "content": "* Valeant pharmaceuticals completes sale of Dendreon to Sanpower Group",
        "date": "06292017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant pharmaceuticals completes sale of Dendreon to Sanpower Group "
    },
    {
        "content": "New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in embattled Canadian drugmaker Valeant Pharmaceuticals International Inc  .",
        "date": "06262017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Hedge fund Paulson & Co discloses 6.3 percent stake in Valeant "
    },
    {
        "content": "June 26 New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in embattled Canadian drugmaker Valeant Pharmaceuticals International Inc .",
        "date": "06262017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Hedge fund Paulson & Co discloses 6.3 pct stake in Valeant "
    },
    {
        "content": "June 26 New York-based hedge fund Paulson & Co on Monday reported a 6.3 percent stake in Canada's Valeant Pharmaceuticals International Inc .",
        "date": "06262017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-Hedge fund Paulson & Co declares 6.3 pct stake in Valeant "
    },
    {
        "content": "* Paulson & Co. Inc reports 6.3 pct stake in Valeant as of June 14 - SEC filing",
        "date": "06262017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Paulson & Co reports 6.3 pct stake in Valeant as of June 14 "
    },
    {
        "content": "Billionaire investor John Paulson  whose hedge fund firm is the biggest owner of Valeant Pharmaceuticals International Inc  shares  on Monday joined the ailing drug company's board as it restructures to repay debt.",
        "date": "06192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Billionaire investor Paulson joins Valeant board  shares jump "
    },
    {
        "content": "June 19 Billionaire investor John Paulson  whose hedge fund firm is the biggest owner of Valeant Pharmaceuticals International Inc shares  on Monday joined the ailing drug company's board as it restructures to repay debt.",
        "date": "06192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Billionaire investor Paulson joins Valeant board  shares jump "
    },
    {
        "content": "June 19 Canadian drugmaker Valeant Pharmaceuticals said it appointed hedge fund manager and billionaire investor John Paulson to its board.",
        "date": "06192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-Valeant adds shareholder John Paulson to board "
    },
    {
        "content": "June 19 Valeant Pharmaceuticals International Inc:",
        "date": "06192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says John Paulson joins company's board of directors "
    },
    {
        "content": "June 6 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday: ** Canadian drugmaker Valeant Pharmaceuticals International Inc  is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG  Bloomberg reported.",
        "date": "06062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "TORONTO  June 8 Canada's main stock index ended higher on Thursday  helped by gains for banking stocks after the Bank of Canada said it considers the system robust and a jump in Valeant Pharmaceuticals after it announced an asset sale.",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends higher as Valeant bounces  banks gain "
    },
    {
        "content": "Canadian drugmaker Valeant Pharmaceuticals International Inc\u00a0  is in talks to\u00a0sell\u00a0its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG  \u00a0Bloomberg reported.",
        "date": "06062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to sell eye-surgery assets to Carl Zeiss: Bloomberg "
    },
    {
        "content": "June 6 Canadian drugmaker Valeant Pharmaceuticals International Inc  is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG  Bloomberg reported.",
        "date": "06062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant in talks to sell eye-surgery assets to Carl Zeiss - Bbg "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   said on Thursday it would sell its iNova Pharmaceuticals business for $930 million  as Chief Executive Joseph Papa steps up efforts to slash the embattled Canadian drugmaker's enormous debt pile.",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant looks to trim debt pile with $930 million iNova sale "
    },
    {
        "content": "June 6 Canadian drugmaker Valeant Pharmaceuticals International Inc  is in talks to sell its Bausch & Lomb unit's surgical products business to Germany's Carl Zeiss Meditec AG  Bloomberg reported.",
        "date": "06062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to sell eye surgical products business - Bbg "
    },
    {
        "content": "* Valeant's U.S.-listed shares rise as much as 8.6 pct (Adds CEO comment from interview  details; updates shares)",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant looks to trim debt pile with $930 mln iNova sale "
    },
    {
        "content": "June 8 Valeant Pharmaceuticals International Inc :",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says \"right place\" for co's debt is \"somewhere in the range of $15 bln-$20 bln\" "
    },
    {
        "content": "* Valeant announces sale of Inova Pharmaceuticals for $930 million",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces sale of Inova Pharmaceuticals for $930 mln "
    },
    {
        "content": "June 8 Embattled Canadian drugmaker Valeant Pharmaceuticals International Inc  said on Thursday it would sell its iNova Pharmaceuticals business for $930 million in cash as it looks to pay down debt.",
        "date": "06082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell its iNova Pharmaceuticals business for $930 mln "
    },
    {
        "content": "* EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients",
        "date": "05222017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-EyeGate receives milestone payment from Valeant "
    },
    {
        "content": "LAS VEGAS Bill Ackman said on Thursday he is poised to go on a great investment run after a humiliating bet forced his hedge fund firm to return to basics.",
        "date": "05192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Humbled by Valeant  Ackman goes back to basics "
    },
    {
        "content": "LAS VEGAS  May 18 Bill Ackman said on Thursday he is poised to go on a great investment run after a humiliating bet forced his hedge fund firm to return to basics.",
        "date": "05192017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Humbled by Valeant  Ackman goes back to basics "
    },
    {
        "content": "* Statement regarding XiFaxan intellectual property litigation",
        "date": "05172017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Salix  Valeant and Actavis agree to stay outstanding litigation "
    },
    {
        "content": "* ANNOUNCES HAVING FILED FOR ARBITRATION SEEKING TERMINATION OF LICENSE AND SUPPLY AGREEMENT WITH VALEANT Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
        "date": "05122017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-COSMO announces having filed for arbitration seeking termination of license and supply agreement with Valeant "
    },
    {
        "content": "* Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals International Inc - SEC filing",
        "date": "05152017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square Capital Management dissolves sole share stake in Valeant Pharmaceuticals "
    },
    {
        "content": "* Valeant announces key appointments in dermatology and corporate communications leadership",
        "date": "05052017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces key appointments in dermatology and corporate communications leadership "
    },
    {
        "content": "* Valeant - Company continues to evaluate opportunities to improve its operating results and may initiate additional cost savings programs",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says may initiate additional cost savings programs to streamline its operations and eliminate redundant processes and expenses "
    },
    {
        "content": "* Valeant announces key appointments in dermatology and corporate communications leadership",
        "date": "05052017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces key appointments in Dermatology and Corporate Communications leadership "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc   raised its 2017 earnings forecast and reported its first profit in six quarters  helped by a one-time tax gain  and its U.S. shares jumped nearly 21 percent.",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant raises profit forecast; shares spike "
    },
    {
        "content": "* Shares up nearly 21 percent (Adds CEO and analyst comments  stock move)",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Drugmaker Valeant raises profit forecast; shares spike "
    },
    {
        "content": "TORONTO  May 9 Canada's main stock index dipped on Tuesday as energy shares fell  offsetting a jump in Home Capital Group Inc on a plan to sell part of its mortgage book  while Valeant Pharmaceuticals International Inc also climbed.",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX dips as losses for energy offset Home Capital  Valeant "
    },
    {
        "content": "May 9 Canada's Valeant Pharmaceuticals International Inc  reported a first-quarter profit on Tuesday  compared with a year-ago loss  due to a one-time income tax benefit  and the drugmaker also raised its full-year adjusted EBITDA forecast.",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Tax benefit helps Valeant post quarterly profit vs. yr-ago loss "
    },
    {
        "content": "May 9 Valeant Pharmaceuticals International Inc :",
        "date": "05092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals reports Q1 GAAP earnings per share $1.79 "
    },
    {
        "content": "May 1 Valeant Pharmaceuticals International Inc :",
        "date": "05012017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant reports debt reduction of about $220 mln "
    },
    {
        "content": " (In April 21 story  corrects paragraph 5 to say Taltz's list price is $4 469 per month. Removes reference of pricing from analyst)",
        "date": "04282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant prices psoriasis treatment at $3 500 per month (April 21) "
    },
    {
        "content": "LAVAL  Quebec Valeant Pharmaceuticals International Inc  weighed down by debt from years of acquisitions  is on pace to meet its target of repaying $5 billion in debt between August  2016 and February  2018  Chief Executive Joe Papa told shareholders on Tuesday.",
        "date": "05022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Drug-maker Valeant on course to debt repayment target -CEO "
    },
    {
        "content": "April 21 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it had priced its recently approved plaque psoriasis treatment at $3 500 per month  ahead of an expected U.S. launch in the second half of 2017.",
        "date": "04282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CORRECTED-UPDATE 2-Valeant prices psoriasis treatment at $3 500 per month (April 21) "
    },
    {
        "content": "LAVAL  Quebec  May 2 Valeant Pharmaceuticals International Inc  weighed down by debt from years of acquisitions  is on pace to meeting its target of repaying $5 billion in debt between August  2016 and February  2018  Chief Executive Joe Papa told shareholders on Tuesday.",
        "date": "05022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drug-maker Valeant on course to debt repayment target: CEO "
    },
    {
        "content": "LAVAL  Quebec  May 2 Valeant Pharmaceuticals International Inc  weighed down by debt from years of acquisitions  is on pace to meet its target of repaying $5 billion in debt between August  2016 and February  2018  Chief Executive Joe Papa told shareholders on Tuesday.",
        "date": "05022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Drug-maker Valeant on course to debt repayment target -CEO "
    },
    {
        "content": "* Orexigen Therapeutics Inc announces new drug submission for Contrave\u00a9 in canada",
        "date": "04252017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Orexigen Therapeutics announces new drug submission for Contrave in Canada "
    },
    {
        "content": "April 21 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it had priced its recently approved plaque psoriasis treatment at $3 500 per month  ahead of an expected U.S. launch in the second half of 2017.",
        "date": "04212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant prices psoriasis treatment at $3 500 per month "
    },
    {
        "content": "April 21 Embattled Canadian drugmaker Valeant Pharmaceuticals International Inc  said on Friday that it had priced its recently approved plaque psoriasis treatment at $3 500 per month.",
        "date": "04212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant prices psoriasis treatment at $3 500 per month "
    },
    {
        "content": "April 21 Valeant Pharmaceuticals International Inc",
        "date": "04212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces pricing for Siliq "
    },
    {
        "content": "April 6 Valeant Pharmaceuticals International Inc:",
        "date": "04062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Bausch + lomb receives 510(k) clearance from FDA for stellaris elite next-generation phacoemulsification platform "
    },
    {
        "content": "BOSTON Billionaire hedge fund manager William Ackman has apologized to clients for betting on Valeant Pharmaceuticals International Inc   telling them he was \"deeply and profoundly sorry\" for losing so much of their money on the investment.",
        "date": "03302017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman apologizes for Valeant losses  calls bet a mistake "
    },
    {
        "content": "BOSTON  March 29 Billionaire investor William Ackman told investors that betting on Valeant Pharmaceuticals International Inc was a \"huge mistake\" and apologized \"deeply and profoundly\" for losing so much of his shareholders' money on the investment.",
        "date": "03292017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman apologizes for Valeant losses  calls bet a mistake "
    },
    {
        "content": "BOSTON  March 29 Billionaire hedge fund manager William Ackman has apologized to clients for betting on Valeant Pharmaceuticals International Inc  telling them he was \"deeply and profoundly sorry\" for losing so much of their money on the investment.",
        "date": "03302017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman apologizes for Valeant losses  calls bet a mistake "
    },
    {
        "content": "March 28 Valeant Pharmaceuticals International Inc",
        "date": "03282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says completed amendment to third amended  restated credit  guaranty agreement dated Feb 13  2012 "
    },
    {
        "content": "March 27 Former Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson has filed a lawsuit against the Canadian drugmaker  alleging it refused to pay him more than 3 million shares he is owed  the Wall Street Journal reported on Monday.",
        "date": "03272017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Former Valeant CEO sues company over unmade compensation -WSJ "
    },
    {
        "content": "March 23 Valeant Pharmaceuticals International Inc:",
        "date": "03232017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO's 2016 compensation was $62.7 mln "
    },
    {
        "content": "* Glycyx Pharmaventures and Valeant Pharmaceuticals agree to binding terms of licensing agreement in the field of oncology",
        "date": "03152017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Glycyx Pharmaventures and Valeant agree to terms of licensing agreement in oncology "
    },
    {
        "content": "March 15 Valeant Pharmaceuticals International Inc:",
        "date": "03152017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant's Bausch + Lomb reports introduction of Biotrue Oneday "
    },
    {
        "content": "    March 15 Futures pointed to a higher opening for Canadian stocks on Wednesday as oil prices rebounded from three-month lows  a day after the S&P/TSX composite index tumbled to its lowest this year.     March futures on the index         were up 0.25 percent at 7:15 a.m. ET.     The rebound in oil prices was due to a surprise drawdown in U.S. inventories and the International Energy Agency's figures suggesting OPEC cuts should push the crude market into deficit in time.     The ma",
        "date": "03152017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Futures indicate higher open as oil rebounds "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc",
        "date": "03162017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-ValuAct reports open market purchse of 500 000 shares of Valeant Pharma "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc  on Monday with a loss of more than $3 billion as he sold his entire stake in the struggling drug company after trying to rescue it for some 18 months. |\u00a0Video ",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square sells Valeant stake  takes $3 billion loss "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc",
        "date": "03162017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharma CFO Paul Herendeen reports open market purchase of co's shares "
    },
    {
        "content": "BOSTON  March 14 Valeant Pharmaceuticals Inc's  stock price fell to its lowest level in eight years on Tuesday after the abrupt exit of its biggest supporter put renewed focus on the Canadian company's most pressing problem: raising capital to cut its roughly $30 billion debt pile.",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares fall as Ackman exit highlights company's challenges "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc",
        "date": "03162017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valueact Holdings reports 5.2 pct stake in Valeant Pharma "
    },
    {
        "content": "March 16 Hedge fund ValueAct Holdings LP raised its stake to 5.2 percent in Valeant Pharmaceuticals International Inc  calling Valeant's shares \"undervalued\" and saying it intends to continue to discuss with the company to \"enhance shareholder value\".",
        "date": "03162017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "ValueAct raises its stake in Valeant Pharmaceuticals "
    },
    {
        "content": "March 13 Pershing Square Capital Management Lp ",
        "date": "03132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square Capital sells investment in Valeant Pharmaceuticals "
    },
    {
        "content": "NEW YORK/WASHINGTON  March 12 The Trump administration's firing of Manhattan U.S. Attorney Preet Bharara sent shockwaves through New York  but veterans of the high-profile office expect a longstanding mission of cracking down on political corruption and Wall Street wrongdoing to remain intact.",
        "date": "03132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Post-firing  NY prosecutor's office likely to plot similar course "
    },
    {
        "content": "* Ackman out of Valeant; he sold 27.2 million shares at $11 & believes he'll be stepping off Co.'s board - CNBC  citing sources  Further company coverage:",
        "date": "03132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ackman sold 27.2 million Valeant shares at $11- CNBC "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman walked away from Valeant Pharmaceuticals International Inc  on Monday with a loss of more than $3 billion as he sold his entire stake in the struggling drug company after trying to rescue it for some 18 months.",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square sells Valeant stake  takes $3 bln loss "
    },
    {
        "content": "* TSX closes down 165.21 points  or 1.06 percent  at 15 379.61",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX hits 2017 low as energy  Valeant weigh "
    },
    {
        "content": "* Pershing Square Capital Management LP says in regulatory filing it dissolved stake in Valeant Pharma as of March 13  2017  Source text (http://bit.ly/2mGFeXe) Further company coverage:",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square Capital Management says in regulatory filing it dissolved stake in Valeant as of March 13  2017 "
    },
    {
        "content": "March 10 Valeant Pharmaceuticals International Inc:",
        "date": "03102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant receives lender consent for refinancing  amendment of credit agreement "
    },
    {
        "content": "March 9 Valeant Pharmaceuticals International Inc",
        "date": "03092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says launched offering of $2.5 bln aggregate principal amount of senior secured notes "
    },
    {
        "content": "WASHINGTON  March 8 Wall Street attorney Jay Clayton will recuse himself from matters involving Barclays Bank  Deutsche Bank AG and other clients he has recently represented if confirmed to head the U.S. Securities and Exchange Commission under the terms of an ethics agreement disclosed on Wednesday.",
        "date": "03082017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-SEC nominee Clayton vows separation from his Wall Street law firm "
    },
    {
        "content": "NEW YORK/WASHINGTON The Trump administration's firing of Manhattan U.S. Attorney Preet Bharara sent shockwaves through New York  but veterans of the high-profile office expect a longstanding mission of cracking down on political corruption and Wall Street wrongdoing to remain intact.",
        "date": "03132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "NY prosecutor\u2019s office likely to plot similar course after Bharara\u2019s firing "
    },
    {
        "content": "NEW YORK/WASHINGTON  March 12 The Trump administration's firing of Manhattan U.S. Attorney Preet Bharara sent shockwaves through New York  but veterans of the high-profile office expect a longstanding mission of cracking down on political corruption and Wall Street wrongdoing to remain intact.",
        "date": "03132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-Post-firing  NY prosecutor's office likely to plot similar course "
    },
    {
        "content": "TORONTO  March 14 Canada's main stock index fell on Tuesday to its lowest close this year as a slide in oil prices weighed on the energy sector  while Valeant Pharmaceuticals International Inc plunged on the exit of an activist investor.",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX posts lowest close this year as energy  Valeant weigh "
    },
    {
        "content": "By Tessa Walsh  Jonathan Schwarzberg  Davide Scigliuzzo and Lisa Lee",
        "date": "03102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant rallies support with key refi "
    },
    {
        "content": "March 14 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Tuesday:",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Deals of the day-Mergers and acquisitions "
    },
    {
        "content": "* All of the TSX's 10 main groups fall; energy group down 2.3 pct",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as energy stocks weigh  Valeant slumps "
    },
    {
        "content": "TORONTO  March 14 Canada's main stock index fell on Tuesday  pressured by losses for the energy group as prices of oil fell to a three-month low  while Valeant Pharmaceuticals International Inc tumbled after billionaire investor William Ackman sold his entire stake.",
        "date": "03142017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as drop in oil prices weighs on energy "
    },
    {
        "content": "March 7 Valeant Pharmaceuticals International Inc",
        "date": "03072017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant commences cash tender offer "
    },
    {
        "content": "March 10 Valeant Pharmaceuticals International Inc",
        "date": "03102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces upsizing of cash tender offer for its 6.75% senior notes due 2018 "
    },
    {
        "content": "March 10 Valeant Pharmaceuticals International Inc",
        "date": "03102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says priced offering of $1.25 bln aggregate principal amount of 6.50% senior secured notes due 2022 "
    },
    {
        "content": "NEW YORK  March 6 Valeant Pharmaceuticals International Inc plans to line up a US$3.06bn incremental term loan and junk bond sale as part of a debt restructuring  sources said.",
        "date": "03062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-LPC: Valeant seeks new debt to support refinancing effort "
    },
    {
        "content": "March 1 Valeant Pharmaceuticals International Inc:",
        "date": "03022017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals corrects misleading report about Salix investigation "
    },
    {
        "content": "* Valeant announces deployment of expanded salix sales force to capture untapped market opportunity",
        "date": "02272017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says has hired more staff to sell Salix drugs "
    },
    {
        "content": "NEW YORK  March 6 Valeant Pharmaceuticals International Inc plans to line up a US$3.06bn incremental term loan as part of a debt restructuring  sources said.",
        "date": "03062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "LPC: Valeant seeks US$3bn loan to support refinancing effort "
    },
    {
        "content": "March 6 Valeant Pharmaceuticals International Inc",
        "date": "03062017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant to seek refinancing and amendment of credit agreement "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   on Tuesday said that 2017 would be another year of transition with revenues falling as much as 8 percent amid drug price pressure and fewer prescriptions.",
        "date": "02282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant predicts tough 2017 with revenue to decline "
    },
    {
        "content": "Feb 28 Valeant Pharmaceuticals International Inc   on Tuesday said that 2017 would be another year of transition with revenues falling as much as 8 percent amid drug price pressure and fewer prescriptions.",
        "date": "02282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant predicts tough 2017 with revenue to decline "
    },
    {
        "content": "* Valeant says q4 was held back by pricing pressure  decline in dermatology prescriptions  egyptian currency",
        "date": "02282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant sees continued pressure on dermatology volumes "
    },
    {
        "content": "Feb 28 Valeant Pharmaceuticals International Inc  :",
        "date": "02282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant reports Q4 adjusted eps of $1.26 "
    },
    {
        "content": "Feb 28 Valeant Pharmaceuticals International Inc   reported a 12.9 percent fall in quarterly revenue on Tuesday  its third straight quarter of a double-digit percentage decrease  as sales declined across its businesses and realized prices fell.",
        "date": "02282017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant Pharma's revenue falls for third straight quarter "
    },
    {
        "content": "NEW YORK  Feb 24 A New York state judge has dismissed a lawsuit accusing the Sequoia Fund  known for its ties to Warren Buffett  of recklessly making a huge  disastrous investment in Valeant Pharmaceuticals International Inc   causing billions of dollars of losses.",
        "date": "02242017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sequoia Fund wins dismissal of lawsuit over huge Valeant stake "
    },
    {
        "content": "NEW YORK  Feb 23 A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.",
        "date": "02232017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Former Valeant and Philidor execs plead not guilty in fraud scheme "
    },
    {
        "content": "NEW YORK A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme.",
        "date": "02232017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Former Valeant and Philidor executives plead not guilty in fraud scheme "
    },
    {
        "content": "* Eyegate Pharmaceuticals Inc - under license agreement  Valeant will pay company an upfront payment of $4.0 million - SEC filing",
        "date": "02212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Eyegate Pharmaceuticals says under license agreement  Valeant to make upfront payment of $4.0 mln - SEC filing "
    },
    {
        "content": "Feb 23 Valeant Pharmaceuticals International Inc  CEO Joe Papa  speaking at RBC investor conference in New York:",
        "date": "02232017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals CEO: sales growth  cutting debt top priorities "
    },
    {
        "content": "* Obagi Medical Products-collaboration with Nextcell Medical Co to claim exclusive distribution of Suzan Obagi's line of skin care products throughout U.S.  Source text for Eikon:  Further company coverage:",
        "date": "02232017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant unit Obagi Medical Products collaborates with Nextcell Medical "
    },
    {
        "content": "* Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product in post-operative pain and inflammation in ocular surgery patients",
        "date": "02212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product "
    },
    {
        "content": "* Says will have exclusive rights and license for sales and distribution of Ammonul in Europe  the Middle East and North Africa until 31 December 2019 for named patient use (NPU) programmes  For the original story: http://bit.ly/2m7ahef Further company coverage:   (Stockholm Newsroom)",
        "date": "02212017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Sobi signs distribution deal for Ammonul with Valeant "
    },
    {
        "content": "Feb 15 The U.S. Food and Drug Administration on Wednesday approved Valeant Pharmaceuticals International Inc's   Siliq to treat adults with moderate-to-severe plaque psoriasis.",
        "date": "02152017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "FDA approves Valeant's drug to treat plaque psoriasis "
    },
    {
        "content": "* Says co  j. Michael pearson and pershing square capital management and william ackman entered into a litigation management agreement",
        "date": "02132017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says Co  J. Michael Pearson  Pershing Square and William Ackman entered litigation management agreement "
    },
    {
        "content": "* Eyegate receives additional milestone payment from Valeant Pharmaceuticals for EGP-437",
        "date": "01092017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Eyegate receives additional milestone payment from Valeant Pharmaceuticals for EGP-437 "
    },
    {
        "content": "* Valeant Pharmaceuticals International Inc - Reiterating its full-year 2016 financial guidance  which was originally communicated in november 2016",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharma reiterates its FY 2016 forecast "
    },
    {
        "content": "TORONTO  Jan 10 Canada's benchmark stock index rose on Tuesday  led by the financial and materials groups as metal prices rose  while shares of drugmaker Valeant Pharmaceuticals International Inc surged as it sold assets.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises with financials and materials; Valeant jumps "
    },
    {
        "content": "Valeant Pharmaceuticals International  is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than $30 billion in debt.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell assets for $2.12 billion to ease debt load "
    },
    {
        "content": "TORONTO  Jan 10 Canada's benchmark stock index rose in morning trade on Tuesday as materials stocks gained with higher commodity prices and drugmaker Valeant Pharmaceuticals International Inc surged as it sold assets.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises with materials stocks; Valeant jumps "
    },
    {
        "content": "Jan 10 Valeant Pharmaceuticals International Inc  -",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals expands parameter range for Bausch+Lomb ultra for presbyopia contact lenses "
    },
    {
        "content": "* Valeant Pharmaceuticals announces results of second phase 3 study for psoriasis treatment IDP-118",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals announces results of second Phase 3 study for psoriasis treatment "
    },
    {
        "content": "PARIS  Jan 10 French cosmetics group L'Oreal  said on Tuesday it was buying three skincare brands - CeraVe  AcneFree and Ambi - from Valeant for $1.3 billion  in a cash deal which L'Oreal said would boost its U.S. revenues.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "L'Oreal to buy three skincare brands from Valeant for $1.3 bln "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc  said its affiliate will sell its Dendreon cancer business to China's Sanpower Group Co Ltd [SPGCL.UL] for $819.9 million  as the drugmaker continues to shed its non-core assets to repay debt.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell Dendreon unit to China's Sanpower for $820 million "
    },
    {
        "content": "Jan 9 Canada's Valeant Pharmaceuticals International Inc said its affiliate will sell its Dendreon cancer business to China's Sanpower Group Co Ltd  for $819.9 million  as the drugmaker continues to shed its non-core assets to repay debt.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to sell Dendreon unit to China's Sanpower for $820 mln "
    },
    {
        "content": "Jan 9 Valeant Pharmaceuticals International Inc  said its affiliate will sell its Dendreon Pharmaceuticals business to China's Sanpower Group Co Ltd for $819.9 million in cash.",
        "date": "01102017",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to sell Dendreon unit to China's Sanpower for $819.9 mln "
    },
    {
        "content": "* Valeant announces the initiation of a primary care sales force for Xifaxan\u007f and Relistor\u007f",
        "date": "11292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces initiation of a primary care sales force for Xifaxan and Relistor "
    },
    {
        "content": "Takeda Pharmaceutical Co Ltd's  negotiations to acquire Valeant Pharmaceuticals International Inc's  Salix stomach-drug business have stalled over price disagreements  people familiar with the matter said on Wednesday.",
        "date": "11302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Takeda's talks to acquire Valeant's Salix stall: sources "
    },
    {
        "content": "Nov 15 Valeant Pharmaceuticals Inc  a heavily indebted Canadian drugmaker trying to sell non-core assets  has received offers for some core businesses  Chief Executive Joe Papa said on Tuesday.",
        "date": "11152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant Pharmaceuticals receives bids for core assets - CEO "
    },
    {
        "content": "NEW YORK A former Valeant Pharmaceuticals International Inc  executive and the former CEO of mail order pharmacy Philidor Rx Services were arrested on Thursday on charges that they engaged in a multimillion-dollar fraud and kickback scheme.",
        "date": "11172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ex-Valeant executive  ex-pharmacy CEO charged for fraud scheme "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Plc   the drugmaker that became a poster child for high drug prices during the U.S. election season  may change its name to help boost its reputation  board member and top investor William Ackman told CNBC on Wednesday.",
        "date": "11112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant may seek to clean up its name by changing it: Ackman "
    },
    {
        "content": "NEW YORK  Nov 10 Valeant Pharmaceuticals International Plc  the drugmaker that became a poster child for high drug prices during the U.S. election season  may change its name to help boost its reputation  board member and top investor William Ackman told CNBC on Wednesday.",
        "date": "11112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant may seek to clean up its name by changing it -Ackman "
    },
    {
        "content": "NEW YORK  Nov 10 Valeant Pharmaceuticals International Plc  the drugmaker that became a poster child for high drug prices during the U.S. election season  may change its name to help boost its reputation  board member and top investor William Ackman told CNBC on Wednesday.",
        "date": "11112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant may seek to clean up its name by changing it -Ackman "
    },
    {
        "content": "Nov 17 Valeant Pharmaceuticals International Inc  :",
        "date": "11172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant comments on issued Philidor criminal charges "
    },
    {
        "content": "* Blackstone Group  Carlyle Group LP  KKR & Co among buyout firms in talks with banks for financing to back bids for Valeant's Australian drug unit - Bloomberg",
        "date": "11102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Blackstone  Carlyle  KKR among firms in talks to bid for Valeant's Inova unit - Bloomberg "
    },
    {
        "content": "WASHINGTON  Nov 7 Valeant Pharmaceuticals  which owns Bausch & Lomb  has agreed to sell Paragon Holdings to settle allegations that its acquisition of the company was illegal under antitrust law  the Federal Trade Commission said on Monday.",
        "date": "11072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant agrees to sell Paragon to settle U.S. antitrust charges "
    },
    {
        "content": "Nov 9 Canadian drugmaker Valeant Pharmaceuticals International Inc  said on Wednesday it received an investigative subpoena from the California Department of Insurance in September over its ties to pharmacies and marketing.",
        "date": "11102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets investigative subpoena over former ties with Philidor "
    },
    {
        "content": "WASHINGTON  Nov 7 Valeant Pharmaceuticals   which owns eye care products maker Bausch & Lomb  has agreed to sell Paragon Holdings to settle allegations that its acquisition of the smaller company was illegal under antitrust law  the Federal Trade Commission said on Monday.",
        "date": "11072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant agrees to sell Paragon to settle U.S. antitrust charges "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc on Tuesday cut its revenue forecast for the year and warned that 2017 could be even more challenging as some products face new competition  sending shares down more than 20 percent.",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant shares sink as company warns of rocky year ahead "
    },
    {
        "content": "After a $67.5 million jury verdict against Johnson & Johnson on Oct. 27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc-based products cause ovarian cancer  the company is hoping to reverse the trend by having the cases heard in a different court.",
        "date": "11072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Analysis: After $195 mln in talc verdicts  J&J strives to change court "
    },
    {
        "content": "Nov 8 Valeant Pharmaceuticals International Inc  on Tuesday cut its revenue forecast for the year and warned that 2017 could be even more challenging as some products face new competition  sending shares down more than 20 percent.",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Valeant shares sink as company warns of rocky year ahead "
    },
    {
        "content": "* Moody's downgrades Valeant (CFR to B3 from B2); negative outlook",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's downgrades Valeant (CFR to B3 FROM B2); negative outlook "
    },
    {
        "content": "* Valeant Pharmaceuticals comments on press report regarding its gastroenterology business unit",
        "date": "11012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says in talks for divestiture of Salix  other assets "
    },
    {
        "content": "Endo International Plc  is facing increasing pricing and competitive pressures in its U.S. generics business and the trends will likely worsen in 2017  newly appointed Chief Executive Paul Campanelli said on Tuesday.",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Endo warns of more pressure on generics business in 2017 "
    },
    {
        "content": "Nov 1 Valeant Pharmaceuticals International Inc  is in talks to sell its Salix stomach business to Japanese pharmaceutical company Takeda Pharamceutical Co Ltd   according to people familiar with the matter.",
        "date": "11012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-Valeant in talks to sell Salix stomach business -sources "
    },
    {
        "content": "TORONTO  Nov 8 Canada's main stock index fell on Tuesday as lower oil prices weighed on energy and Valeant Pharmaceuticals International Inc reported adjusted profit that missed estimates  while investors awaited the outcome of the U.S. presidential election.",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as lower oil  Valeant weigh "
    },
    {
        "content": "WILMINGTON  Del. Valeant Pharmaceuticals International Inc was sued on behalf of former investors in Sprout Pharmaceuticals Inc  which it bought last year for $1 billion  over its alleged failure to market the female libido pill Addyi successfully.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant sued for botching marketing of female libido pill "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc's  former chief executive and chief financial officer are at the center of a U.S. criminal probe against the drugmaker over its ties to a specialty pharmacy that helped boost its sales  Bloomberg reported on Monday.",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant ex-CEO  ex-CFO focus of U.S. criminal probe -report "
    },
    {
        "content": "Nov 1 Valeant Pharmaceuticals International Inc  is in talks to sell its Salix stomach business to Japanese pharmaceutical company Takeda Pharamceutical Co Ltd   according to people familiar with the matter.",
        "date": "11012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to sell Salix stomach business -sources "
    },
    {
        "content": "* Valeant is in talks to sell its Salix stomach-drug business for about $10 billion - WSJ  Source text - http://on.wsj.com/2eaPVeQ Further company coverage:",
        "date": "11012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant in talks to sell Salix stomach-drug unit for about $10 bln - WSJ "
    },
    {
        "content": "Nov 8 Valeant Pharmaceuticals International Inc  executives  speaking on a conference call:",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals sees lower 2017 revenue  adj EBITDA "
    },
    {
        "content": "* Orexigen Therapeutics Inc - Orexigen expects Valeant to file for regulatory approvals in both countries in first half of 2017",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Orexigen signs commercialization  distributorship agreement with Valeant for Vontrave in Australia  New Zealand "
    },
    {
        "content": "WILMINGTON  Del.  Nov 2 Valeant Pharmaceuticals International Inc was sued on behalf of former investors in Sprout Pharmaceuticals Inc  which it bought last year for $1 billion  over its alleged failure to market the female libido pill Addyi successfully.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant sued for botching marketing of female libido pill "
    },
    {
        "content": "Oct 31 Valeant Pharmaceuticals International Inc's former chief executive and chief financial officer are at the center of a U.S. criminal probe against the drugmaker over its ties to a specialty pharmacy that helped boost its sales  Bloomberg reported on Monday.",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant ex-CEO  ex-CFO focus of U.S. criminal probe -report "
    },
    {
        "content": "Oct 31 Valeant Pharmaceuticals International Inc  :",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant comments on report of investigation by U.S. Attorney's office "
    },
    {
        "content": "reported an 11 percent fall in quarterly revenue due to faltering sales  and cut its full-year profit and revenue forecasts.",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant posts 11 pct fall in revenue; cuts FY forecast "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  is exploring a sale of its eye-surgery equipment business  which could fetch as much as $2.5 billion  the Wall Street Journal reported.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant exploring sale of eye-surgery equipment business: WSJ "
    },
    {
        "content": "TORONTO  Oct 31 Canada's benchmark stock index edged higher on Monday  as broad gains were canceled out as weaker oil prices weighed on energy stocks and by a slump in Valeant Pharmaceuticals International Inc after a report its former executives are the focus of a U.S. criminal probe.",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends barely higher as energy stocks  Valeant weigh "
    },
    {
        "content": "* Valeant Pharmaceuticals International revising 2016 full year guidance",
        "date": "11082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant reports Q3 non-GAAP EPS $1.55 "
    },
    {
        "content": "Nov 2 Valeant Pharmaceuticals International Inc  is exploring a sale of its eye-surgery equipment business  which could fetch as much as $2.5 billion  the Wall Street Journal reported.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant exploring sale of eye-surgery equipment business - WSJ "
    },
    {
        "content": "* Valeant exploring sale of eye-surgery equipment business which could fetch $2.5 billion in a sale; talks still preliminary - CNBC citing DJ   Further company coverage:",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant exploring sale of eye-surgery equipment business which could fetch $2.5 bln - CNBC citing DJ "
    },
    {
        "content": "U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc's  former chief executive and chief financial officer as they build a fraud case against the drugmaker  Bloomberg reported.",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant ex-CEO  ex-CFO focus of U.S. criminal probe: Bloomberg "
    },
    {
        "content": "Oct 31 U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc's former chief executive and chief financial officer as they build a fraud case against the drugmaker  Bloomberg reported.",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant ex-CEO  ex-CFO focus of U.S. criminal probe - Bloomberg "
    },
    {
        "content": "* Valeant ex-CEO  ex-CFO are focus of U.S. criminal probe - Bloomberg  citing sources  Source text - http://bloom.bg/2fxFqHl Further company coverage:",
        "date": "10312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant ex-CEO  ex-CFO are focus of U.S. criminal probe - Bloomberg "
    },
    {
        "content": "* Valeant exploring sale of eye-surgery equipment business; sale of the business could fetch $2.5 billion - WSJ  citing sources  Source text - http://on.wsj.com/2eev3U0 Further company coverage:",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant exploring sale of eye-surgery equipment business - WSJ "
    },
    {
        "content": "WILMINGTON  Del.  Nov 2 Valeant Pharmaceuticals International Inc was sued on Wednesday on behalf of investors in Sprout Pharmaceuticals Inc  which it bought last year for $1 billion  over its alleged failure to successfully market the female libido pill Addyi.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant sued by ex-Sprout investors over libido pill "
    },
    {
        "content": "Allergan Plc's chief executive officer on Wednesday took the blame for disappointing quarterly earnings as the drugmaker underestimated sales declines for its older medicines  forcing it to cut its 2016 profit forecast.",
        "date": "11022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Allergan CEO takes blame for big miss on quarterly earnings "
    },
    {
        "content": "Oct 14 Valeant Pharmaceuticals International Inc  :",
        "date": "10142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces price changes for neurology  GI  urology portfolis "
    },
    {
        "content": "* Valeant appoints Louis W. Yu  Ph.D. as chief quality officer",
        "date": "10062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant appoints Louis W. Yu as chief quality officer "
    },
    {
        "content": "Sept 16 Valeant Pharmaceuticals International Inc said its discount and rebates program for two high-priced heart drugs would cover over 90 percent U.S. hospitals once it had finalized the last of the 14 group purchasing organizations.",
        "date": "09162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says discount program for heart drugs on track "
    },
    {
        "content": "Sept 12 Eyegate Receives Additional Milestone Payment From Valeant Pharmaceuticals For Egp",
        "date": "09122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Eyegate says is eligible to get additional milestone payment from Valeant for EGP-437 "
    },
    {
        "content": "NEW YORK Noted value investor Bill Miller said on Tuesday that Valeant Pharmaceuticals International Inc  the troubled Canadian drugmaker  is one of his top holdings  with the company's expected cash flows making the stock attractive.",
        "date": "09132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Bill Miller: Valeant shares could post 25-30 percent returns over five years "
    },
    {
        "content": "WASHINGTON  Sept 11 Taro Pharmaceutical Industries Ltd and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing  the company disclosed.",
        "date": "09112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-U.S. Justice Department subpoenas Taro over generic drug pricing "
    },
    {
        "content": "Sept 16 Valeant Pharmaceuticals International Inc :",
        "date": "09162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant comments on discount and rebate program for Nitropress and Isuprel "
    },
    {
        "content": "WASHINGTON Taro Pharmaceutical Industries Ltd  and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing  the company disclosed.",
        "date": "09122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. Justice Department subpoenas Taro over generic drug pricing "
    },
    {
        "content": "NEW YORK  Sept 13 Noted value investor Bill Miller said on Tuesday that Valeant Pharmaceuticals International Inc  the troubled Canadian drugmaker  is one of his top holdings  with the company's expected cash flows making the stock attractive.",
        "date": "09132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Bill Miller: Valeant shares could post 25-30 pct returns over 5 years "
    },
    {
        "content": "WASHINGTON  Sept 11 Taro Pharmaceutical Industries Ltd. and two of its senior officers received grand jury subpoenas last week in connection with a federal antitrust investigation into generic drug pricing  the company disclosed late on Friday.",
        "date": "09112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. Justice Department subpoenas Taro over generic drug pricing "
    },
    {
        "content": "* Valeant Pharmaceuticals CEO Joe Papa  speaking on CNBC  said he will 'never say never' on a potential sale of Valeant's Bausch + Lomb business  but is focused on selling non-core assets;",
        "date": "09072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals CEO won't rule out Bausch sale-CNBC "
    },
    {
        "content": "* Valeant and Progenics announce the U.S. commercial launch of FDA approved Relistor tablets  Source text for Eikon:  Further company coverage:",
        "date": "09062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant and Progenics announce the U.S. commercial launch of FDA-approved Relistor tablets "
    },
    {
        "content": "Activist investor William Ackman  wielding a stake of nearly 10 percent in Chipotle Mexican Grill Inc   is likely to push for board changes and a franchising model  analysts said  as the fast-casual Mexican food chain struggles to win back customers.",
        "date": "09072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman may push Chipotle for board changes  franchising: analysts "
    },
    {
        "content": "BOSTON  Sept 1 Billionaire investor William Ackman's portfolios climbed nearly 6 percent in August  boosted by strong gains at drug company Valeant Pharmaceuticals International Inc  where changes that the hedge fund manager has helped push for appear to be instilling new confidence.",
        "date": "09022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman's Pershing Square Holdings gains 5.8 percent in August "
    },
    {
        "content": "Sept 9 Seagate Technology Plc has invited ValueAct Capital in as an investor  selling a roughly 4 percent stake to the activist hedge fund  which will also get a front-row view of its board meetings  the hard-drive maker said on Friday.",
        "date": "09092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Seagate Tech invites ValueAct in as major shareholder "
    },
    {
        "content": "BOSTON  Sept 1 Billionaire investor William Ackman's portfolios climbed nearly 6 percent in August  boosted by strong gains at drug company Valeant Pharmaceuticals International Inc  where changes that the hedge fund manager has helped push for appear to be instilling new confidence.",
        "date": "09012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square Holdings gains 5.8 percent in August "
    },
    {
        "content": "Aug 30 Valeant Pharmaceuticals International Inc  :",
        "date": "08302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant acquires Canadian rights for Contrave in treatment of obesity "
    },
    {
        "content": "NEW YORK  Aug 29 Valeant Pharmaceuticals International Inc  was sued on Monday by buyers of its drugs  who claimed they were forced to pay exorbitant prices stemming from the Canadian company's ties to a specialty pharmacy that helped boost sales.",
        "date": "08292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant is sued over Philidor ties  alleged racketeering "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  was sued on Monday by buyers of its drugs  who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.",
        "date": "08302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant is sued over Philidor ties  alleged racketeering "
    },
    {
        "content": "NEW YORK  Aug 29 Valeant Pharmaceuticals International Inc  was sued on Monday by buyers of its drugs  who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.",
        "date": "08292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant is sued over Philidor ties  alleged racketeering "
    },
    {
        "content": "BOSTON  Aug 26 Billionaire investor William Ackman said on Friday that Jordan Rubin  who had worked closely on Pershing Square Capital Management's controversial investment in battered drug maker Valeant Pharmaceuticals  is leaving the hedge fund.",
        "date": "08262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-MOVES-Pershing Square's Valeant analyst to exit  Ackman sees stock rising "
    },
    {
        "content": "BOSTON  Aug 26 Billionaire investor William Ackman said on Friday that Jordan Rubin  who had worked closely on the controversial investment in battered drug maker Valeant Pharmaceuticals  is leaving the hedge fund.",
        "date": "08262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "MOVES-Pershing Square's Valeant analyst to exit  Ackman optimistic price "
    },
    {
        "content": "* On August 23 entered into an amendment to its third amended and restated credit and guaranty agreement  dated as of February 13  2012",
        "date": "08232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant enters into amendment  restates credit and guaranty agreement "
    },
    {
        "content": "TORONTO  Aug 22 Canada's main stock index ended higher on Monday  boosted by Alimentation Couche-Tard Inc's  $4.4 billion U.S. expansion and by a jump in Valeant Pharmaceuticals International Inc after it hired a new chief financial officer.",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as Couche-Tard  Valeant jump "
    },
    {
        "content": "* Paul Herendeen to receive base salary of $1 million  a target annual bonus opportunity equal to 120 percent of base salary",
        "date": "08232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant- Paul Herendeen to receive base salary of $1 mln "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  named Zoetis Inc  executive Paul Herendeen as its chief financial officer  replacing Robert Rosiello  the latest in a series of management changes at the Canadian drugmaker.",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant hires Zoetis's Paul Herendeen as CFO "
    },
    {
        "content": "Aug 22 Valeant Pharmaceuticals International Inc  named Zoetis Inc executive Paul Herendeen as its chief financial officer  replacing Robert Rosiello  the latest in a series of management changes at the Canadian drugmaker.",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant hires Zoetis's Paul Herendeen as CFO "
    },
    {
        "content": "Aug 22 Valeant Pharmaceuticals International Inc  :",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant appoints Paul Herendeen as chief financial officer "
    },
    {
        "content": "Aug 22 Valeant Pharmaceuticals International Inc   said on Monday former Zoetis Inc  executive Paul Herendeen will take over as chief financial officer from Robert Rosiello  effective immediately.",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant names former Zoetis executive Paul Herendeen as CFO "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc.  is expected to announce it has hired Paul Herendeen of Zoetis Inc  as its new chief financial officer  according to a Wall Street Journal report on Sunday citing sources close to the companies.",
        "date": "08222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant expected to announce Herendeen as new CFO: WSJ "
    },
    {
        "content": "T. Rowe Price Group Inc has sued Valeant Pharmaceuticals International Inc   alleging that investors in the Canadian drugmaker lost billions of dollars as a result of the company's \"fraudulent scheme\".",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "T. Rowe Price sues Valeant over \"fraudulent scheme\" "
    },
    {
        "content": "T. Rowe Price Group Inc  has sued Valeant Pharmaceuticals International Inc    alleging that investors in the Canadian drugmaker lost billions of dollars as a result of the company's \"fraudulent scheme\".",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "T. Rowe Price sues Valeant over 'fraudulent scheme' "
    },
    {
        "content": "Aug 18 T. Rowe Price Group Inc has sued Valeant Pharmaceuticals International Inc   alleging that investors in the Canadian drugmaker lost billions of dollars as a result of the company's \"fraudulent scheme\".",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-T. Rowe Price sues Valeant over \"fraudulent scheme\" "
    },
    {
        "content": "* Valeant says aware of T Rowe Price lawsuit filing  says it has not been served yet",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says aware of T Rowe Price lawsuit filing  says it has not been served yet "
    },
    {
        "content": "BOSTON  Aug 15 For many prominent hedge fund managers who bet Pfizer Inc and Allergan Plc  would merge to become the world's biggest pharmaceuticals company  the second quarter started with a thud that send many in search of new opportunities.",
        "date": "08152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Hedge funds made big changes at drug companies in 2nd qtr -filings "
    },
    {
        "content": "Aug 18 T Rowe Price Group Inc has sued Valeant Pharmaceuticals International Inc   alleging that investors in the Canadian drugmaker lost billions of dollars due to its use of a secret pharmacy network  among others.",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "T. Rowe Price sues Valeant "
    },
    {
        "content": "Aug 18 Valeant Pharmaceuticals International Inc   said its lenders had approved an amendment to its credit facility  giving the drugmaker more flexibility to sell assets and repay loans by taking on other debt.",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant amends credit facility for second time in six months "
    },
    {
        "content": "Aug 18 Valeant Pharmaceuticals International Inc  :",
        "date": "08182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals receives lender consent for credit facility amendment "
    },
    {
        "content": "TORONTO  Aug 11 Canada's main stock index made a small gain on Thursday as energy stocks rose with higher oil prices  while Valeant shares fell 11 percent after a report that the drug company is the subject of a criminal investigation.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends slightly higher  energy stocks up on higher oil "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc  shares fell about 11 percent on Thursday as new details about a criminal investigation into the drugmaker reignited investor concerns about the company's past business relationship with a mail-order pharmacy that sold its products.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant stock falls as report of criminal probe adds to woes "
    },
    {
        "content": "NEW YORK  Aug 11 Valeant Pharmaceuticals International Inc shares fell about 11 percent on Thursday as new details about a criminal investigation into the drugmaker reignited investor concerns about the company's past business relationship with a mail-order pharmacy that sold its products.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant stock falls as report of criminal probe adds to woes "
    },
    {
        "content": "TORONTO  Aug 11 Canada's main stock index rose on Thursday in a broad but shallow bounce as steadying oil prices helped energy stocks  while drug maker Valeant Pharmaceuticals International Inc slumped on a report it is the target of a criminal probe.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises in broad but shallow rebound  Valeant falls "
    },
    {
        "content": "NEW YORK/SAN FRANCISCO U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc  over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales  the Wall Street Journal reported on Wednesday.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant under criminal investigation over Philidor ties: WSJ "
    },
    {
        "content": "NEW YORK/SAN FRANCISCO  Aug 10 U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales  the Wall Street Journal reported on Wednesday.",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant under criminal investigation over Philidor ties -WSJ "
    },
    {
        "content": "* Cannot comment on or speculate about possible course of any ongoing investigation",
        "date": "08112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says cannot comment on or speculate about possible course of any ongoing investigation "
    },
    {
        "content": "Aug 10 U.S. federal prosecutors are investigating whether drugmaker Valeant Pharmaceuticals International Inc  defrauded insurers by hiding a relationship with pharmacy Philidor that boosted sales of its drugs  the Wall Street Journal reported  citing people familiar with the matter.",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant under criminal investigation -WSJ "
    },
    {
        "content": "* Valeant pharmaceuticals announces relaunch of generic ofloxacin otic solution",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharma says announces relaunch of generic ofloxacin otic solution "
    },
    {
        "content": "* Federal prosecutors investigating whether Valeant defrauded insurers by shrouding ties to a mail-order pharmacy that boosted sales of its drugs - WSJ",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Federal prosecutors probe whether Valeant defrauded insurers by shrouding ties to mail-order pharmacy- WSJ "
    },
    {
        "content": "* Half of the TSX's 10 main groups rise; materials up 1.2 pct",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX barely higher at 13-month high  gold miners lead "
    },
    {
        "content": "Allergan Plc's  chief executive officer said on Monday he is not interested in using the drugmaker's cash pile for big deals  one week after selling its generics business for $40.5 billion.",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Allergan focused on 'stepping stone' deals  not big ones like Biogen "
    },
    {
        "content": "Aug 8 Allergan Plc's chief executive officer said on Monday he is not interested in using the drugmaker's cash pile for big deals  one week after selling its generics business for $40.5 billion.",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Allergan focused on 'stepping stone' deals  not big ones like Biogen "
    },
    {
        "content": "BOSTON  Aug 9 Six weeks before Valeant Pharmaceuticals International Inc revealed plans to reorganize and pay down debt  similar ideas to improve the drugmaker's fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman  according to a source who participated.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Before Valeant overhaul  Ackman met investors at brainstorming event "
    },
    {
        "content": "* Moody's: Valeant's proposed amendment is positive for liquidity",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's says Valeant's proposed amendment is positive for liquidity "
    },
    {
        "content": "Aug 8 Canadian drugmaker Valeant Pharmaceuticals International Inc on Monday named a new general counsel and announced the departure of its public relations head.",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant names new general counsel  says PR head to leave "
    },
    {
        "content": "Aug 8 Valeant Pharmaceuticals International Inc  :",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals announces licensing agreement with Norgine B.V. for NER1006 in U.S. and Canada "
    },
    {
        "content": "* Estimated legal liability  initially measured at fair value on date of Salix acquisition  should be reduced by $39 million",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant updates on settlement agreements related to Salix unit "
    },
    {
        "content": "TORONTO  Aug 9 Canada's main stock index extended its rally at a 13-month high on Tuesday  boosted by a surge in shares of Valeant Pharmaceutical International Inc  after the drug maker said it would sell billions of dollars of assets to pay down debt.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Valeant surge helps TSX extend 13-month high "
    },
    {
        "content": "BOSTON  Aug 9 Six weeks before Valeant Pharmaceuticals International Inc revealed plans to reorganize and pay down debt  similar ideas to improve the drugmaker's fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman  according to a source who participated.",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-Before Valeant overhaul  Ackman met investors at brainstorming event "
    },
    {
        "content": "BOSTON Six weeks before Valeant Pharmaceuticals International Inc revealed plans to reorganize and pay down debt  similar ideas to improve the drugmaker's fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman  according to a source who participated.",
        "date": "08102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Before Valeant overhaul  Ackman met investors at brainstorming event "
    },
    {
        "content": "* Valeant Pharmaceuticals announces changes to executive management team",
        "date": "08082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces changes to executive management team "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   will sell billions of dollars of non-core assets and could accept offers for its main businesses  its chief executive said on Tuesday  as the drugmaker worked to restore investor trust after a year of bad news.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant looks to sell billions in assets to cut debt  stock soars "
    },
    {
        "content": "* Indexes end: Dow +0.02 pct  S&P +0.04 pct  Nasdaq +0.24 pct   (Updates to close)",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Nasdaq hits record high  other indexes hover near highs "
    },
    {
        "content": "Aug 9 Valeant Pharmaceuticals International Inc   will sell billions of dollars of non-core assets and could accept offers for its main businesses  its chief executive said on Tuesday  as the drugmaker worked to restore investor trust after a year of bad news.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Valeant looks to sell billions in assets to cut debt  stock soars "
    },
    {
        "content": "TORONTO  Aug 9 Canada's main stock index ended higher on Tuesday  its fifth straight rising session and best close in more than a year  as Valeant shares surged 25 percent after the drug maker said it would sell billions of dollars in assets to pay down debt.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises to fresh one-year-plus high  Valeant surges "
    },
    {
        "content": "July 28 Valeant Pharmaceuticals International Inc :",
        "date": "07282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals adds Sarah Kavanagh to its board of directors "
    },
    {
        "content": "* Indexes: Dow and S&P flat  Nasdaq up 0.25 pct   (Updates to afternoon)",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall Street catches its breath after recent rally "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  has received unsolicited interest for its core assets  although the company is not actively shopping them  Chief Executive Officer Joe Papa said on Tuesday.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO receives unsolicited buyer interest for core assets "
    },
    {
        "content": "Aug 9 Valeant Pharmaceuticals International Inc   has received unsolicited interest for its core assets  although the company is not actively shopping them  Chief Executive Officer Joe Papa said on Tuesday.",
        "date": "08092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "INTERVIEW-Valeant CEO receives unsolicited buyer interest for core assets "
    },
    {
        "content": "* Has been informed by its partner Bausch + Lomb  a Valeant unit  of receipt of a complete response letter from U.S. FDA concerning latanoprostene bunod",
        "date": "07222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-FDA to inspect Nicox partner Bausch + Lomb "
    },
    {
        "content": "* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016",
        "date": "07192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant and Progenics announce FDA approvals for relistor "
    },
    {
        "content": "July 22 Valeant Pharmaceuticals International Inc",
        "date": "07222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says no safety concerns  additional clinical trials for approval of Latanoprostene Bunod "
    },
    {
        "content": "NEW YORK  July 14 Billionaire investor Bill Ackman said on Thursday that he was still betting against Herbalife Ltd shares and that the company needed to make \"material changes to its incentive structure.\"",
        "date": "07142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Hedge fund manager Ackman still betting against Herbalife "
    },
    {
        "content": "July 14 Valeant Pharmaceuticals International Inc said on Thursday its former CEO Michael Pearson remains a significant shareholder of the Canadian drugmaker.",
        "date": "07142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says ex-CEO Pearson remains a significant shareholder "
    },
    {
        "content": "July 14 Canadian drugmaker Valeant Pharmaceuticals International Inc said on Thursday its former Chief Executive Michael Pearson  who has sold shares worth almost $100 million  remained a significant shareholder.",
        "date": "07142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant says ex-CEO Pearson remains a significant shareholder "
    },
    {
        "content": "July 15 Valeant Pharmaceuticals International Inc :",
        "date": "07152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant to host conference call on Aug. 9 to discuss Q2 results "
    },
    {
        "content": "July 14 Valeant Pharmaceuticals International Inc :",
        "date": "07142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says former CEO Pearson remains \"significant\" shareholder "
    },
    {
        "content": "July 13 Andrew Left  who runs short-selling firm Citron Research  is planning to take a short position in Valeant Pharmaceuticals International Inc again  TheStreet reported.",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Citron's Left to go short on Valeant again - TheStreet "
    },
    {
        "content": "Andrew Left  who runs short-selling firm Citron Research  is planning to take a short position in Valeant Pharmaceuticals International Inc again  TheStreet reported.",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Citron's Left to go short on Valeant again: TheStreet "
    },
    {
        "content": "TORONTO  July 6 Canada's benchmark stock index ended higher on Wednesday  recovering from early losses as oil price gains boosted energy stocks and Valeant Pharmaceuticals surged by the most in three months.",
        "date": "07062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as energy stocks turn higher  Valeant jumps "
    },
    {
        "content": "* Former Valeant CEO Pearson sold nearly 5 million Valeant shares and options for $96.8 million - CNBC  Source text: (http://cnb.cx/29XOtj4) Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Former Valeant CEO Pearson sold nearly 5 mln shares  options for $96.8 mln -CNBC "
    },
    {
        "content": "July 13 Ruane  Cunniff & Goldfarb Inc  the investment firm that runs the Sequoia Fund and once the largest shareholder of Valeant Pharmaceuticals International Inc   said it exited its position in the embattled Canadian drugmaker by mid-June.",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sequoia Fund exits Valeant position after losses "
    },
    {
        "content": "* Elected to sell position in Valeant Pharmaceuticals  exited completely by mid-june  Source text : (http://bit.ly/29CPklT) Further company coverage:    (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Sequoia fund says it sold position in Valeant Pharmaceuticals completely by mid-june "
    },
    {
        "content": "July 12 Valeant Pharmaceuticals International Inc",
        "date": "07132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Sequoia Fund tells clients it has completely exited Valeant's position- CNBC "
    },
    {
        "content": "July 1 Valeant Pharmaceuticals International Inc  :",
        "date": "07012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals announces new licensing arrangement for Brodalumab in Europe "
    },
    {
        "content": "MADRID Spanish drugmaker Almirall  which is building up its business in skin treatments  could be interested in acquiring dermatology assets from Canada's Valeant Pharmaceuticals  the head of the Barcelona-based company said on Monday.    Valeant is looking at divesting various products as it tries to reduce its massive debt load  with new CEO Joe Papa open to selling a range of assets if the price is right.",
        "date": "07042016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Spain's Almirall eyes Valeant skin drugs to boost dermatology "
    },
    {
        "content": "June 17 Valeant Pharmaceuticals International Inc",
        "date": "06172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant pharmaceuticals says invests in Canadian operations "
    },
    {
        "content": "June 16 Valeant Pharmaceuticals International Inc",
        "date": "06162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says launches new Preservision\u007f AREDS 2 formula + multivitamin "
    },
    {
        "content": "June 21 Valeant Pharmaceuticals International Inc :",
        "date": "06212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals appoints Sam Eldessouky chief accounting officer "
    },
    {
        "content": "* Chairman joseph papa reports open market purchase of 202 000 shares in multiple transactions at average price of $24.48per share - sec filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom +1-646-223-8780)",
        "date": "06132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-CEO Papa buys 202 000 Valeant shares - filing "
    },
    {
        "content": "June 15 Valeant Pharmaceuticals International Inc",
        "date": "06152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharma appoints Thomas Ross  Sr. lead independent director "
    },
    {
        "content": "LAVAL  Quebec Valeant Pharmaceuticals International Inc's  new chief executive officer left the door open to selling major assets on Tuesday as the company tries to reduce its massive debt load.",
        "date": "06142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO open to selling core assets if price is right "
    },
    {
        "content": "LAVAL  Quebec  June 14 Valeant Pharmaceuticals International Inc's  new chief executive officer left the door open to selling major assets on Tuesday as the company tries to reduce its massive debt load.",
        "date": "06142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant CEO open to selling core assets if price is right "
    },
    {
        "content": "June 14 Valeant Pharmaceuticals International Inc",
        "date": "06142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says has a \"number of bankers\" working on non-core asset sales "
    },
    {
        "content": "June 14 Valeant Pharmaceuticals International Inc CEO Joe Papa speaking at annual general meeting:",
        "date": "06142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals to pay $1.7 bln of debt 2016 "
    },
    {
        "content": "* Unclear how Valeant will look in 18 months -former investor",
        "date": "06142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "New Valeant CEO meets investors as doubts grow about drug company "
    },
    {
        "content": "* Pershing Square - Unwound Over-the-counter European-style Put Options Referencing A Total Of 9.1 Mln Shares Of Valeant Pharmaceuticals' Common stock",
        "date": "06102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square updates on Valeant's call and put options "
    },
    {
        "content": "* Corporate family rating remains unchanged at B2  and the outlook remains unchanged at negative  Source text for Eikon:",
        "date": "06102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's raises Valeant's liquidity rating to SGL-3 from SGL-4 "
    },
    {
        "content": "* Valeant is attempting to restructure deal with Walgreens - FT  citing sources  Source text - (http://on.ft.com/28kwZSO) Further company coverage:    (Bengaluru Newsroom)",
        "date": "06082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant is attempting to restructure deal with Walgreens - FT  citing sources "
    },
    {
        "content": "Reuters) - Valeant Pharmaceuticals International Inc  slashed its 2016 forecasts on Tuesday  as its new chief executive said he would focus on rebuilding the reputation of a \"distracted organization\" with a debt-loaded balance sheet. |\u00a0Video ",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant CEO cuts outlook for 'distracted' company  shares plunge "
    },
    {
        "content": "* Files its quarterly report   (Adds details about quarterly report  updates shares)",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Valeant CEO cuts outlook for 'distracted' company  shares plunge "
    },
    {
        "content": "* Valeant Pharmaceuticals to webcast 2016 annual meeting of shareholders",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals to webcast 2016 annual meeting on June 14 "
    },
    {
        "content": "* Valeant to participate in FDA advisory committee meeting on July 19  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant to participate in FDA advisory committee meeting on July 19 "
    },
    {
        "content": "* Affirmation reflects good cash flow and expectation that discretionary cash flow will be used for debt repayment",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's affirms Valeant's rating including B2 CFR with negative outlook "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products  causing the submission of thousands of fraudulent reimbursement claims to the U.S. government.",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant pays $54 mln to settle U.S. kickback  fraud claims "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products  causing the submission of thousands of fraudulent reimbursement claims to the U.S. government.",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant pays $54 million to settle U.S. kickback  fraud claims "
    },
    {
        "content": "* Ruane  Cunniff & Goldfarb Inc.  reports 4.72% passive stake in Valeant Pharmaceuticals International Inc as of  May 31  2016   - SEC filing",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ruane  Cunniff & Goldfarb cuts passive stake in Valeant Pharmaceuticals to 4.72 pct "
    },
    {
        "content": "June 7 Valeant Pharmaceuticals International Inc  :",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Canada to invest in its Manitoba plant "
    },
    {
        "content": "June 3 Troubled Canadian drugmaker Valeant Pharmaceuticals International Inc said it received another notice of default from bondholders for the delay in filing its first-quarter report.",
        "date": "06032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets another default notice from bondholders "
    },
    {
        "content": "May 31 Valeant Pharmaceuticals Inc    which has come under scrutiny for its business and accounting practices  said on Tuesday it would host a conference call on June 7 to discuss first-quarter results.",
        "date": "05312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to report first-quarter results on June 7 "
    },
    {
        "content": "NEW YORK  June 9 Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products  causing the submission of thousands of fraudulent reimbursement claims to the U.S. government.",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant pays $54 mln to settle U.S. kickback  fraud claims "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   is considering the sale of Egyptian drugmaker Amoun Pharmaceutical Co to accelerate its debt-reduction plan  Bloomberg reported  citing people with knowledge of the matter.",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant said to weigh sale of Egyptian drugmaker Amoun: Bloomberg "
    },
    {
        "content": "June 9 Valeant Pharmaceuticals International Inc   is considering the sale of Egyptian drugmaker Amoun Pharmaceutical Co to accelerate its debt-reduction plan  Bloomberg reported  citing people with knowledge of the matter.",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant said to weigh sale of Egyptian drugmaker Amoun-Bloomberg "
    },
    {
        "content": "June 7 Reuters) - Valeant Pharmaceuticals International Inc    which is under scrutiny for business and accounting practices  posted a 9.3 percent rise in quarterly revenue  helped by the acquisitions of Salix Pharmaceuticals and certain assets of Dendreon Corp.",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant Q1 revenue rises 9.3 percent "
    },
    {
        "content": "June 7 Valeant Pharmaceuticals International Inc  :",
        "date": "06072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals Q1 adjusted non-gaap EPS $1.27 "
    },
    {
        "content": "* Valeant said to weigh sale of Egypt drugmaker Amoun to cut debt - Bloomberg",
        "date": "06092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant said to weigh sale of Egypt drugmaker amoun to cut debt - BBG "
    },
    {
        "content": "June 3 Valeant Pharmaceuticals International Inc  :",
        "date": "06032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant gets additional default notice; still expects 10-Q filing by June 10 "
    },
    {
        "content": "May 31 Valeant Pharmaceuticals International Inc  :",
        "date": "05312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals provides update on regulatory matters "
    },
    {
        "content": "* Under separation agreement with former CEO pearson  he will provide consulting services to company through december 31  2017",
        "date": "05312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant's former CEO may remain as consultant through 2017 "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd  and TPG Capital Management LP [TPG.UL] this spring that the Canadian drugmaker rejected  according to a source familiar with the matter.",
        "date": "05272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant rejected joint takeover bid from Takeda  TPG in spring: source "
    },
    {
        "content": "May 24 The Securities and Exchange Commission is concerned about the way Canadian drugmaker Valeant Pharmaceuticals International Inc has been disclosing its \"non-GAAP\" financial measures  regulatory filings showed on Tuesday.",
        "date": "05242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "SEC raises concerns about Valeant's use of \"Non-GAAP\" measures "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals Inc  plans to lower its debt by at least $1.5 billion this year  Chief Executive Officer Joseph Papa said on Monday during his first large meeting with investors since taking the top job three weeks ago.",
        "date": "05232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant CEO Papa plans to lower debt by more than $1.5 billion in 2016 "
    },
    {
        "content": "May 26 Valeant Pharmaceuticals International Inc  received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP  this spring that the Canadian drugmaker rejected  according to a source familiar with the matter.",
        "date": "05272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant rejected joint takeover bid from Takeda  TPG in spring - source "
    },
    {
        "content": "* Valeant received joint takeover approach from Takeda  TPG a few weeks before Joseph Papa became CEO - Source   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "05272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant received joint takeover approach from Takeda  TPG before Joseph Papa became CEO - source "
    },
    {
        "content": "The Securities and Exchange Commission is concerned about the way Canadian drugmaker Valeant Pharmaceuticals International Inc  has been disclosing its \"non-GAAP\" financial measures  regulatory filings showed on Tuesday.",
        "date": "05242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "SEC raises concerns about Valeant's use of 'Non-GAAP' measures "
    },
    {
        "content": "May 24 The Securities and Exchange Commission is concerned about the way Canadian drugmaker Valeant Pharmaceuticals International Inc has been disclosing its \"non-GAAP\" financial measures  regulatory filings showed on Tuesday.",
        "date": "05242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-SEC raises concerns about Valeant's use of \"Non-GAAP\" measures "
    },
    {
        "content": "NEW YORK  May 23 Valeant Pharmaceuticals Inc  plans to lower its debt by at least $1.5 billion this year  Chief Executive Officer Joseph Papa said on Monday during his first large meeting with investors since taking the top job three weeks ago.",
        "date": "05232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant CEO Papa plans to lower debt by more than $1.5 bln in 2016 "
    },
    {
        "content": "May 26 Valeant Pharmaceuticals International Inc  received a joint takeover offer from Japan's Takeda Pharmaceutical Co Ltd and TPG Capital Management LP  this spring that the Canadian drugmaker rejected  the Wall Street Journal reported  citing people familiar with the matter.",
        "date": "05262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant rejected joint takeover bid from Takeda  TPG in spring-WSJ "
    },
    {
        "content": "* SEC takes issue with Valeant's practice of stripping out acquisition-related costs from Non-GAAP measures - WSJ citing SEC comment letters to Valeant",
        "date": "05242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-SEC reviewing Valeant's use of 'Non-GAAP' financial measures - WSJ "
    },
    {
        "content": "* Valeant's Papa says there are still a couple of valeant drugs where he needs to work on pricing",
        "date": "05232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says that he has spoken with Congressional representatives "
    },
    {
        "content": "NEW YORK  May 23 Valeant Pharmaceuticals Inc's  Chief Executive Officer Joseph Papa said on Monday that three weeks into the job  he sees there is a lot to work on at the Canadian drugmaker but that he is encouraged by its pipeline of new drugs.",
        "date": "05232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's new CEO Papa says there is a lot to work on "
    },
    {
        "content": "* Valeant received joint takeover approach from Takeda  TPG that it rejected this spring before hiring new CEO - CNBC  citing DJ",
        "date": "05262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant approached by earlier rejected Takeda  TPG for takeover-CNBC "
    },
    {
        "content": "NEW YORK  May 17 Johnson & Johnson will keep arguing in court that its talc-based powders are safe  an outside lawyer who has defended the company in lawsuits said  even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.",
        "date": "05182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-J&J to stand behind talc's safety at upcoming trials -lawyer "
    },
    {
        "content": "May 26 Embattled drugmaker Valeant Pharmaceuticals International Inc appointed Sam Eldessouky senior vice president and corporate controller  effective May 31.",
        "date": "05262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant appoints Tyco's Sam Eldessouky corporate controller "
    },
    {
        "content": "May 26 Valeant Pharmaceuticals International Inc  appointed Tyco International Plc executive Sam Eldessouky as corporate controller as the Canadian drugmaker works to rebuild its reputation amid criticism of its accounting methods.",
        "date": "05262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant appoints Tyco's Sam Eldessouky corporate controller "
    },
    {
        "content": "May 18 - Johnson & Johnson will keep arguing in court that its talc-based powders are safe  an outside lawyer who has defended the company in lawsuits said  even after losing two multimillion-dollar verdicts to plaintiffs who alleged that J&J Baby Powder and Shower to Shower caused ovarian cancer.",
        "date": "05182016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "J&J to stand behind talc's safety at upcoming trials -lawyer "
    },
    {
        "content": "May 26 Valeant Pharmaceuticals International Inc  -",
        "date": "05262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals names Sam Eldessouky SVP and corporate controller "
    },
    {
        "content": "May 19 Beleagured Canadian drugmaker Valeant Pharmaceuticals International Inc  said it received a notice of default from bondholders for the delay in filing its quarterly report.",
        "date": "05192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets notice of default from bondholders "
    },
    {
        "content": "* Brian M. Stolz tendered his resignation as senior vice president neurology  dentistry and generics  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",
        "date": "05202016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says Brian Stolz resigned as senior VP neurology  dentistry & generics "
    },
    {
        "content": "* Valeant Pharmaceuticals considering disposal Of Obagi Medical Products Inc  dermatology company it acquired in 2013  as well as Provenge - Bloomberg",
        "date": "05172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant considering disposal of Obagi Medical Products as well as Provenge - Bloomberg "
    },
    {
        "content": "BOSTON Some of Valeant Pharmaceuticals International Inc.'s most loyal supporters lost hope during the first quarter and either exited the embattled company or significantly cut back their stakes  regulatory filings released on Monday show.",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Regulatory filings show which Valeant investors exited in first quarter "
    },
    {
        "content": "May 19 Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc  said it received a notice of default from bondholders for the delay in filing its first-quarter report.",
        "date": "05192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant gets notice of default from bondholders "
    },
    {
        "content": "* Valeant Pharmaceuticals receives notice of default from bondholders",
        "date": "05192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant receives notice of default from bondholders "
    },
    {
        "content": "TORONTO  May 17 Canada's main stock index gained on Tuesday as the energy group rose on higher oil prices and Valeant Pharmaceuticals International Inc surged after it said it would make required securities filings to Canadian regulators.",
        "date": "05172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as energy stocks  Valeant gain "
    },
    {
        "content": "* Expects to make Canadian required filings on or before June 10  2016.",
        "date": "05172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals provides update regarding regulatory matters "
    },
    {
        "content": "BOSTON  May 16 Some of Valeant Pharmaceuticals International Inc.'s most loyal supporters lost hope during the first quarter and either exited the embattled company or significantly cut back their stakes  regulatory filings released on Monday show.",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Regulatory filings show which Valeant investors exited in Q1 "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc said on Monday it would raise the discounts to hospitals on its heart drugs Nitropress and Isuprel to as much as 40 percent off list prices after shareholder William Ackman pledged to revisit controversial price increases on the treatments.",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to increase hospital discounts for two heart drugs "
    },
    {
        "content": "May 16 Valeant Pharmaceuticals International Inc   said on Monday it would raise the discounts to hospitals on its heart drugs Nitropress and Isuprel to as much as 40 percent off list prices after shareholder William Ackman pledged to revisit controversial price increases on the treatments.",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant to increase hospital discounts for two heart drugs "
    },
    {
        "content": "May 16 Valeant Pharmaceuticals International Inc  :",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals announces expanded discounts for Nitropress "
    },
    {
        "content": "* Valeant Pharmaceuticals announces expanded discounts for Nitropress and Isuprel",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals announces expanded discounts for Nitropress and Isuprel "
    },
    {
        "content": "May 16 Valeant Pharmaceuticals International Inc   said on Monday it would make available to all hospitals in the United States an enhanced rebate program to reduce the price of its heart drugs Nitropress and Isuprel.",
        "date": "05162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to provide rebate programs for two heart drugs "
    },
    {
        "content": "NEW YORK  May 13 David Tepper's hedge-fund firm Appaloosa bought nearly 1 million shares in Valeant Pharmaceuticals International Inc in the first three months of 2016  according to regulatory filings  but sold them during the first quarter.",
        "date": "05132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "David Tepper's Appaloosa bought and sold Valeant shares in first quarter "
    },
    {
        "content": "May 11 Pershing Square Holdings Ltd In Letter To Shareholders",
        "date": "05112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square releases Q1 letter to shareholders "
    },
    {
        "content": "LAS VEGAS  May 11 William Doyle  a key figure in Pershing Square Capital Management's controversial investment in battered drug company Valeant Pharmaceuticals  is leaving the hedge fund  its founder  William Ackman  told investors on Wednesday.   (Reporting by Svea Herbst-Bayliss; Editing by Chris Reese)",
        "date": "05112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Key player in Pershing Square's Valeant bet leaving firm "
    },
    {
        "content": "LAS VEGAS  May 11 William Doyle  a key figure in Pershing Square Capital Management's controversial investment in battered drug company Valeant Pharmaceuticals  is leaving the hedge fund  its founder  William Ackman  told investors on Wednesday.",
        "date": "05112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Key player in Pershing Square's Valeant bet leaving firm "
    },
    {
        "content": "* Does not expect that it will be in a position to file the form 10-Q within the 5-day extension period provided in rule 12b-25(b)",
        "date": "05102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals files for non-timely 10-Q "
    },
    {
        "content": "* David Tepper's Appaloosa LP has already sold Q1 Valeant stake - CNBC citing source  Further company coverage:    (Bengaluru Newsroom)",
        "date": "05132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-David Tepper's Appaloosa LP has already sold Q1 Valeant stake - CNBC citing source "
    },
    {
        "content": "* Valeant CEO Papa to CNBC - I'm comfortable we've got a plan to take care of debt holders  Further company coverage:    (Bengaluru Newsroom)",
        "date": "05092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO Papa to CNBC - I'm comfortable we've got a plan to take care of debt holders "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   said on Monday it expected to file its first-quarter report with U.S. and Canadian regulators on or before June 10  ahead of a July 31 deadline  and reiterated its first-quarter forecasts.",
        "date": "05092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to file quarterly report by June 10  reiterates forecast "
    },
    {
        "content": "May 9 Valeant Pharmaceuticals International Inc   said on Monday it expected to file its first-quarter report with U.S. and Canadian regulators on or before June 10  ahead of a July 31 deadline  and reiterated its first-quarter forecasts.",
        "date": "05092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant to file quarterly report by June 10  reiterates forecast "
    },
    {
        "content": "May 9 Valeant Pharmaceuticals Announces Expected Timing Of Form 10",
        "date": "05092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says expects to file quarterly report by June 10 "
    },
    {
        "content": "* Board of directors will oversee patient access and pricing committee",
        "date": "05052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals International says forms new patient access and pricing committee "
    },
    {
        "content": "May 9 Valeant Pharmaceuticals International Inc  said on Monday it expects to file its first-quarter report with the regulators on or before June 10  ahead of the July 31 deadline.",
        "date": "05092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says will file its quarterly report by June 10 "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  which has acknowledged mistakes in its drug pricing practices amid U.S. congressional probes  said on Thursday it has formed a new committee to oversee pricing of the company's drugs.",
        "date": "05052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant forms internal committee to oversee drug pricing "
    },
    {
        "content": "* Valeant pharmaceuticals announces patient access and pricing committee to oversee pricing of drugs  Source text for Eikon:  Further company coverage:",
        "date": "05052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant announces committee to oversee drug pricing "
    },
    {
        "content": "* Announced a collaboration to develop first app of its kind for Iphone and Ipad to assist surgeons  who perform cataract surgery",
        "date": "05052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharma announces collaboration between Bausch + Lomb and IBM "
    },
    {
        "content": "* Moody's confirms Valeant's B2 CFR upgrades PDR to B2-PD outlook negative  Source text for Eikon:  Further company coverage:",
        "date": "05032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Moody's confirms Valeant's B2 CFR  upgrades PDR to B2-PD  outlook negative "
    },
    {
        "content": "* Valeant Pharmaceuticals International Inc. Corporate credit rating creditwatch revised to positive from developing",
        "date": "05032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-S&P on Valeant - Corporate credit rating creditwatch revised to positive from developing "
    },
    {
        "content": "* Joseph Papa assumes role of chairman and chief executive officer of Valeant Pharmaceuticals",
        "date": "05032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals names Joseph Papa as CEO and chairman "
    },
    {
        "content": "BOSTON/NEW YORK Billionaire investor William Ackman on Monday mounted a vigorous defense of Valeant Pharmaceuticals   ruling out any sale of the drug company's \"crown jewel\" assets but saying price cuts and even a new name may be in its future.",
        "date": "05022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman defends Valeant  hints at more changes "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman had some good news to share with clients on Monday  saying that his Pershing Square Holdings portfolio gained 10.2 percent last month as battered drug company Valeant Pharmaceuticals  climbed.",
        "date": "05022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square Holdings gains 10.2 percent in April "
    },
    {
        "content": "NEW YORK  April 30 Warren Buffett and Charlie Munger made clear that they are no fans of embattled drugmaker Valeant Pharmaceuticals International Inc .",
        "date": "04302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Buffett  Munger slam Valeant; drugmaker turned into 'a sewer' "
    },
    {
        "content": "BOSTON  May 2 Billionaire investor William Ackman had some good news to share with clients on Monday  saying that his Pershing Square Holdings portfolio gained 10.2 percent last month as battered drug company Valeant Pharmaceuticals climbed.",
        "date": "05022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman's Pershing Square Holdings gains 10.2 pct in April "
    },
    {
        "content": "* Ackman says he believes the government will \"do its job\" regarding Herbalife - CNBC",
        "date": "05022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ackman expects Valeant to grow Bausch & Lomb  Salix products  dermatology "
    },
    {
        "content": "NEW YORK  April 30 Warren Buffett and Charlie Munger made clear that they are no fans of embattled drugmaker Valeant Pharmaceuticals International Inc .",
        "date": "04302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Buffett  Munger slam Valeant; drugmaker turned into 'a sewer' "
    },
    {
        "content": "* Ackman says initial investment in Valeant was passive  and that was a mistake",
        "date": "05022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ackman says initial Valeant investment was passive  and that was a mistake "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  on Friday issued a 2015 financial report that met an important deadline for creditors  revealing new details on a range of financial and legal issues  and it also announced changes to its board.",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant annual report reveals new issues  company overhauls board "
    },
    {
        "content": "April 29 Valeant Pharmaceuticals International Inc",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says Michael Pearson 2015 total compensation $143.1 mln "
    },
    {
        "content": "April 29 Valeant Pharmaceuticals International Inc has requested that Quebec securities regulator Autorite des Marches Financiers lift its cease-trade order against directors and key officers",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Quebec regulator receives Valeant request to lift cease-trade order "
    },
    {
        "content": "April 29 Valeant Pharmaceuticals International Inc :",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says 3 new independent directors nominated to board "
    },
    {
        "content": "* Restates q4 results after review; now says q4 gaap loss per share $1.12; co on march 15 reported q4 gaap loss per share of $0.98",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals restates Q4 results after review "
    },
    {
        "content": "April 29 Valeant Pharmaceuticals International Inc",
        "date": "04292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals files annual report on form 10-K for 2015 "
    },
    {
        "content": "WASHINGTON/NEW YORK Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals  to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman  Valeant pledge reforms after spiking drug prices "
    },
    {
        "content": "WASHINGTON Democrats on a powerful U.S. congressional panel are questioning whether Canada-based Valeant Pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky-rocketing drug prices  according to an internal memo seen by Reuters on Tuesday.",
        "date": "04262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "House Democrats question if Valeant is withholding records "
    },
    {
        "content": "Drugmaker Valeant Pharmaceuticals International Inc's  new chief executive  Joseph Papa  will receive a base salary of $1.5 million  the company said in a filing on Wednesday.",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to pay new CEO Papa base salary of $1.5 million "
    },
    {
        "content": "* Valeant to name 4 new directors as soon as Friday as 5 board members step down; departing  directors to include Valueact's Mason Morfit -CNBC  citing DJ    (Bengaluru Newsroom)",
        "date": "04282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant to name 4 new directors as soon as Friday -CNBC  citing DJ "
    },
    {
        "content": "Former Perrigo Co Plc  head Joseph Papa was named Chief Executive Officer at Valeant Pharmaceuticals International  on Monday  a role in which investors said he should focus on returning the company to growth.",
        "date": "04252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant names Papa CEO after he resigns from Perrigo "
    },
    {
        "content": "WASHINGTON  April 26 Democrats on a powerful U.S. congressional panel are questioning whether Canada-based Valeant Pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky-rocketing drug prices  according to an internal memo seen by Reuters on Tuesday.",
        "date": "04262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-U.S. House Democrats question if Valeant is withholding records "
    },
    {
        "content": "WASHINGTON/NEW YORK  April 27 Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Ackman  Valeant pledge reforms after spiking drug prices "
    },
    {
        "content": "April 27 Drugmaker Valeant Pharmaceuticals International Inc is expected to name four new directors as soon as Friday  the Wall Street Journal reported.",
        "date": "04282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to name four new directors as soon as Friday -WSJ "
    },
    {
        "content": "April 27 Drugmaker Valeant Pharmaceuticals International Inc is expected to name four new directors as soon as Friday  the Wall Street Journal reported.",
        "date": "04282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to name four new directors as soon as Friday -WSJ "
    },
    {
        "content": "April 25 Former Perrigo Co Plc head Joseph Papa was named Chief Executive Officer at Valeant Pharmaceuticals International on Monday  a role in which investors said he should focus on returning the company to growth.",
        "date": "04252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Valeant names Papa CEO after he resigns from Perrigo "
    },
    {
        "content": "* Valeant's receipt of more notices of default is a negative development",
        "date": "04252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's says Valeant's receipt of more notices of default is negative development "
    },
    {
        "content": "WASHINGTON  April 26 Democrats on a powerful U.S. congressional panel are questioning whether Canada-based Valeant Pharmaceuticals may be wrongfully withholding documents in connection with its ongoing probe into sky-rocketing drug prices  according to an internal memo seen by Reuters on Tuesday.",
        "date": "04262016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. House Democrats question if Valeant is wrongfully withholding records "
    },
    {
        "content": "April 27 Valeant Pharmaceuticals International Inc",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says new CEO Papa will get base salary of $1.5 mln "
    },
    {
        "content": "WASHINGTON/NEW YORK Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO tells U.S. Senate of regret over raising drug prices "
    },
    {
        "content": "April 22 Canadian drugmaker Valeant Pharmaceuticals International Inc said it received additional notices of default from its bondholders as a result of a delay in filing its annual report.",
        "date": "04222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets additional notices of default from bondholders "
    },
    {
        "content": "* Valeant Chairman Robert Ingram also considering leaving the board- CNBC  citing dow jones   Further company coverage:",
        "date": "04282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Chairman Robert Ingram also considering leaving the board- CNBC  citing DJ "
    },
    {
        "content": "April 25 Valeant Pharmaceuticals International Inc",
        "date": "04252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals Inc names Joseph Papa to be CEO and chairman "
    },
    {
        "content": "April 27 Valeant Pharmaceuticals International Inc",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Ackman to call Valeant board Thursday to discuss drug pricing "
    },
    {
        "content": "Drugmaker Valeant Pharmaceuticals International Inc  is seeking to appoint Joseph Papa  Perrigo Co Plc's  boss   as its new chief executive  a source familiar with the matter said.",
        "date": "04222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to hire Perrigo's Papa as CEO: source "
    },
    {
        "content": "April 22 Drugmaker Valeant Pharmaceuticals International Inc is seeking to appoint Joseph Papa  Perrigo Co Plc's boss   as its new chief executive  a source familiar with the matter said.",
        "date": "04222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant in talks to hire Perrigo's Papa as CEO -source "
    },
    {
        "content": "April 27 Drugmaker Valeant Pharmaceuticals International Inc's new chief executive  Joseph Papa  will receive a base salary of $1.5 million  the company said in a filing on Wednesday.",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to pay new CEO Papa base salary of $1.5 mln "
    },
    {
        "content": "WASHINGTON  April 27 Outgoing Valeant Pharmaceuticals Chief Executive Michael Pearson plans to tell a U.S. Senate panel on Wednesday that he regrets his decision to acquire and jack up the price of two life-saving heart drugs  saying it was all a \"mistake.\"",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-Valeant CEO to tell U.S. Senate he regrets raising heart drug prices "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  has brought in investment banks to review its options amid interest from buyout firms and other companies in a number of its businesses  according to people familiar with the matter.",
        "date": "04152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Exclusive: Valeant calls in investment banks to weigh options - sources "
    },
    {
        "content": "April 21 Valeant Pharmaceuticals International Inc is seeking to name Perrigo Co Plc's Joseph Papa as its new chief executive  CNBC tweeted  citing Dow Jones.",
        "date": "04222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant wants Perrigo's Papa as its new CEO - CNBC  citing Dow Jones "
    },
    {
        "content": "NEW YORK  April 19 As Valeant Pharmaceuticals considers a multibillion-dollar auction to pare down $30 billion in debt  its challenge will be choosing which assets to sell without compromising any of its key businesses  analysts and investment bankers said.",
        "date": "04192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "RPT-DEALTALK-Debt-laden Valeant faces tough choices in asset sales "
    },
    {
        "content": "WASHINGTON  April 27 Outgoing Valeant Pharmaceuticals Chief Executive Michael Pearson plans to tell a U.S. Senate panel on Wednesday that he regrets his decision to acquire and jack up the price of two life-saving heart drugs  saying it was all a \"mistake.\"",
        "date": "04272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO to tell U.S. Senate he regrets raising heart drug prices "
    },
    {
        "content": "BOSTON  April 15 Hedge fund Lone Pine Capital's Lone Cypress fund lost 8 percent during the first quarter as bets on Valeant Pharmaceuticals Inc and Energy Transfer/Williams Companies  tumbled.",
        "date": "04152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Lone Pine's Cypress Fund down 8 pct in 1st qtr  hurt by Valeant "
    },
    {
        "content": "NEW YORK As Valeant Pharmaceuticals considers a multibillion-dollar auction to pare down $30 billion in debt  its challenge will be choosing which assets to sell without compromising any of its key businesses  analysts and investment bankers said.",
        "date": "04192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Debt-laden Valeant faces tough choices in asset sales "
    },
    {
        "content": "NEW YORK  April 19 As Valeant Pharmaceuticals considers a multibillion-dollar auction to pare down $30 billion in debt  its challenge will be choosing which assets to sell without compromising any of its key businesses  analysts and investment bankers said.",
        "date": "04192016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "DEALTALK-Debt-laden Valeant faces tough choices in asset sales "
    },
    {
        "content": "April 14 Standard & Poor's downgraded Valeant Pharmaceuticals International Inc's  corporate credit rating on Thursday after the drugmaker got a notice of default from bondholders as a result of a delay in filing its annual report.",
        "date": "04142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "S&P cuts Valeant's rating after getting notice from bondholders "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  said on Tuesday that it received a notice of default from its bondholders as a result of a delay filing its annual report.",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Drugmaker Valeant's bondholders intend to call default "
    },
    {
        "content": "April 13 Valeant Pharmaceuticals International Inc :",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals says on schedule to file 10-k on or before April 29 "
    },
    {
        "content": "April 11 Valeant Pharmaceuticals International Inc",
        "date": "04112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals enter amendment  waiver to third amended restated agreement "
    },
    {
        "content": "BOSTON The exclusive club of Americas-based hedge funds managing more than $1 billion in assets shrunk a bit in 2015 after market gyrations in the second half of the year took a bite out of returns and prompted some investors to pull money  data released on Wednesday show.",
        "date": "04142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Hedge funds' billion-dollar club loses members in 2015 "
    },
    {
        "content": "* Valeant Pharmaceuticals International Inc. corporate credit rating lowered to 'B' from 'B+' and placed on watch developing",
        "date": "04142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-S&P says Valeant corporate credit rating lowered to 'B' from 'B+' "
    },
    {
        "content": "April 12 Valeant Pharmaceuticals International Inc said on Tuesday that it received a notice of default from its bondholders as a result of a delay filing its annual report.",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Drugmaker Valeant's bondholders intend to call default "
    },
    {
        "content": "April 12 Valeant Pharmaceuticals International Inc :",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals receives notice of default from bondholders due to delayed 10-K Filing "
    },
    {
        "content": "BOSTON  April 13 The exclusive club of Americas-based hedge funds managing more than $1 billion in assets shrunk a bit in 2015 after market gyrations in the second half of the year took a bite out of returns and prompted some investors to pull money  data released on Wednesday show.",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Hedge funds' billion-dollar club loses members in 2015 "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc said on Monday it had asked outgoing Chief Executive Michael Pearson to cooperate with the U.S. Senate Committee on Aging after he failed to show up at a hearing on Friday.",
        "date": "04112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant asks CEO Pearson to cooperate with U.S. Senate committee "
    },
    {
        "content": "April 11 Valeant Pharmaceuticals International Inc",
        "date": "04112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant board of directors issues statement on J. Michael Pearson's cooperation with Senate Committee on aging "
    },
    {
        "content": "* Valeant Pharmaceuticals International Inc  Pershing's ackman says \"Valeant is not selling Bausch and Lomb\"  adds co is  \"only considering selling non-core assets\"-CNBC  Further company coverage:",
        "date": "04082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Pershing's ackman says \"Valeant is not selling Bausch and Lomb\"  adds co is  \"only considering selling non-core assets\"-CNBC "
    },
    {
        "content": "April 12 Valeant Pharmaceuticals International Inc said it received a notice of default from its bond holders as a result of its failure to file its annual report on time.",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's bond holders intend to call default "
    },
    {
        "content": "* Lowers Valeant's liquidity rating to sGL-4; rating reviews continue",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Moody's lowers Valeant's liquidity rating to SGL-4 "
    },
    {
        "content": "* Big Valeant bond investor Centerbridge notifies company of intention to call a default - CNBC  citing Dow Jones    (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Big Valeant bond investor Centerbridge notifies co of intention to call default - CNBC  citing Dow Jones "
    },
    {
        "content": "WASHINGTON  April 12 A top Democrat in the U.S. House of Representatives on Tuesday called on Valeant Pharmaceuticals International Inc for more details on its relationship with Philidor RX services and chided the company for not providing Congress any documents or other requested information.",
        "date": "04122016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Top Democrat  in letter  blasts Valeant CEO for lack of cooperation "
    },
    {
        "content": "April 13 Valeant Pharmaceuticals International Inc's  outgoing chief executive  Michael Pearson  consented to be deposed by a U.S. Senate committee later this month  after the panel threatened to hold him in contempt for failing to comply with a subpoena.",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant CEO agrees to be deposed by Senate committee "
    },
    {
        "content": "April 13 Valeant Pharmaceuticals International Inc's  outgoing Chief Executive Michael Pearson will depose before the Senate Special Committee on Aging to comply with a congressional subpoena  the committee said.",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO Pearson agrees to depose before Senate committee "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  said on Thursday its lenders had agreed to give it an extra month to file its annual report  providing breathing room for the embattled drugmaker as it tries to win back investor confidence.",
        "date": "04072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant gets extra month to file annual report "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman's Pershing Square Holdings  Ltd fund lost 7.1 percent last month  hurt largely by Valeant Pharmaceuticals'  roughly 60 percent tumble in March.",
        "date": "04022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's fund falls 7 percent in March  hurt by Valeant "
    },
    {
        "content": "BOSTON  April 1 Billionaire investor William Ackman's Pershing Square Holdings  Ltd fund lost 7.1 percent last month  hurt largely by Valeant Pharmaceuticals'  roughly 60 percent tumble in March.",
        "date": "04012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's fund falls 7 pct in March  hurt by Valeant "
    },
    {
        "content": "* Conclusion of Valeant's ad hoc committee a positive development   Source text: http://bit.ly/25JgazH Further company coverage:    (Bengaluru newsroom)",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Moody's says conclusion of Valeant's ad hoc committee a positive development "
    },
    {
        "content": "NEW YORK  April 4 Valeant Pharmaceuticals International Inc will cut its sales force for Addyi  a treatment aimed at female sexual dysfunction  as well as some employees who sell dermatology products  according to an internal memo seen by Reuters.",
        "date": "04042016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to cut Addyi  dermatology sales forces -memo "
    },
    {
        "content": "* U.S. Senate Special Committee on Aging says Senate Special Committee on Aging to depose Michael Pearson",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-U.S. Senate Special Committee on Aging to depose Valeant CEO Pearson "
    },
    {
        "content": "April 7 Valeant Pharmaceuticals International Inc said on Thursday its lenders had agreed to give it an extra month to file its annual report  providing breathing room for the embattled drugmaker as it tries to win back investor confidence.",
        "date": "04072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant gets extra month to file annual report "
    },
    {
        "content": "April 7 Valeant Pharmaceuticals International Inc",
        "date": "04072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant gets lender consent for credit facility amendment "
    },
    {
        "content": "Embattled drugmaker Valeant Pharmaceuticals International Inc  said on Tuesday that a board committee had completed a review of the company's accounting practices and had not found any new items that would require additional restatements.",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says accounting review finds no new issues  shares jump "
    },
    {
        "content": "NEW YORK  April 4 Valeant Pharmaceuticals International Inc will cut its sales force for Addyi  a treatment aimed at female sexual dysfunction  as well as some employees who sell dermatology products  according to an internal memo seen by Reuters.",
        "date": "04042016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to cut Addyi  dermatology sales forces -memo "
    },
    {
        "content": "* Valeant Pharmaceuticals CEO Mike Pearson will give deposition to U.S Senate committee investigating drug pricing  avoiding contempt - Bloomberg",
        "date": "04132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO Pearson to give deposition to U.S. Senate drug pricing committee - Bloomberg "
    },
    {
        "content": "April 7 Valeant Pharmaceuticals International Inc :",
        "date": "04072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant gets lender approval to file annual report by May 31 "
    },
    {
        "content": "April 7 Valeant Pharmaceuticals International Inc  said on Thursday it had obtained approval from its lenders for an amendment and waiver to its credit facility  giving the embattled drugmaker an extra month to file its annual report.",
        "date": "04072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets extra month from lenders to file annual report "
    },
    {
        "content": "April 6 Valeant Pharmaceuticals Internationational Inc :",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals has secured commitment from majority loan holders to amend terms of debt- WSJ  citing source "
    },
    {
        "content": "April 5 Embattled drugmker Valeant Pharmaceuticals International Inc said on Tuesday that a board committee had completed a review of the company's accounting practices and had not found any new items that would require additional restatements.",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant says accounting review finds no new issues  shares jump "
    },
    {
        "content": "* Valeant and Progenics announce pdufa date extension for oral relistor",
        "date": "04042016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Progenics Pharma  Valeant say FDA extended Relistor PDUFA to July 19 "
    },
    {
        "content": "TORONTO  April 6 Canada's main stock index rose on Wednesday  led by energy stocks as oil prices rallied and helped by a sharp rise in the shares of drugmaker Valeant.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises  led by energy stocks and Valeant "
    },
    {
        "content": "BOSTON Billionaire activist investor William Ackman on Wednesday offered a more optimistic outlook for Valeant Pharmaceuticals Inc.  saying the embattled drug maker's annual report will be filed soon and that its search for a new CEO is moving forward.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman says Valeant may find new CEO in weeks  not months "
    },
    {
        "content": "April 5 Valeant Pharmaceuticals International Inc :",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant ad hoc committee completes review of Philidor  related accounting matters "
    },
    {
        "content": "* Downgrades certain Valeant ratings including CFR to B2 from B1",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Moody's downgrades certain Valeant ratings including CFR to B2 "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  said on Wednesday it was asking its lenders for another month to file its annual report  seeking to reduce the risk of a default on its $30 billion debt if it misses the current April 29 deadline. |\u00a0Video ",
        "date": "03302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant seeks more time to file annual report "
    },
    {
        "content": "WASHINGTON  March 28 The chief executive of Valeant Pharmaceuticals International Inc  which is under scrutiny for dramatically hiking the price of older drugs  has been summoned to testify at a U.S. congressional hearing on April 27  the panel said on Monday.",
        "date": "03282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO subpoenaed to testify before U.S. Senate panel "
    },
    {
        "content": "BOSTON  April 6 Billionaire activist investor William Ackman on Wednesday offered a more optimistic outlook for Valeant Pharmaceuticals Inc.  saying the embattled drug maker's annual report will be filed soon and that its search for a new CEO is moving forward.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman says Valeant may find new CEO in weeks  not months "
    },
    {
        "content": "April 5 Canada's Valeant Pharmaceuticals International Inc  said a board committee completed a review of the company's accounting practices and did not find any new items that would require restatements.",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant completes accounting review; finds no new issues "
    },
    {
        "content": "April 5 Canadian stock futures inched lower on Tuesday as oil prices slipped to a one-month low  following a surprise fall in gasoline demand in the United States and scepticism over a potential deal to freeze output.",
        "date": "04052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX set to open lower as oil prices slip "
    },
    {
        "content": "March 31 Valeant Pharmaceuticals International Inc's directors and key officers have received a cease-trade order by the securities regulator in the Canadian province of Quebec  on the company's request  Valeant said on Thursday.",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-UPDATE 2-Regulator orders drugmaker Valeant management to cease trading "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc's  directors and key officers have received a cease-trade order by the securities regulator in the Canadian province of Quebec  on the company's request  Valeant said on Thursday.",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Regulator orders drugmaker Valeant management to cease trading "
    },
    {
        "content": "March 30 Valeant Pharmaceuticals International Inc said on Wednesday it was asking its lenders for another month to file its annual report  seeking to reduce the risk of a default on its $30 billion debt if it misses the current April 29 deadline.",
        "date": "03302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant seeks more time to file annual report "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  said it was asking its lenders to extend until May 31 the deadline for it to file its annual report  lessening the chance of a default on its $30 billion debt if it misses the current deadline of April 29.",
        "date": "03302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant seeks lender approval to extend deadline for annual report "
    },
    {
        "content": "March 30 Valeant Pharmaceuticals International Inc  said it had asked its lenders to agree to waive a condition of its credit facility that would put it in breach of covenants if the company did not file its annual report by April 29  as planned.",
        "date": "03302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant seeks waiver from lenders related to filing annual report "
    },
    {
        "content": "BOSTON  April 6 Billionaire investor William Ackman on Wednesday said the board of embattled drug maker Valeant Pharmaceuticals Inc. could find a new chief executive officer in \"weeks\" and said the stock will become \"investable\" again once the annual report is filed.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "RPT-Ackman says Valeant board may find new CEO in weeks  not months "
    },
    {
        "content": "BOSTON  April 6 Billionaire investor William Ackman on Wednesday said the board of embattled drug maker Valeant Pharmaceuticals Inc. could find a new chief executive officer in \"weeks\" and said the stock will become \"investable\" again once the annual report is filed.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman says Valeant board may find new CEO in weeks  not months "
    },
    {
        "content": "March 31 Valeant Pharmaceuticals International Inc's directors and key officers have received a cease-trade order by the securities regulator in the Canadian province of Quebec  on the company's request  Valeant said on Thursday.",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Regulator orders drugmaker Valeant management to cease trading "
    },
    {
        "content": "March 31 Quebec's securities regulator  the Authorite des marches financiers  said Thursday it would issue a new cease trade order against Valeant Pharmaceuticals International Inc officers  if the company's filings aren't completed by April 15.   (Reporting By Allison Lampert)",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Quebec regulator could issue new cease trade order against Valeant "
    },
    {
        "content": "March 30 Valeant Pharmaceuticals International Inc",
        "date": "03302016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals seeks to extend deadline for filing 10-K "
    },
    {
        "content": "TORONTO  April 6 Canada's main stock index fell on Wednesday as banks and gold miners slipped  although losses were muted by energy stock gains as oil prices rose.",
        "date": "04062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as banks  miners weigh; Valeant and energy stocks up "
    },
    {
        "content": "March 31 Valeant Pharmaceuticals International Inc's directors and key officers have received a cease-trade order by the securities regulator in the Canadian province of Quebec  on the company's request  Valeant said on Thursday.",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant directors  CEO ordered to cease trading shares "
    },
    {
        "content": "* Valeant officers   including William Ackman get cease trade orders from canadian securities regulator- WSJ",
        "date": "03312016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant officers   including William Ackman get cease trade orders from canadian securities regulator- WSJ "
    },
    {
        "content": "Investors in Sprout Pharmaceuticals  which makes the first drug to treat low sexual desire in women and was bought by Valeant Pharmaceuticals International Inc last year  say the drug has been priced too high  Bloomberg reported on Friday.",
        "date": "03252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Sprout investors say Valeant prices 'female Viagra' too high: Bloomberg "
    },
    {
        "content": "March 25 Investors in Sprout Pharmaceuticals  which makes the first drug to treat low sexual desire in women and was bought by Valeant Pharmaceuticals International Inc  last year  say the drug has been priced too high  Bloomberg reported on Friday.",
        "date": "03252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sprout investors say Valeant prices 'female Viagra' too high - Bloomberg "
    },
    {
        "content": "BOSTON U.S. legislators investigating price hikes in the pharmaceutical industry have asked William Ackman's hedge fund for information on Valeant Pharmaceuticals International Inc   according to a person familiar with the matter.",
        "date": "03252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Senate's request for info from Ackman related to Valeant: source "
    },
    {
        "content": "* Pershing Square Holdings' 'BBB+' ratings not yet impacted by valeant decline",
        "date": "03252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Fitch says Pershing Square's ratings not yet impacted by Valeant decline "
    },
    {
        "content": "BOSTON  March 25 U.S. legislators investigating price hikes in the pharmaceutical industry have asked William Ackman's hedge fund for information on Valeant Pharmaceuticals International Inc  according to a person familiar with the matter.",
        "date": "03252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Senate's request for info from Ackman related to Valeant-source "
    },
    {
        "content": "BOSTON  March 24 Billionaire investor William Ackman  whose hedge fund is one of the biggest investors in drug company Valeant  has been asked to supply information to U.S. legislators probing price hikes in the pharmaceutical industry.",
        "date": "03242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Ackman's hedge fund cooperating with U.S. on drug pricing probe -letter "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman  whose hedge fund is one of the biggest investors in drug company Valeant  has been asked to supply information to U.S. legislators probing price hikes in the pharmaceutical industry.",
        "date": "03242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's hedge fund cooperating with U.S. on drug pricing probe -letter "
    },
    {
        "content": "NEW YORK  March 22 The business model of Valeant Pharmaceuticals International Inc  target of a securities investigation and under scrutiny for its pricing and accounting practices  \"was based on leverage and financial engineering \" fund manager Bill Gross of Janus Capital Group Inc  said Tuesday.",
        "date": "03222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Janus' Gross says Valeant based on leverage  financial engineering "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman  whose hedge fund is one of the biggest investors in drug company Valeant  has been asked to supply information to U.S. legislators probing price hikes in the pharmaceutical industry.",
        "date": "03242016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's hedge fund cooperating with U.S. on drug pricing probe: letter "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc's  largest stakeholder  Sequoia Fund  said it sold about 1.5 million shares of the company's stock last week  the Wall Street Journal reported on Monday.",
        "date": "03222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sequoia Fund sold 1.5 million Valeant shares: WSJ "
    },
    {
        "content": "March 21 Valeant Pharmaceuticals International Inc's largest stakeholder  Sequoia Fund  said it sold about 1.5 million shares of the company's stock last week  the Wall Street Journal reported on Monday.",
        "date": "03222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sequoia Fund sold 1.5 mln Valeant shares - WSJ "
    },
    {
        "content": "* Valeant Pharmaceuticals International Inc. 'B+' rating placed on CreditWatch Negative",
        "date": "03162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-S&P places Valeant Pharmaceuticals' 'B+' rating on CreditWatch Negative "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc's  shares plunged 50 percent on Tuesday after the company said a delay in filing its annual report put it in danger of a default on its $30 billion in debt. |\u00a0Video ",
        "date": "03162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant faces debt default risk; shares plunge 50 percent "
    },
    {
        "content": "BOSTON Hedge funds on Tuesday lost an estimated $5.3 billion on drugmaker Valeant Pharmaceuticals'  stock meltdown  with billionaire investors William Ackman and Jeffrey Ubben taking the brunt of the hit - losing  more than $700 million each  according to data from research firm Symmetric.IO. |\u00a0Video ",
        "date": "03162016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's stock rout serves up $5.3 billion in hedge fund losses "
    },
    {
        "content": "March 14 * ValueAct Capital CEO Jeff Ubben to CNBC - Oil could push to $100 by 2019  * ValueAct Capital CEO Jeff Ubben On Valeant to CNBC - CEO Pearson is the right guy for the job",
        "date": "03142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CORRECTED-BRIEF-ValueAct's Ubben says Valeant CEO Pearson is right guy for job-CNBC "
    },
    {
        "content": "WASHINGTON/NEW YORK A move by Valeant Pharmaceuticals International Inc  to single out two former top executives over its accounting problems is likely a bid to win leniency with government agencies investigating the drugmaker  according to accounting and securities experts.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant's harsh words on ex-executives may play into government probes "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman adjusted his battered hedge fund portfolio on Wednesday when he sold 20 million shares of snack maker Mondelez International   one day after another key holding  Valeant Pharmaceuticals   lost half of its value.",
        "date": "03172016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman sells part of Mondelez stake  has no plans for other sales "
    },
    {
        "content": "March 14 Stock futures pointed to a lower opening for Canada's main index on Monday as Brent crude prices fell below $40 a barrel after Iran dashed hopes that there would be a coordinated production freeze any time soon  returning bearish sentiment to the market over a glut that has sent prices crashing.",
        "date": "03142016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Futures lower as oil prices fall "
    },
    {
        "content": "WASHINGTON/NEW YORK  March 21 A move by Valeant Pharmaceuticals International Inc to single out two former top executives over its accounting problems is likely a bid to win leniency with government agencies investigating the drugmaker  according to accounting and securities experts.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's harsh words on ex-executives may play into govt probes "
    },
    {
        "content": "TORONTO  March 15 Canada's main stock index fell on Tuesday as Valeant Pharmaceuticals International Inc  tanked  overshadowing gains for gold miners and financials ahead of a Federal Reserve interest rate decision on Wednesday.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as Valeant plunge offsets gains for gold miners  financials "
    },
    {
        "content": "* Sequoia Fund  Valeant Pharmaceutical's Largest Shareholder  Sold 1.5m Shares Of Vrx Last Week - CNBC  CITING DJ   Further company coverage:    )",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Sequoia fund  Valeant Pharma's largest shareholder  sold 1.5 mln shares of Valeant last week - CNBC  citing DJ "
    },
    {
        "content": "NEW YORK  March 21 Options traders in U.S.-listed shares of Valeant Pharmaceuticals International Inc  are bracing for more volatility  as changes to the drugmaker's management and board did little to ease uncertainty about the stock's direction.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Options traders still see huge risk after Valeant CEO ouster "
    },
    {
        "content": "BOSTON  March 15 Hedge funds on Tuesday lost an estimated $5.3 billion on drugmaker Valeant Pharmaceuticals'  stock meltdown  with billionaire investors William Ackman and Jeffrey Ubben taking the brunt of the hit - losing  more than $700 million each  according to data from research firm Symmetric.IO.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's stock rout serves up $5.3 billion in hedge fund losses "
    },
    {
        "content": "TORONTO  March 15 Canada's main stock index fell on Tuesday as shares of Valeant Pharmaceuticals International Inc tanked  offsetting gains for the broader market ahead of a Federal Reserve interest rate decision on Wednesday.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as Valeant plunge offsets broader gains "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    target of a securities investigation and under scrutiny for its pricing and accounting practices  said on Monday that its longtime chief executive officer was leaving just three weeks after returning from a medical leave.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "TIMELINE: Shakeup at Valeant as longtime CEO Pearson leaving "
    },
    {
        "content": "March 21 Valeant Pharmaceuticals International Inc   target of a securities investigation and under scrutiny for its pricing and accounting practices  said on Monday that its longtime chief executive officer was leaving just three weeks after returning from a medical leave.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "TIMELINE-Shakeup at Valeant as longtime CEO Pearson leaving "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    which has been under scrutiny over its pricing and accounting practices  cut its 2016 sales and earnings forecast on Monday  and said a delay in filing its annual report put it in danger of a default on its $30 billion debt.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Timeline: More trouble for Valeant as possible debt default looms "
    },
    {
        "content": "March 15 Valeant Pharmaceuticals International Inc's shares plunged 50 percent on Tuesday after the company said a delay in filing its annual report put it in danger of a default on its $30 billion in debt.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Drugmaker Valeant faces debt default risk; shares plunge 50 pct "
    },
    {
        "content": "NEW YORK  March 11 Drug company Valeant Pharmaceuticals Inc is under pressure from investors to introduce more transparency into its operations and expand its management ranks to regain credibility in the investment community  people familiar with the situation said.",
        "date": "03112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant under pressure to beef up management as new board meets "
    },
    {
        "content": "NEW YORK  March 8 Embattled drug company Valeant Pharmaceuticals International Inc  whose stock price has tumbled 38 percent this year  will appoint three new board members as soon as Wednesday  people familiar with the matter said on Tuesday.",
        "date": "03082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant to appoint three new directors as soon as Wednesday - sources "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    the subject of intense scrutiny over its business practices and pricing policies  said it would release preliminary quarterly results and guidance on March 15  raising hopes the company will serve up some positive news after months of uncertainty.",
        "date": "03072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant sets earnings date  shares jump on hope for positive news "
    },
    {
        "content": "March 15 Valeant Pharmaceuticals International Inc   which has been under scrutiny over its pricing and accounting practices  cut its 2016 sales and earnings forecast on Monday  and said a delay in filing its annual report put it in danger of a default on its $30 billion debt.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "TIMELINE-More trouble for Valeant as possible debt default looms "
    },
    {
        "content": "March 15 Valeant Pharmaceuticals International Inc",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says best estimate on filing 10k is in April "
    },
    {
        "content": "TORONTO  March 21 Canada's main stock index ended higher on Monday  helped by rising banks and telecom stocks and by a surge in Valeant Pharmaceuticals International Inc after it parted ways with its CEO and invited an activist investor to its board.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as banks  telecoms gain; Valeant surges "
    },
    {
        "content": "March 21 Valeant Pharmaceuticals International Inc :",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO ouster not a mutual decision - CNBC  citing source "
    },
    {
        "content": "NEW YORK  March 8 Embattled drug company Valeant Pharmaceuticals  whose stock price has tumbled 38 percent this year  is mulling giving board seats to activist hedge fund Pershing Square Capital Management  one of its biggest investors  and two other people  a person familiar with the matter said.",
        "date": "03082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant mulls 3 new directors including one from Pershing Square - source "
    },
    {
        "content": "* Dow up 0.3 pct  S&P off 0.07 pct  Nasdaq down 0.4 pct   (Updates to late afternoon)",
        "date": "03072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-S&P 500 flat as energy spike offsets tech slide "
    },
    {
        "content": "* Indexes up: Dow 0.42 pct  S&P 0.17 pct  Nasdaq 0.13 pct   (Updates to early afternoon)",
        "date": "03072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St set for five-day winning streak as oil surges "
    },
    {
        "content": "March 15 Valeant Pharmaceuticals International Inc will attempt next week with bank lenders to extend deadline for annual and first-quarter reports",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant seeks to extend deadline for filing reports "
    },
    {
        "content": "March 15 Orexigen Therapeutics Inc said it agreed to buy the U.S. rights to its flagship obesity drug from partner Takeda Pharmaceutical Co Ltd and will tap Canada's Valeant Pharmaceutical International Inc to sell the pill in parts of Europe.",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Orexigen buys U.S. obesity pill rights from Takeda  partners Valeant "
    },
    {
        "content": "March 21 Embattled Canadian drugmaker Valeant Pharmaceuticals International Inc  said on Monday Chief Executive Michael Pearson would step down and that the company had appointed activist investor William Ackman to its board.",
        "date": "03212016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says CEO Pearson to step down  names Ackman to board "
    },
    {
        "content": "March 10 A U.S. congressional committee stepped up the pressure on Valeant Pharmaceuticals International Inc   on Thursday  urging the company to explain why it was withholding documents related to an investigation into drug pricing.",
        "date": "03102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. panel asks Valeant to justify withholding documents "
    },
    {
        "content": "March 7 Valeant Pharmaceuticals International Inc   the subject of intense scrutiny over its business practices and pricing policies  said it would release preliminary quarterly results and guidance on March 15  raising hopes the company will serve up some positive news after months of uncertainty.",
        "date": "03072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant sets earnings date  shares jump on hope for positive news "
    },
    {
        "content": "March 7 Valeant Pharmaceuticals International Inc  said it would release preliminary fourth-quarter results on March 15  followed by a conference call on the same day.",
        "date": "03072016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to release 4th-qtr results on March 15 "
    },
    {
        "content": "* \u007fOrexigen will retain regulatory affairs responsibilities in EU countries\u007f",
        "date": "03152016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Orexigen announces commercialization and distributorship deal with Valeant for Mysimba "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    responding to investors' queries  said on Thursday that Executive Vice President Deb Jorn had not been asked to leave  reiterating that she had resigned for personal reasons.",
        "date": "03032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant reiterates key executive resigned  was not asked to go "
    },
    {
        "content": "Embattled Valeant Pharmaceuticals International Inc   said on Wednesday it has added a representative from shareholder Pershing Square Capital Management to its board of directors as well as two other new directors. |\u00a0Video ",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant gives Pershing Square 1 board seat  adds 2 other directors "
    },
    {
        "content": "NEW YORK A U.S. regulatory probe of Valeant Pharmaceuticals International Inc   disclosed by the company on Monday  is focused on the drugmaker's relationship with specialty pharmacy Philidor RX Services and was triggered by Valeant\u2019s own request that regulators investigate a short seller's allegations  people familiar with the matter said.",
        "date": "03022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Exclusive: SEC probe of Valeant began with review of short seller - sources "
    },
    {
        "content": "Feb 29 Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission.",
        "date": "03012016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant shares slide on news of probe by U.S. SEC "
    },
    {
        "content": "March 10 A U.S. congressional committee stepped up the pressure on Valeant Pharmaceuticals International Inc   on Thursday  urging the company to explain why it was withholding documents related to an investigation into drug pricing.",
        "date": "03102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-U.S. panel asks Valeant to justify withholding documents "
    },
    {
        "content": "* U.S.-listed stock fall about 3 percent   (Adds analyst comment  detail)",
        "date": "03032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant reiterates key executive resigned  was not asked to go "
    },
    {
        "content": "March 9 Embattled Valeant Pharmaceuticals International Inc  said on Wednesday it has added a representative from shareholder Pershing Square Capital Management to its board of directors as well as two other new directors.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant gives Pershing Square 1 board seat  adds 2 other directors "
    },
    {
        "content": "TORONTO  March 9 Canada's main stock index gained on Wednesday  with bank and energy stocks up as the Bank of Canada held rates steady and oil prices rose  while Valeant  shares jumped after the drugmaker added an activist investor to its board.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX up with oil; energy  banking stocks  Valeant lead way "
    },
    {
        "content": "March 2 Canada's main stock index was poised to open lower on Wednesday  after four days of gains  as oil prices slipped after a U.S. industry report showed crude stockpiles rose to a record.",
        "date": "03022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Futures lower as oil prices retreat "
    },
    {
        "content": "NEW YORK A U.S. regulatory probe of Valeant Pharmaceuticals International Inc  disclosed by the company on Monday  is focused on the drugmaker's relationship with specialty pharmacy Philidor RX Services and was triggered by Valeant's own request that regulators investigate a short seller's allegations  people familiar with the matter said.",
        "date": "03022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "SEC probe of Valeant began with review of short seller -sources "
    },
    {
        "content": "March 10 Valeant Pharmaceuticals International Inc:",
        "date": "03102016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant says did not produce documents to Oversight Committee  cites attorney-client privilege "
    },
    {
        "content": "Feb 29 Shares in Valeant Pharmaceuticals International Inc fell as much as 21 percent on Monday after the embattled drugmaker revealed that it was under investigation by the U.S. Securities and Exchange Commission.",
        "date": "02292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "REFILE-UPDATE 3-Valeant shares slide on news of probe by U.S. SEC "
    },
    {
        "content": "March 3 Canadian drugmaker Valeant Pharmaceuticals International Inc  on Thursday reiterated that executive vice president Deb Jorn had resigned for personal reasons  and had not been asked to leave.",
        "date": "03032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant reiterates exec VP Deb Jorn resigned for personal reasons "
    },
    {
        "content": "March 2 Valeant Pharmaceuticals International Inc  said it appointed Ari Kellen executive vice president  succeeding Deb Jorn who has resigned  effective immediately.",
        "date": "03032016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant appoints Ari Kellen executive vice president "
    },
    {
        "content": "March 9 Valeant Pharmaceuticals International Inc   under scrutiny for its accounting and business practices  said it had given shareholder Pershing Square Capital Management a seat on its board and added two additional directors.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gives Pershing Square a seat on its board "
    },
    {
        "content": "TORONTO  Feb 29 Canada's main stock index ended higher on Monday  with gains for energy companies due to rise in oil offsetting a plunge in shares of Valeant Pharmaceuticals International Inc after the drug company said it was being probed by a U.S. securities regulator.",
        "date": "02292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as energy gains offset slump in Valeant "
    },
    {
        "content": "Feb 29 Shares in embattled drugmaker Valeant Pharmaceuticals International Inc  fell 9 percent on Monday a day after the company said its chief executive officer had returned from medical leave  canceled the release of fourth-quarter earnings  and withdrew 2016 financial guidance.",
        "date": "02292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares drop as CEO returns  cancels earnings report "
    },
    {
        "content": "NEW YORK Embattled drug company Valeant Pharmaceuticals International Inc  whose stock price has tumbled 38 percent this year  will appoint three new board members as soon as Wednesday  people familiar with the matter said on Tuesday.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to appoint three new directors as soon as Wednesday: sources "
    },
    {
        "content": "NEW YORK Billionaire investor Bill Ackman on Tuesday called embattled drug company Valeant Pharmaceuticals a \"very valuable asset\" but forecast that if the company's situation does not stabilize soon new management will be brought in or the company will be sold.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Fund manager Ackman calls Valeant 'very valuable asset' "
    },
    {
        "content": "The health of Valeant Pharmaceuticals International Inc's  Michael Pearson is improving  the company said on Thursday  but CNBC reported that there was debate within the board over whether he was ready to return to work.",
        "date": "02252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant board debating Pearson's return as health improves: CNBC "
    },
    {
        "content": "NEW YORK  March 8 Billionaire investor Bill Ackman on Tuesday called embattled drug company Valeant Pharmaceuticals a \"very valuable asset\" but forecast that if the company's situation does not stabilize soon new management will be brought in or the company will be sold.",
        "date": "03092016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Fund manager Ackman calls Valeant 'very valuable asset' "
    },
    {
        "content": "Feb 25 The health of Valeant Pharmaceuticals International Inc's Michael Pearson is improving  the company said on Thursday  but CNBC reported that there was debate within the board over whether he was ready to return to work.",
        "date": "02252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant board debating Pearson's return as health improves-CNBC "
    },
    {
        "content": "Feb 22 U.S.-listed shares of Valeant Pharmaceuticals International Inc  slumped as much as 13 percent on Monday  the second consecutive day of steep declines  wiping out more than $6 billion in market value since Thursday's close.",
        "date": "02222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares sink for second straight day "
    },
    {
        "content": "Shares of Valeant Pharmaceuticals International Inc  rose 9 percent on Tuesday  the morning after the drugmaker said a board committee investigation into its dealings with distributor Philidor Rx Services would result in a profit restatement.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant shares jump 9 percent after announcement of plans to restate "
    },
    {
        "content": "Feb 22 Shares of Valeant Pharmaceuticals International Inc  slumped about 18 percent on Monday  the second consecutive day of steep declines  wiping out more than $6 billion in the Canadian drugmaker's market value since Thursday.",
        "date": "02222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant shares sink for second straight day "
    },
    {
        "content": "Feb 23 Johnson & Johnson was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-J&J must pay $72 mln for cancer death linked to talcum powder - lawyers "
    },
    {
        "content": "Feb 23 Shares of Valeant Pharmaceuticals International Inc rose 9 percent on Tuesday  the morning after the drugmaker said a board committee investigation into its dealings with distributor Philidor Rx Services would result in a profit restatement.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant shares jump 9 pct after announcement of plans to restate "
    },
    {
        "content": "Feb 22 Valeant Pharmaceuticals International Inc  is expected to restate its earnings after an internal review that likely concerns sales of its drugs to specialty pharmacy Philidor Rx Services  CNBC reported  citing Dow Jones.",
        "date": "02222016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to restate earnings after internal review-CNBC  citing DJ "
    },
    {
        "content": "Feb 23 Johnson & Johnson was ordered by a Missouri state jury to pay $72 million of damages to the family of a woman whose death from ovarian cancer was linked to her use of the company's talc-based Baby Powder and Shower to Shower for several decades.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "J&J must pay $72 mln for cancer death linked to talcum powder -lawyers "
    },
    {
        "content": "Feb 23 Shares of Valeant Pharmaceuticals International Inc were up more than 6 percent in early U.S. trading on Tuesday following a two-day selloff  with some analysts saying that selling of the Canadian drugmaker's stock had been overdone.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares recover a bit after two-day slide "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  said it would restate its financial results for 2014 and 2015 after identifying some sales to Philidor that should have been recognized when products were dispensed to patients.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to restate results after Philidor review "
    },
    {
        "content": "Feb 22 Valeant Pharmaceuticals International Inc  said it would restate its financial results for 2014 and 2015 after identifying some sales to Philidor that should have been recognized when products were dispensed to patients.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to restate results after Philidor review "
    },
    {
        "content": "Feb 22 Valeant Pharmaceuticals International Inc  said it would restate its financial results for 2014 and 2015 after identifying some sales to Philidor that should have been recognized when products were dispensed to patients.",
        "date": "02232016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-Valeant to restate results after Philidor review "
    },
    {
        "content": "NEW YORK  Jan 29 Express Scripts Holding Co   the U.S. No. 1 pharmacy benefits manager  said on Friday it would stop covering Glumetza  a diabetes drug made by Valeant Pharmaceuticals International Inc  after a generic competitor enters the market on Feb. 1.",
        "date": "01292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Express Scripts drops coverage of Valeant diabetes drug Glumetza "
    },
    {
        "content": "A decision by Turing Pharmaceuticals to increase profits by raising the price of a lifesaving drug by 5 000 percent drove some patient co-pays up to $16 000  according to excerpts of documents that congressional committee members made public on Tuesday.",
        "date": "02022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Documents show profit-seeking behind price hikes at Turing  Valeant "
    },
    {
        "content": "Shares of Valeant Pharmaceuticals International Inc  jumped 6 percent on Friday  after the company responded to criticism by Democratic presidential contender Hillary Clinton over price hikes for its migraine drug.",
        "date": "01292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant defends price hikes after Clinton remarks; shares jump "
    },
    {
        "content": "Shares of Valeant Pharmaceuticals International Inc  fell on Thursday after the campaign of Democratic presidential contender Hillary Clinton posted a blog from an Iowa event detailing exorbitant price hikes for a migraine drug made by the company.",
        "date": "01292016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Clinton targets Valeant price hikes in campaign appearance "
    },
    {
        "content": "WASHINGTON/NEW YORK  Feb 2 A decision by Turing Pharmaceuticals to increase profits by raising the price of a lifesaving drug by 5 000 percent drove some patient co-pays up to $16 000  according to excerpts of documents that congressional committee members made public on Tuesday.",
        "date": "02022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Documents show profit-seeking behind price hikes at Turing  Valeant "
    },
    {
        "content": "Jan 28 Shares of Valeant Pharmaceuticals International Inc fell on Thursday after the campaign of Democratic presidential contender Hillary Clinton posted a blog from an Iowa event detailing exorbitant price hikes for a migraine drug made by the company.",
        "date": "01282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Clinton targets Valeant price hikes in campaign appearance "
    },
    {
        "content": "BOSTON  Jan 26 Sitting on a double-digit loss that is the deepest in his firm's history  billionaire investor Bill Ackman on Tuesday told investors that he made mistakes last year in not cutting two big positions but said he sees plenty of new investment opportunities.",
        "date": "01272016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman acknowledges mistakes in 2015  details changes in portfolio "
    },
    {
        "content": "WASHINGTON/NEW YORK  Feb 2 A decision by Turing Pharmaceuticals to raise the price of a lifesaving drug by 5 000 percent drove up some patient co-pays to as high as $16 000  according to excerpts of documents that congressional committee members released on Tuesday.",
        "date": "02022016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Newly released documents show profit-seeking behind price hikes at Turing  Valeant "
    },
    {
        "content": "Jan 28 Shares of Valeant Pharmaceuticals International Inc fell on Thursday after the campaign of Democratic presidential contender Hillary Clinton posted a blog from an Iowa event detailing exorbitant price hikes for a migraine drug made by the company.",
        "date": "01282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Clinton targets Valeant price hikes in campaign appearance "
    },
    {
        "content": "Jan 25 Valeant Pharmaceuticals International Inc's ailing chief executive  Michael Pearson  said he was on the road to recovery but was uncertain about when he would return from medical leave.",
        "date": "01252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's Pearson says timing of return uncertain "
    },
    {
        "content": "PALM BEACH  Fla. Hedge funds are starting the year off negative.",
        "date": "01282016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Bearish views abound at elite hedge fund conference "
    },
    {
        "content": "* Unexpected complications resulted in longer hospital stay-Pearson",
        "date": "01252016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant's Pearson says timing of return uncertain "
    },
    {
        "content": "Jan 13 Valeant Pharmaceuticals International Inc   sought  on Wednesday to win back investors  pitching the beleaguered company's plans to grow revenues internally and sell drugs through pharmacy chain Walgreens.",
        "date": "01132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant Pharmaceuticals woos investors  stock dips "
    },
    {
        "content": "Jan 13 Valeant Pharmaceuticals International Inc  :",
        "date": "01132016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant Pharmaceuticals says no update on CEO's health "
    },
    {
        "content": "NEW YORK  Jan 11 The investment firm that runs the Sequoia Fund  long known for its ties to Warren Buffett  was sued by shareholders who claim it recklessly took a huge stake in embattled drug company Valeant Pharmaceuticals International Inc  causing more than $2 billion in losses.",
        "date": "01112016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Sequoia Fund is sued over big Valeant stake "
    },
    {
        "content": "TORONTO  Jan 8 Canada's benchmark stock index dropped slightly on Friday as mining stocks weakened and Valeant Pharmaceuticals International Inc shed more than 6 percent  while energy stocks firmed despite a drop in crude oil prices.",
        "date": "01082016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX dips as mining stocks  Valeant weigh  energy stocks gain "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc on Wednesday named board member and former Chief Financial Officer Howard Schiller as interim chief executive to replace Michael Pearson  who has been hospitalized with severe pneumonia since late December.",
        "date": "01062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant names interim CEO; timing of Pearson's return unknown "
    },
    {
        "content": "Jan 6 Valeant Pharmaceuticals International Inc  on Wednesday named board member and former Chief Financial Officer Howard Schiller as interim chief executive to replace Michael Pearson  who has been hospitalized with severe pneumonia since late December.",
        "date": "01062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant names interim CEO; timing of Pearson's return unknown "
    },
    {
        "content": "Jan 6 Canadian drugmaker Valeant Pharmaceuticals International Inc  appointed Howard Schiller its interim chief executive  effective immediately.",
        "date": "01062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant appoints Howard Schiller interim CEO "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   will appoint an interim chief executive officer to replace Michael Pearson who is hospitalized  a source familiar with the matter told Reuters  news that sent shares down 7 percent on Tuesday.   The source did not clarify whether the CEO would be temporary or would permanently replace Pearson  56  who is recovering from a severe case of pneumonia.",
        "date": "01062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to appoint interim CEO as Pearson remains hospitalized: source "
    },
    {
        "content": "Jan 5 Valeant Pharmaceuticals International Inc   will appoint an interim chief executive officer to replace Michael Pearson who is hospitalized  a source familiar with the matter told Reuters  news that sent shares down 7 percent on Tuesday.",
        "date": "01062016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant to appoint interim CEO as Pearson remains hospitalized - source "
    },
    {
        "content": "TORONTO  Dec 29 Canada's main stock index ended lower on Tuesday amid weakness in resource stocks and a deep drop in Valeant Pharmaceuticals International Inc as the market played catch-up with Wall Street following an extended Christmas break.",
        "date": "12292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as resource stocks drag  Valeant slumps "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   is planning to appoint a new CEO as Chief Executive Michael Pearson remains hospitalized  the Wall Street Journal said  citing people familiar with the matter.",
        "date": "01052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant plans to appoint new CEO as Pearson remains hospitalized: WSJ "
    },
    {
        "content": "TORONTO  Dec 29 Canada's main stock index retreated on Tuesday amid weakness in mining stocks and a greater than 9 percent drop in Valeant Pharmaceuticals International Inc as the market reopened following an extended Christmas break.",
        "date": "12292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as mining stocks  Valeant weigh "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc  on Monday said a group of company executives will immediately take over for its chief executive officer until he returns from medical leave  news that sent its shares tumbling 10 percent.",
        "date": "12292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant selects trio to fill in for ailing CEO; shares dive "
    },
    {
        "content": "Jan 5 Valeant Pharmaceuticals International Inc   is planning to appoint a new CEO as Chief Executive Michael Pearson remains hospitalized  CNBC tweeted  citing Dow Jones.",
        "date": "01052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant planning to appoint a new CEO - CNBC  citing Dow Jones "
    },
    {
        "content": "BOSTON Billionaire investor William Ackman's Pershing Square Holdings hedge fund ended 2015 with a 20.5 percent loss after Valeant Pharmaceuticals   a top holding  was battered in the second half of the year.",
        "date": "01052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square ends 2015 with 20.5 pct drop "
    },
    {
        "content": "NEW YORK  Dec 28 Valeant Pharmaceuticals International Inc  on Monday said a group of company executives will immediately take over for its chief executive officer until he returns from medical leave  news that sent its shares tumbling 10 percent.",
        "date": "12292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant selects trio to fill in for ailing CEO; shares dive "
    },
    {
        "content": "BOSTON  Jan 5 Billionaire investor William Ackman's Pershing Square Holdings hedge fund ended 2015 with a 20.5 percent loss after Valeant Pharmaceuticals  a top holding  has battered in the second half of the year.",
        "date": "01052016",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square Holdings ends 2015 down 20.5 pct "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc  on Monday said a group of company executives will immediately take over for its chief executive officer until he returns from medical leave  news that sent its shares tumbling 10 percent.",
        "date": "12282015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant selects trio to fill in for ailing CEO  shares dive "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc  Chief Executive J. Michael Pearson has been moved to another hospital where he is being treated for a severe case of pneumonia  a company spokeswoman told Bloomberg on Sunday.",
        "date": "12272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant CEO Pearson remains hospitalized for pneumonia: Bloomberg "
    },
    {
        "content": "NEW YORK  Dec 28 Valeant Pharmaceuticals International Inc  on Monday said a group of company executives will immediately take over for its chief executive officer until he returns from medical leave  news that sent its shares tumbling 10 percent.",
        "date": "12282015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant selects trio to fill in for ailing CEO  shares dive "
    },
    {
        "content": "NEW YORK  Dec 27 Valeant Pharmaceuticals International Inc Chief Executive J. Michael Pearson has been moved to another hospital where he is being treated for a severe case of pneumonia  a company spokeswoman told Bloomberg on Sunday.",
        "date": "12272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO Pearson remains hospitalized for pneumonia- Bloomberg "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc  Chief Executive J. Michael Pearson was hospitalized with a \"severe case of pneumonia\" on Friday and is receiving treatment  a company spokeswoman said.",
        "date": "12252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant says CEO J. Michael Pearson hospitalized with severe pneumonia "
    },
    {
        "content": "NEW YORK  Dec 25 Valeant Pharmaceuticals International Inc Chief Executive J. Michael Pearson was hospitalized with a \"severe case of pneumonia\" on Friday and is receiving treatment  a company spokeswoman said.",
        "date": "12252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant says CEO J. Michael Pearson hospitalized with severe pneumonia "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals Chief Executive J. Michael Pearson was hospitalized with severe pneumonia on Friday  the New York Times reported  citing a company spokeswoman.",
        "date": "12252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO J. Michael Pearson hospitalized with severe pneumonia - NYT "
    },
    {
        "content": "NEW YORK  Dec 25 Valeant Pharmaceuticals  Chief Executive J. Michael Pearson was hospitalized with severe pneumonia on Friday  the New York Times reported  citing a company spokeswoman.",
        "date": "12252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO J. Michael Pearson hospitalized with severe pneumonia -NYT "
    },
    {
        "content": "Drugmaker Valeant Pharmaceuticals International Inc   on Wednesday said that fourth-quarter profit was hit when it cut ties with pharmacy Philidor Rx Services  but that it could contain the damage next year and grow profit.",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant says can contain hit to dermatology  projects 2016 growth "
    },
    {
        "content": "BOSTON  Dec 16 Billionaire hedge fund investor William Ackman  whose funds have suffered double-digit losses this year  on Tuesday told investors that 2015 could be his firm's worst ever  but said clients are generally sticking with him.",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Ackman tells investors that this year could be his firm's worst ever "
    },
    {
        "content": "* Shares rise 8 percent   (Adds detail from meeting  CVS Health comment)",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant says can contain hit to dermatology  projects 2016 growth "
    },
    {
        "content": "TORONTO  Dec 15 Canada's main stock index bounded higher off 2013 lows on Tuesday  helped by big gains in the energy sector as crude oil halted a slide to 11-year lows and shares in Valeant Pharmaceuticals International Inc  surged 16 percent.",
        "date": "12152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX jumps off 2013 lows as energy bounces  Valeant soars "
    },
    {
        "content": "* Valeant CEO says company is not contemplating a break-up    (Reporting By Caroline Humer)",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says company is not exploring any divestitures "
    },
    {
        "content": "WASHINGTON Democrats on a U.S. House of Representatives panel are planning to call Valeant Pharmaceuticals Chief Executive Michael Pearson to testify in early 2016 about steep price hikes for some of the company's drugs  a Democratic aide said.",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "House Democrats to seek testimony from Valeant in coming weeks "
    },
    {
        "content": "Reuters) - Valeant Pharmaceuticals International Inc on Tuesday said it reached a deal to distribute its drugs through leading pharmacy chain Walgreens Boots Alliance Inc  boosting credibility with wary investors and sending its shares up 17 percent.",
        "date": "12152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets boost from new distribution deal with Walgreens "
    },
    {
        "content": "* Deal with Walgreens more than replaces Philidor-Valeant CEO",
        "date": "12152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant gets boost from new distribution deal with Walgreens "
    },
    {
        "content": "* CEO says will get back to acquisitions  but not next year  when it will focus on paying down debt instead - CNBC",
        "date": "12152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says will get back to acquisitions - but not next year "
    },
    {
        "content": "WASHINGTON  Dec 16 Democrats on a U.S. House of Representatives panel are planning to call Valeant Pharmaceuticals Chief Executive Michael Pearson to testify in early 2016 about steep price hikes for some of the company's drugs  a Democratic aide said.",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-U.S. House Democrats to seek testimony from Valeant in coming weeks "
    },
    {
        "content": "* Valeant CEO says will not budget research and development as a certain percentage of sales  but will review it regularly",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says double digit organic growth will continue "
    },
    {
        "content": " (In December 13 item  corrects first paragraph to delete reference to Valeant as a U.S. company)",
        "date": "12142015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant hires attorney  crisis management firm as U.S. scrutiny mounts "
    },
    {
        "content": "WASHINGTON/NEW YORK Dec 13 U.S. pharmaceuticals firm Valeant  under mounting pressure from Congress and prosecutors over its drug pricing  has hired an attorney in Washington  DC and crisis public relations experts with political connections  according to sources familiar with the matter.",
        "date": "12132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant hires attorney  crisis management firm as U.S. scrutiny mounts "
    },
    {
        "content": "Dec 15 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it signed a deal to distribute its skin and eye products at a discount in more than 8 000 Walgreens Boots Alliance Inc  retail pharmacy locations.",
        "date": "12152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant signs distribution deal with Walgreens  offers price cuts "
    },
    {
        "content": "WASHINGTON  Dec 16 Democrats on a U.S. House of Representatives panel are planning to call Valeant Pharmaceuticals Chief Executive Michael Pearson to testify in early 2016 about steep price hikes for some of the company's drugs  a Democratic aide said.",
        "date": "12162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. House Democrats to seek testimony from Valeant in coming weeks "
    },
    {
        "content": "WASHINGTON/NEW YORK Dec 14 Pharmaceuticals firm Valeant  under mounting pressure from Congress and prosecutors over its drug pricing  has hired an attorney in Washington  DC and crisis public relations experts with political connections  according to sources familiar with the matter.",
        "date": "12142015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CORRECTED-Valeant hires attorney  crisis management firm as U.S. scrutiny mounts "
    },
    {
        "content": "WASHINGTON/NEW YORK A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection.",
        "date": "12092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Senate panel focuses on toll of Valeant  Turing drug price spikes "
    },
    {
        "content": "Valeant Pharmaceuticals   is reaching out to potential buyers for its specialty contact lens manufacturing division  Paragon Vision Sciences  amid scrutiny from the Federal Trade Commission  according to two people familiar with the matter.",
        "date": "12082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Exclusive: Valeant considers selling contact lens maker Paragon - sources "
    },
    {
        "content": "WASHINGTON/NEW YORK  Dec 9 A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection.",
        "date": "12092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Senate panel focuses on toll of Valeant  Turing drug price spikes "
    },
    {
        "content": "WASHINGTON  Dec 9 A pediatric doctor in Alabama had to scramble to find a less expensive supply of a lifesaving drug to treat an infant who was suffering from a parasitic infection.",
        "date": "12092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Medical professionals to discuss toll of Valeant  Turing drug price spikes "
    },
    {
        "content": "Activist investor Bill Ackman's hedge fund has significantly increased its investment in Valeant Pharmaceuticals International   and signaled it may play a greater role in the beleaguered drugmaker\u2019s strategy  according to a regulatory filing.",
        "date": "11232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman boosts stake in drugmaker Valeant "
    },
    {
        "content": "Nov 23 Bill Ackman's Pershing Square Capital Management raised its stake in Valeant Pharmaceuticals International Inc  to 9.9 percent  making it the second largest shareholder in the company.",
        "date": "11232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman raises stake in Valeant Pharma "
    },
    {
        "content": "BOSTON Hedge fund managers' favorite stocks stumbled hard this year to post their worst returns since the financial crisis with health-care companies  such as Valeant Pharmaceuticals   leading the way lower  according to new data from Goldman Sachs.",
        "date": "11232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Hedge funds' favorite stocks lag broader market: Goldman data "
    },
    {
        "content": "Nov 20 Valeant Pharmaceuticals International Inc   said on Friday that it would host its investor day on Dec. 16 to discuss its financial guidance and business operations.",
        "date": "11202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant to host investor day on Dec. 16  discuss forecast  business "
    },
    {
        "content": "TORONTO  Nov 19 Canada's main stock index rose on Thursday  led by a surge in Valeant Pharmaceuticals International Inc and helped by gains for gold miners and financial stocks.",
        "date": "11192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises on mining  financial gains; Valeant surges "
    },
    {
        "content": "NEW YORK  Nov 16 Some of the world's biggest hedge funds extended bets on Valeant during the third quarter  only weeks before the pharmaceutical company's stock went into a tailspin after criticism over its pricing strategy and accounting practices.",
        "date": "11162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Prominent funds piled into Valeant ahead of tailspin "
    },
    {
        "content": "NEW YORK Billionaire hedge fund manager William Ackman's Pershing Square Holdings portfolio has lost 24.5 percent this year  extending its fall this week as its biggest holding  Valeant Pharmaceuticals  declined further  the company said on its website.",
        "date": "11182015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square Holdings off 24.5 percent YTD "
    },
    {
        "content": "WASHINGTON  Nov 16 The top Democrat on a U.S. House of Representatives investigative panel is requesting interviews with a handful of executives at Valeant   who were directly involved in the operations of specialty pharmacy Philidor  according to a Nov 16 letter seen by Reuters.",
        "date": "11162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. congressman seeks interviews with Valeant employees tied to Philidor "
    },
    {
        "content": "NEW YORK  Nov 18 Billionaire hedge fund manager William Ackman's Pershing Square Holdings portfolio has lost 24.5 percent this year  extending its fall this week as its biggest holding  Valeant Pharmaceuticals  declined further  the company said on its website.",
        "date": "11182015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square Holdings off 24.5 pct YTD "
    },
    {
        "content": "* Valeant sees dermatology disruption after cuts Philidor ties",
        "date": "11132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Swedish drugmaker Meda could be hit by Valeant's pharmacy woes "
    },
    {
        "content": "NEW YORK Omega Advisors sold its stake in Valeant Pharmaceuticals International Inc  in recent weeks after buying more shares during the third quarter  the hedge fund's vice chairman said on Monday. |\u00a0Video ",
        "date": "11162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Hedge fund Omega sold entire stake in Valeant: Einhorn "
    },
    {
        "content": "NEW YORK Blackstone Group LP   which invests clients' money with William Ackman's Pershing Square Capital Management  is sticking with the hedge fund manager despite his heavy losses in Valeant Pharmaceuticals International Inc   said Tom Hill  president and chief executive officer of Blackstone Alternative Asset Management.",
        "date": "11162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Blackstone remains confident in Ackman's Pershing Square: Hill "
    },
    {
        "content": "Nov 18 Valeant Pharmaceuticals International Inc  will likely offer cash and stock incentives to more key U.S. staff as it aims to avoid mass departures from the heavily scrutinized company  a spokeswoman said on Wednesday.",
        "date": "11182015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to offer cash  stock to keep staff after turmoil "
    },
    {
        "content": "* Meda out-licensed its dermatological products Elidel and Xerese to Valeant in North America in 2011",
        "date": "11162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Meda says 2016 royalties from Valeant about half amount of 2015 "
    },
    {
        "content": "* Likely to make tuck-in acquisitions  but debt repayment the focus - spokeswoman",
        "date": "11182015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant seeing 'anxiety' among US staff  will expand retention program - spokeswoman "
    },
    {
        "content": "Cutting ties with a controversial specialty pharmacy will hurt the dermatology business of Valeant Pharmaceuticals International Inc  in the short term  the company's chief executive said on Tuesday.",
        "date": "11102015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant to feel sting of closing controversial pharmacy "
    },
    {
        "content": "Activist investor Bill Ackman said Valeant Pharmaceuticals International Inc's   stock was an \"extraordinary bargain\" given its low price.",
        "date": "11092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman says Valeant stock 'extraordinary bargain' "
    },
    {
        "content": "TORONTO/WINNIPEG  Nov 10 Valeant Pharmaceuticals International Inc  said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.",
        "date": "11102015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Drugmaker Valeant to feel sting of closing controversial pharmacy "
    },
    {
        "content": "Bill Ackman  Valeant Pharmaceuticals International Inc's   third-largest shareholder  said the Canadian drugmaker will likely use its free cash flow to pay down debt in the next 18 months.",
        "date": "11092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman says Valeant likely to pay down debt in the next 18 months "
    },
    {
        "content": "Nov 9 Bill Ackman  Valeant Pharmaceuticals International Inc's  third-largest shareholder  said the Canadian drugmaker will likely use its free cash flow to pay down debt in the next 18 months.",
        "date": "11092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Ackman says Valeant likely to pay down debt in the next 18 months "
    },
    {
        "content": "* Energy group falls 3 pct; industrials  materials  utilities down",
        "date": "11112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX lower as energy stocks  Valeant weigh "
    },
    {
        "content": "Nov 6 Large investors holding stock in Valeant Pharmaceuticals International Inc  are split over whether to support the embattled drug company's chief executive or to advocate for new leadership  as the company struggles to recover from a stock plunge sparked by allegations of faulty accounting.",
        "date": "11072015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant investors divided on fate of CEO Pearson "
    },
    {
        "content": "A U.S. judge said Valeant Pharmaceuticals International Inc   and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan Inc before making an unsuccessful takeover bid for the maker of Botox.",
        "date": "11122015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant  Ackman must face U.S. insider trading lawsuit "
    },
    {
        "content": "BOSTON  Nov 6 Concentrated bets on Valeant Pharmaceuticals  left some hedge funds nursing heavy losses last month when the industry darling's stock price tumbled nearly 50 percent.",
        "date": "11062015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Big bets on Valeant hit some hedge funds hard in October "
    },
    {
        "content": "Shares of Mallinckrodt Plc  closed down 17 percent after short-seller Citron Research called the drugmaker \"a far worse offender of the reimbursement system\" in a tweet.",
        "date": "11102015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Citron turns spotlight on Mallinckrodt  shares plunge "
    },
    {
        "content": "Nov 9 Activist investor Bill Ackman said Valeant Pharmaceuticals International Inc's  stock was an \"extraordinary bargain\" given its low price.",
        "date": "11092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman says Valeant stock \"extraordinary bargain\" "
    },
    {
        "content": "Nov 11 A U.S. judge said Valeant Pharmaceuticals International Inc  and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan Inc before making an unsuccessful takeover bid for the maker of Botox.",
        "date": "11112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant  Ackman must face U.S. insider trading lawsuit "
    },
    {
        "content": "BOSTON Concentrated bets on Valeant Pharmaceuticals   left some hedge funds nursing heavy losses last month when the industry darling's stock price tumbled nearly 50 percent.",
        "date": "11062015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Big bets on Valeant hit some hedge funds hard in October "
    },
    {
        "content": "BOSTON/NEW YORK Billionaire investor Bill Ackman expressed confidence in Valeant Pharmaceuticals International Inc's chief executive on Thursday as shares in the drugmaker fell as much as 20 percent to their lowest level since 2013 on concerns over its business practices.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows "
    },
    {
        "content": "NEW YORK Billionaire investor Carl Icahn made a cryptic reference suggesting he has an interest in embattled drug maker Valeant on Tuesday  and said he was speaking to U.S. politicians about a corporate cash repatriation law that would deter so-called tax inversion deals.",
        "date": "11032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Icahn nods at Valeant interest  pushes for cash repatriation law "
    },
    {
        "content": "NEW YORK/WASHINGTON A U.S. Senate panel on Wednesday launched a bipartisan probe into pharmaceutical pricing  seeking documents from four drugmakers including Valeant Pharmaceuticals and Turing Pharmaceuticals  companies embroiled in controversy over price hikes on lifesaving drugs.",
        "date": "11042015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. Senate panel probing Valeant  Turing over drug costs "
    },
    {
        "content": "BOSTON Concentrated bets on Valeant Pharmaceuticals   left some hedge funds nursing heavy losses last month when the industry darling's stock price tumbled nearly 50 percent.",
        "date": "11072015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Big bets on Valeant hit some hedge funds hard in October "
    },
    {
        "content": "BOSTON/NEW YORK  Nov 5 Billionaire investor Bill Ackman expressed confidence in Valeant Pharmaceuticals International Inc's chief executive on Thursday as shares in the drugmaker fell as much as 20 percent to their lowest level since 2013 on concerns over its business practices.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows "
    },
    {
        "content": "TORONTO  Nov 5 A plunge in shares of drugmaker Valeant and sharp retreats in several other companies on the back of disappointing earnings reports pushed Canada's main stock index lower on Thursday.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX weighed down by earnings disappointments; Valeant plunge "
    },
    {
        "content": "NEW YORK  Nov 3 Billionaire investor Carl Icahn made a cryptic reference suggesting he has an interest in embattled drug maker Valeant on Tuesday  and said he was speaking to U.S. politicians about a corporate cash repatriation law that would deter so-called tax inversion deals.",
        "date": "11032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Icahn nods at Valeant interest  pushes for cash repatriation law "
    },
    {
        "content": "NEW YORK  Nov 3 Just before Bill Ackman gave a presentation on Friday to defend one of his biggest investments  Valeant Pharmaceuticals  from allegations of accounting and insurance fraud  he was taunted by John Hempton  who runs a small hedge fund from Australia. It was the latest act in a long-running feud.",
        "date": "11032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's crisis fuels feud between Ackman and Australian fund manager Hempton "
    },
    {
        "content": "* Senate panel seeks information from four drugmakers on pricing",
        "date": "11042015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-U.S. Senate panel probing Valeant  Turing over drug costs "
    },
    {
        "content": "* Says agreement concerns exclusive promotion  distribution and sale  in Greece and Cyprus  of analgesic Algon from Valeant's unit PharmaSwiss Hellas",
        "date": "11112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Lavipharm signs long term agreement with Valeant Group "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc sought to reassure doctors on Monday that the company's decision to cut ties to a controversial specialty pharmacy would not disrupt doctors' ability to prescribe the company's drugs to patients.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Exclusive: Valeant sends letter to doctors  seeks to reassure over pharmacy ties "
    },
    {
        "content": "TORONTO  Nov 5 Canada's main stock index ended lower on Thursday  weighed down by a plunge in shares of drug maker Valeant Pharmaceuticals and disappointing reports from auto parts maker Magna International  pipeline operator Enbridge Inc and telecom company Telus Corp.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls on string of disappointing earnings  Valeant slumps "
    },
    {
        "content": "WASHINGTON The Democratic members of a U.S. House of Representatives investigative committee asked Republicans on Wednesday to call a vote to subpoena Valeant Pharmaceuticals and Turing Pharmaceuticals  amid accusations the companies wrongfully hiked the prices of lifesaving drugs.",
        "date": "11042015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "House oversight panel Democrats urge vote to subpoena Valeant  Turing "
    },
    {
        "content": "WASHINGTON  Nov 4 The Democratic members of a U.S. House of Representatives investigative committee asked Republicans on Wednesday to call a vote to subpoena Valeant Pharmaceuticals and Turing Pharmaceuticals  amid accusations the companies wrongfully hiked the prices of lifesaving drugs.",
        "date": "11042015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US House oversight panel Democrats urge vote to subpoena Valeant  Turing "
    },
    {
        "content": "TORONTO  Nov 2 Canada's main stock index gained on Monday as Valeant Pharmaceuticals International Inc  bounced on the absence of fresh allegations by short-selling Citron Research against the company. Resource stocks moved higher.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as Valeant rebounds  resource stocks gain "
    },
    {
        "content": "NEW YORK Influential short-selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals International Inc  on Monday as many investors had anticipated  giving the beleaguered shares of the Canadian drugmaker a boost.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Citron publishes no new allegations against Valeant  shares rise "
    },
    {
        "content": "Shares of PDL BioPharma Inc fell to their record low  a day after the company said Valeant Pharmaceuticals International Inc delayed royalty payments for diabetes pill  Glumetza  hurting its quarterly results.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "PDL BioPharma says Valeant delayed royalties on diabetes pill "
    },
    {
        "content": "NEW YORK  Nov 5 Valeant Pharmaceuticals International Inc  shares fell as much as 20 percent on Thursday  building on weeks of steep losses over concerns about its ties to specialty pharmacy Philidor Rx Services  which is accused of improperly boosting sales of Valeant drugs.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares tumble 20 percent  retrace ground to 2013 levels "
    },
    {
        "content": "BOSTON  Oct 30 Hedge fund billionaire William Ackman spent nearly four hours on Friday trying to convince the world that drug maker Valeant was a good buy but it was short-seller Andrew Left's tweet promising fresh allegations about the Canadian company that got noticed.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman lecture no match for Citron tweet as Valeant tumbles anew "
    },
    {
        "content": "Valeant Pharmaceuticals Inc. sustained hits on several fronts on Thursday after CVS Health Corp and Express Scripts dropped Philidor from their networks in a sign the fallout from the drugmaker's connection with the specialty pharmacy is spreading.",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CVS  Express Scripts drop Valeant's Philidor; stock dives "
    },
    {
        "content": "NEW YORK  Nov 2 Influential short-selling firm Citron Research did not publish new allegations against Valeant Pharmaceuticals International Inc on Monday as many investors had anticipated  giving the beleaguered shares of the Canadian drugmaker a boost.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Citron publishes no new allegations against Valeant  shares rise "
    },
    {
        "content": "TORONTO  Nov 5 Canada's main stock index fell on Thursday as a string of disappointing earnings reports and a fresh slump in drug maker Valeant offset gains among energy stocks as oil prices edged higher.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as Valeant  Magna plunge "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   seeking to allay investor concerns about its business practices  said Friday it is cutting ties with a specialty pharmacy called Philidor Rx Services accused of helping it inflate revenue. |\u00a0Video ",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant says Philidor pharmacy shutting down as it cuts ties "
    },
    {
        "content": "Oct 29 Valeant Pharmaceuticals Inc. sustained hits on several fronts on Thursday after CVS Health Corp and Express Scripts dropped Philidor from their networks in a sign the fallout from the drugmaker's connection with the specialty pharmacy is spreading.",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-CVS  Express Scripts drop Valeant's Philidor; stock dives "
    },
    {
        "content": "* Indexes down: Dow .13 pct  S&P .04 pct  Nasdaq .42 pct   (Updates close with Valeant down after the bell; LinkedIn up)",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St slips on tech results  chances of Fed hike "
    },
    {
        "content": "Oct 29 Shares of Valeant Pharmaceuticals Inc. fell further on Thursday after CVS Health Corp and Express Scripts dropped Philidor Rx from their networks in a sign the fall-out from the drugmaker's connection with the specialty pharmacy is spreading.",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-CVS  Express Scripts drop Valeant's Philidor; stock dives "
    },
    {
        "content": "The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc  illegally cornered the market for a component of a new type of contact lens  an industry source told Reuters.",
        "date": "10272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "FTC looking at Valeant's contact lens dealings -source "
    },
    {
        "content": "Nov 2 Goldman Sachs on Monday downgraded Valeant Pharmaceuticals International Inc's  stock  nearly two weeks after an influential short seller accused the Canadian drug maker of cooking its books.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Goldman Sachs says Valeant has long road ahead  cuts rating "
    },
    {
        "content": "A U.S. Senate panel on Wednesday launched a bipartisan probe into pharmaceutical pricing  seeking documents from four drugmakers including Valeant Pharmaceuticals and Turing Pharmaceuticals  companies embroiled in controversy over price hikes on lifesaving drugs.",
        "date": "11052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Senate panel probing Valeant  Turing over drug costs "
    },
    {
        "content": "Oct 26 Valeant Pharmaceuticals International Inc   laid out a defense of its relationship with a specialty pharmacy on Monday  but failed to dispel all investor concerns.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "TIMELINE-Deals  and doubts  mark Valeant's acquisition history "
    },
    {
        "content": "Oct 29 Drugstore chain CVS Health Corp  said it had dropped Philidor Rx  a specialty pharmacy associated with Valeant Pharmaceuticals Inc   from its Caremark program.",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CVS Health drops Philidor  adds to Valeant's woes "
    },
    {
        "content": "The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc   illegally cornered the market for a component of a new type of contact lens  an industry source told Reuters.",
        "date": "10272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "FTC looking at Valeant's contact lens dealings: source "
    },
    {
        "content": "Oct 27 The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc  illegally cornered the market for a component of a new type of contact lens  an industry source told Reuters.",
        "date": "10272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-FTC looking at Valeant's contact lens dealings -source "
    },
    {
        "content": "Nov 2 Short-seller Citron Research did not make any new allegations on Canadian drugmaker Valeant Pharmaceuticals International Inc  in a report published on Monday.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Citron does not release new allegations on Valeant "
    },
    {
        "content": "TORONTO  Oct 30 Canada's main stock index fell on Friday  weighed down by Valeant Pharmaceuticals International Inc after it cut ties with a beleaguered pharmacy business  and by retreats in the heavyweight energy and financial sectors.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Valeant pulls down TSX; resource and bank stocks weigh "
    },
    {
        "content": "NEW YORK  Oct 26 The pharmacy at the center of suspicions over Valeant Pharmaceuticals International Inc's   business practices began as a small pilot project two years ago and quickly grew to account for 7 percent of the drugmaker's revenue.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "From pilot to profit-maker  Valeant's pharmacy rose quickly "
    },
    {
        "content": "Oct 29 Valeant Pharmaceuticals International Inc's  largest shareholder  Ruane  Cunniff & Goldfarb Inc  has urged the company to consider paying down debt.",
        "date": "10292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Largest shareholder urges Valeant to pay down debt "
    },
    {
        "content": "NEW YORK  Oct 25 As Valeant Pharmaceuticals prepares to defend its drug sales practices to Wall Street on Monday  new details are emerging about the tangled relationships - and litigation - among Valeant's specialty pharmacy partners.",
        "date": "10252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Legal tangle in California may shed light on specialty pharmacies "
    },
    {
        "content": "Oct 27 The U.S. Federal Trade Commission is looking into whether Canadian drugmaker Valeant Pharmaceuticals International Inc  illegally cornered the market for a key material used to make rigid contact lenses  ProPublica reported  citing people familiar with the matter.",
        "date": "10272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "FTC looking at Valeant's contact lens dealings - ProPublica "
    },
    {
        "content": "TORONTO  Nov 2 Canada's main stock index opened slightly higher on Monday  helped by a rebound in Valeant Pharmaceuticals International Inc but weighed by resource stocks as commodity prices fell.",
        "date": "11022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as Valeant rebounds; energy stocks weigh "
    },
    {
        "content": "TORONTO  Oct 30 Canada's main stock index fell sharply on Friday  pushed lower by a slump in Valeant Pharmaceuticals International Inc after it cut ties with a specialty pharmacy accused of helping it inflate revenue  and by retreats in heavyweight banks.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls 1.9 as Valeant slumps  banks weigh "
    },
    {
        "content": "NEW YORK Social media circles remained critical of Valeant Pharmaceuticals International Inc   on Monday despite the drugmaker's efforts to defend itself against accusations of an accounting fraud.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's defense does little to improve social media sentiment "
    },
    {
        "content": "NEW YORK The one-time hedge fund executive now running a biotech firm at the center of a drug-pricing controversy on Monday said he has bailed from a losing bet he made on another contentious drug maker: Valeant Pharmaceuticals International Inc  .",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Controversial pharma CEO Martin Shkreli bails on Valeant bet "
    },
    {
        "content": "Oct 30 Valeant Pharmaceuticals International Inc    seeking to allay investor concerns about its business practices  said Friday it is cutting ties with a specialty pharmacy called Philidor Rx Services accused of helping it inflate revenue.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant says Philidor pharmacy shutting down as it cuts ties "
    },
    {
        "content": "BOSTON Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals  but faulted the company for a weak response to fraud allegations that have sunk its stock.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Ackman: Valeant's main problem is PR  not fraud "
    },
    {
        "content": "NEW YORK  Oct 26 Short interest in U.S.-traded Valeant Pharmaceuticals International Inc shares stood at its highest in nearly a year in the first half of October  exchange data showed on Monday  indicating bearish investors were stacking up against the stock even before a negative report torpedoed the shares last week.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Short interest piled on Valeant ahead of scathing report "
    },
    {
        "content": "TORONTO  Oct 23 Canada's main stock index rose on Friday  helping it post a 1.4 percent gain on the week  as shares of embattled Valeant Pharmaceuticals International Inc bounced and a range of financial and materials stocks also gained.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX gains as Valeant bounces  index adds 1.4 pct on week "
    },
    {
        "content": "BOSTON  Oct 30 Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals  but faulted the company for a weak response to fraud allegations that have sunk its stock.",
        "date": "10302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Ackman: Valeant's main problem is PR  not fraud "
    },
    {
        "content": "NEW YORK  Oct 26 (IFR) - Valeant bonds were volatile on Monday morning but steadied after the drugmaker's management sought to alleviate investor fears of potential fraud at the company.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant bonds steady after analyst call "
    },
    {
        "content": "TORONTO  Oct 26 Canada's main stock index ended 1.2 percent lower on Monday  hurt by sharp falls in energy companies  gold miners and other resource stocks  while Valeant Pharmaceutical International Inc shares' 5 percent fall also weighed.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls more than 1 pct; resource stocks  Valeant weigh "
    },
    {
        "content": "Oct 23 Valeant Pharmaceuticals Inc  shares rebounded on Friday following four days of steep losses triggered by allegations it used specialty pharmacies to inflate revenue  which the company plans to refute in detail on Monday.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "TAKE A LOOK-Valeant's rough week in the markets "
    },
    {
        "content": "Oct 26 Drugmaker Valeant Pharmaceuticals International Inc  laid out a detailed defense on Monday of its relationship with a little-known specialty pharmacy  but its arguments failed to calm all investor concerns.",
        "date": "10262015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Drugmaker Valeant raises detailed defense but doubts remain "
    },
    {
        "content": "BOSTON/NEW YORK  Oct 22 Valeant Pharmaceuticals' market slide has hurt the returns of several large U.S. hedge funds  but for smaller players with outsized bets on the drug company the fallout could be far more painful  according to industry watchers.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant slump poses big threat to small hedge funds "
    },
    {
        "content": "NEW YORK  Oct 23 (IFR) - The pharma sector needs more than medicine to get over its latest malaise.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant woes underline problems for pharma "
    },
    {
        "content": "TORONTO/NEW YORK Valeant Pharmaceuticals International Inc  moved to reassure investors on Thursday after being accused of using specialty pharmacies to inflate revenue  and said it would refute them in detail on a conference call with investors.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant vows to refute 'phantom sales' allegations "
    },
    {
        "content": "TORONTO/NEW YORK  Oct 22 Valeant Pharmaceuticals International Inc moved to reassure investors on Thursday after being accused of using specialty pharmacies to inflate revenue  and said it would refute them in detail on a conference call with investors.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant vows to refute \"phantom sales\" allegations "
    },
    {
        "content": "Valeant Pharmaceuticals Inc  shares rebounded on Friday from four days of steep losses over allegations of fraud  which it denied  but this week's stock selloff has already cost the company's chief executive well over $1 billion.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant stock rebounds  but allegations shrink CEO's fortune "
    },
    {
        "content": "Oct 23 Valeant Pharmaceuticals Inc   shares rebounded on Friday from four days of steep losses over allegations of fraud  which it denied  but this week's stock selloff has already cost the company's chief executive well over $1 billion.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant stock rebounds  but allegations shrink CEO's fortune "
    },
    {
        "content": "Oct 22 Valeant Pharmaceuticals Inc's  share slumped for the second straight day on Wednesday  a day after influential shortseller Citron Research said the Canadian drugmaker used specialty pharmacies to create \"phantom sales\".",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares continue slide since Citron report "
    },
    {
        "content": "TORONTO The plunge in the stock price of Valeant Pharmaceuticals International Inc   has not only cost some of Wall Street's titans billions of dollars this week  it also wiped $1.5 billion from the personal wealth of its head Mike Pearson.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant share price meltdown wipes $1.5 billion from CEO's wealth "
    },
    {
        "content": "TORONTO  Oct 23 The plunge in the stock price of Valeant Pharmaceuticals International Inc  has not only cost some of Wall Street's titans billions of dollars this week  it also wiped $1.5 billion from the personal wealth of its head Mike Pearson.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant share price meltdown wipes $1.5 bln from CEO's wealth "
    },
    {
        "content": "TORONTO  Oct 22 Valeant Pharmaceuticals International Inc  said on Thursday it plans to host a conference call on Monday to lay out and address all the recent allegations that have been made against the company.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to host call to address  refute short-seller allegations "
    },
    {
        "content": "Oct 23 Valeant Pharmaceuticals Inc   shares rebounded on Friday from four days of steep losses over allegations it used specialty pharmacies to inflate revenue  which the company plans to refute in detail on Monday.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant rebounds ahead of Monday call to address allegations "
    },
    {
        "content": "TORONTO  Oct 23 Canada's main stock index rose on Friday as materials stocks cheered a Chinese interest rate cut that boosted prices for base metals  and shares of embattled Valeant Pharmaceuticals International Inc also bounced.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX higher as Valeant bounces  China rate cut helps miners "
    },
    {
        "content": "NEW YORK The controversy surrounding Valeant Pharmaceuticals'  strategy and its market slide this week are bad news for Wall Street investment banks that stand to lose one of their best clients.",
        "date": "10232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant's looming M&A hiatus deals blow to investment banks "
    },
    {
        "content": "* Dow down 0.3 pct  S&P down 0.6 pct  Nasdaq down 0.8 pct   (Adds eBay up after the bell  Community Health down  latest volume)",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St declines; Valeant  healthcare weigh "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   which has been criticized for raising drug prices and is being investigated by the U.S. government  predicted on Monday that lower price increases are ahead for the whole industry.",
        "date": "10202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant CEO sees new drug pricing environment ahead "
    },
    {
        "content": "TORONTO  Oct 22 Canada's main stock index gained in early trade on Thursday in a broad rebound led by energy stocks as oil prices rose  while embattled Valeant Pharmaceuticals International Inc dropped 10 percent.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX opens higher as energy shares gain; Valeant down 10 pct "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc's stock plunged as much as 40 percent on Wednesday after an influential short-seller accused the company of using specialty pharmacies to inflate its revenue  an allegation that the drugmaker denied.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant shares plunge on short-seller scrutiny of pharmacy revenue "
    },
    {
        "content": "Mike Pearson's methods heading one of the world's most acquisitive drugmakers have long been viewed as troubling to some  merely unorthodox to others.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Often criticized  Valeant's unusual CEO comes under heavy fire "
    },
    {
        "content": "LOS ANGELES Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc  have put a spotlight on the little-known and fast-growing specialty pharmacy industry.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Specialty pharmacies in spotlight as Valeant ties questioned "
    },
    {
        "content": "NEW YORK  Oct 19    Valeant Pharmaceuticals International Inc CEO J. Michael Pearson said on Monday that outside pressures are creating a new pricing environment for all pharmaceutical companies and that Valeant expects to keep increases to 10 percent or less next year.",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO sees new drug pricing environment ahead "
    },
    {
        "content": "* Valeant shares cut losses  last down 18 pct   (Adds background  updates share price  market values)",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant shares plunge on short-seller scrutiny of pharmacy revenue "
    },
    {
        "content": "NEW YORK A simple promise turned Valeant Pharmaceutical International Inc and some of its rivals into stock market darlings: we will buy more companies and make more money selling drugs. Now investors worry if they can still deliver.",
        "date": "10222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant plunge spotlights cracks in specialty pharma's M&A facade "
    },
    {
        "content": "* Targets neurological division for sale   (Adds Breakingviews link)",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 6-Valeant CEO sees new drug pricing environment ahead "
    },
    {
        "content": "TORONTO  Oct 19 Canada's main stock index fell on Monday as a slump in crude oil prices hurt energy stocks and worries over slowing Chinese demand dragged down miners.",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX slips on retreat in resource stocks  Valeant "
    },
    {
        "content": "* Dow down 0.3 pct  S&P down 0.6 pct  Nasdaq down 0.8 pct   (Updates to close)",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St falls; Valeant  healthcare drop "
    },
    {
        "content": "TORONTO  Oct 21 A plunge in shares of Valeant Pharmaceuticals International Inc helped push Canada's main stock index down 1 percent on Wednesday  with falls in the price of oil and other commodities weighing on energy and mining stocks.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls 1 pct on Valeant plunge  resource slip "
    },
    {
        "content": "Oct 21 Mike Pearson's methods heading one of the world's most acquisitive drugmakers have long been viewed as troubling to some  merely unorthodox to others.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "NEWSMAKER-Often criticized  Valeant's unusual CEO comes under heavy fire "
    },
    {
        "content": "TORONTO  Oct 21 Canada's main stock index fell 1 percent on Wednesday  with most of the damage done by an influential short-seller's accusations that Valeant Pharmaceuticals International Inc artificially inflates it revenue.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends 1 pct lower as Valeant tumbles "
    },
    {
        "content": "* Valeant CEO says generics with no competitors account for $75 million in revenues quarterly",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Valeant CEO says is in touch with government on investigations "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  which is under fire for massive price hikes of its two heart drugs  reported a better-than-expected quarterly profit  boosted mainly by strong performance in its U.S. dermatology business.",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Strong dermatology product sales help Valeant top estimates "
    },
    {
        "content": "NEW YORK Andrew Left's Citron Research is largely a one-man investment research operation that has shaken financial markets in both the United States and China from his home office in Beverly Hills  California.",
        "date": "10212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Citron's Left hits nerve with new Valeant broadside "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    already under fire over steep price hikes for two heart drugs  said it had been subpoenaed by U.S. prosecutors seeking details on its patient assistance programs  drug pricing and distribution practices.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant subpoenaed by US prosecutors over drug pricing "
    },
    {
        "content": "TORONTO  Oct 16 Canada's main stock index rose on Friday  helped by a bounce back in Valeant Pharmaceuticals International Inc and gains in heavyweight financial stocks.",
        "date": "10162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX gains  buoyed by financials  Valeant rebound "
    },
    {
        "content": "Oct 19 Valeant Pharmaceuticals International Inc    which is under fire for massive price hikes of its two heart drugs  reported a 36 percent rise in quarterly revenue  as sales of dermatology products rose in the United States.",
        "date": "10192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant Pharma revenue rises 36 pct "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc    already under fire over steep price hikes for two heart drugs  said it had been subpoenaed by U.S. prosecutors seeking details on its patient assistance programs  drug pricing and distribution practices.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant subpoenaed by U.S. prosecutors; shares drop "
    },
    {
        "content": "Oct 15 Valeant Pharmaceuticals International Inc    already under fire over steep price hikes for two heart drugs  said it had been subpoenaed by U.S. prosecutors seeking details on its patient assistance programs  drug pricing and distribution practices.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant subpoenaed by U.S. prosecutors; shares drop "
    },
    {
        "content": "TORONTO  Oct 15 Canada's main stock index slipped on Thursday  as a pullback among energy stocks and a U.S. subpoena for Valeant Pharmaceuticals International Inc   weighed.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX slips as energy stocks pull back  Valeant falls "
    },
    {
        "content": "TORONTO  Oct 15 Canada's main stock index slipped on Thursday  weighed down by energy stocks as oil settled down for a fourth straight day and by Valeant Pharmaceuticals International Inc  which has been subpoenaed by U.S. prosecutors over its drug pricing.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends down as energy stocks   Valeant weigh "
    },
    {
        "content": "TORONTO  Oct 15 Canada's main stock index was barely lower on Thursday  as a resource retreat and U.S. subpoena for Valeant Pharmaceuticals International Inc offset gains across much of the rest of the index led by financials and industrial shares.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Resource retreat  Valeant subpoena push TSX lower "
    },
    {
        "content": "TORONTO  Oct 15 Canada's main stock index slipped at the open on Thursday  hurt by a retreat among resource stocks on lower oil prices and a slump in Valeant Pharmaceuticals International Inc after it was subpoenaed by U.S. prosecutors over drug pricing.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX slips on resource retreat  Valeant subpoena "
    },
    {
        "content": "Oct 15 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it was subpoenaed by U.S. prosecutors seeking information on its pricing decisions  drug distribution and patient assistance programs.",
        "date": "10152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant subpoenaed by US prosecutors over drug pricing concerns "
    },
    {
        "content": "NEW YORK  Oct 6 William Ackman  head of hedge fund firm Pershing Square Capital Management  said on Tuesday that financial market volatility was being driven by short-term money without regard to long-term economic fundamentals and that Valeant Pharmaceuticals International Inc was the most undervalued stock among his top holdings.",
        "date": "10062015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Bill Ackman says short-term money driving market volatility "
    },
    {
        "content": "BOSTON  Oct 1 Billionaire hedge fund manager William Ackman's Pershing Square Holdings fund is nursing a 12.6 percent loss for 2015  an investor who received Ackman's letter on Thursday said  marking a dramatic reversal of fortune for one of last year's best performing managers.",
        "date": "10022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Ackman's Pershing Square off 12.6 pct for year after Valeant tumble "
    },
    {
        "content": "TORONTO  Sept 30 Canada's main stock index surged more than 2 percent on Wednesday as Valeant Pharmaceuticals International Inc rebounded and higher-than-expected domestic growth data gave a range of sectors a healthy boost amid end-of-quarter positioning.",
        "date": "09302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends up 2.1 percent; Valeant rebounds "
    },
    {
        "content": "Democratic lawmakers on Monday attacked \"massive\" price increases of two heart drugs by Canada's Valeant  fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.",
        "date": "09292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Democrats take aim at drug prices  prompting sharp drops in biotech stocks "
    },
    {
        "content": "Sept 28 Democratic lawmakers on Monday attacked \"massive\" price increases of two heart drugs from Canada's Valeant Pharmaceuticals International Inc  fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.",
        "date": "09282015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-U.S. House Democrats slam Valeant's drug price hikes; shares sink "
    },
    {
        "content": "TORONTO  Sept 30 Canada's main stock index rallied more than 1 percent on Wednesday as higher-than-expected domestic growth data provided a healthy boost to sentiment and as Valeant Pharmaceuticals International Inc shares rebounded after being battered by charges of price gauging.",
        "date": "09302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rallies as Valeant rebounds  July GDP data upbeat "
    },
    {
        "content": "TORONTO  Sept 30 Canada's main stock index rallied more than 1 percent shortly after the open as Valeant Pharmaceuticals International Inc shares rebounded after being battered by charges of price gauging and as higher-than-expected domestic growth data also gave other sectors a healthy boost.",
        "date": "09302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX jumps soon after open on GDP data  Valeant rally "
    },
    {
        "content": "Sept 28 Democratic lawmakers on Monday attacked \"massive\" price increases of two heart drugs by Canada's Valeant  fueling a rout in drugmaker shares on worries of a government and insurer clampdown on U.S. drug prices.",
        "date": "09292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-U.S. House Democrats slam Valeant's drug price hikes; shares sink "
    },
    {
        "content": "Sept 28 All 18 Democratic members of a U.S. House of Representatives committee on Monday urged their chairman to subpoena Canada's Valeant Pharmaceuticals International Inc to force it to provide documents related to \"massive\" price increases for two of its heart drugs.",
        "date": "09282015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "U.S. House Democrats take aim at price hikes for Valeant drugs; shares drop "
    },
    {
        "content": "WASHINGTON  Sept 21 Democratic presidential candidate Hillary Clinton will unveil a plan this week to cap out-of-pocket costs for specialty drugs  she said on Monday  after her tweet accusing companies of \"price gouging\" sent biotech stocks tumbling.",
        "date": "09212015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Democrat Clinton to unveil plan to fight drug 'price gouging' "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc   is buying rights to AstraZeneca Plc's  late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc  in May.",
        "date": "09012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant picks up AstraZeneca psoriasis drug after Amgen exit "
    },
    {
        "content": "Sept 1 Canada's Valeant Pharmaceuticals International Inc  is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.",
        "date": "09012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant picks up AstraZeneca psoriasis drug after Amgen exit "
    },
    {
        "content": "Sept 1 Canada's Valeant Pharmaceuticals International Inc  said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.",
        "date": "09012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant gets right to develop AstraZeneca's psoriasis drug "
    },
    {
        "content": "Sept 2 Canada's Valeant Pharmaceuticals International Inc  agreed to buy surgical device maker Synergetics USA Inc  its eighth acquisition this year.",
        "date": "09022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to buy ophthalmic surgical device maker Synergetics "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc   said on Thursday it would buy Sprout Pharmaceuticals  which makes a controversial new drug to treat low sexual desire in women  for about $1 billion.",
        "date": "08202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant to buy 'female Viagra' maker Sprout Pharma "
    },
    {
        "content": "* Valeant shares fall   (Adds comments from Valeant  Spruce; analyst reaction)",
        "date": "08202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant to buy 'female Viagra' maker Sprout Pharma "
    },
    {
        "content": "Aug 20 Canada's Valeant Pharmaceuticals International Inc is nearing a deal to pay $1 billion for Sprout Pharmaceuticals  the company that just won approval to sell the first drug that aims to boost a woman's libido  the Wall Street Journal reported.",
        "date": "08202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant nears deal for \"female Viagra\" maker Sprout Pharmaceuticals - WSJ "
    },
    {
        "content": "TORONTO  Aug 4 Canada's main stock index rose on Tuesday as strength in shares of Valeant Pharmaceuticals International Inc helped offset a decline in the energy and mining sectors.",
        "date": "08042015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends higher as Valeant offsets weakness in resources "
    },
    {
        "content": "* All but one of 10 main groups fall; Valeant boosts health stocks",
        "date": "07272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-China worry hits Canada's TSX hard "
    },
    {
        "content": "TORONTO  July 24 Canada's main stock index extended its losses for the week on Friday  hurt by profit taking on Canadian drugmaker Valeant Pharmaceuticals International Inc and continued declines in the key financials  materials and energy groups.",
        "date": "07242015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX extends losses  dragged by Valeant  banks  resources "
    },
    {
        "content": "* Noted the confirmation by Valeant Pharmaceuticals International Inc's.   wholly owned subsidiary  Bausch + Lomb  that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Vesneo(TM)",
        "date": "07242015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Bausch + Lomb confirms submission of Vesneo(TM) NDA to US FDA "
    },
    {
        "content": "MONTREAL Canadian drugmaker Valeant Pharmaceuticals International Inc   reported a higher-than-expected quarterly profit on Thursday  helped by strength in its U.S. dermatology business  and its shares hit a record high.",
        "date": "07232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant profit beats estimates as U.S. sales stay strong "
    },
    {
        "content": "MONTREAL  July 23 Canadian drugmaker Valeant Pharmaceuticals International Inc  reported a higher-than-expected quarterly profit on Thursday  helped by strength in its U.S. dermatology business  and its shares hit a record high.",
        "date": "07232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant profit beats estimates as U.S. sales stay strong "
    },
    {
        "content": "July 23 Drugmaker Valeant Pharmaceuticals International Inc  reported a better-than-expected quarterly profit  helped by strength in its dermatology business in the United States  sending its shares higher in early trade.",
        "date": "07232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant profit beats estimates as U.S. sales stay strong "
    },
    {
        "content": "Canadian drugmaker Valeant Pharmaceuticals International Inc   said it would buy Egypt's largest drugmaker  Amoun Pharmaceutical  for about $800 million.",
        "date": "07172015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant to buy Egyptian drugmaker Amoun for about $800 million "
    },
    {
        "content": "July 17 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it would buy Egypt's largest drugmaker  Amoun Pharmaceutical  for about $800 million.",
        "date": "07172015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to buy Egyptian drugmaker Amoun for about $800 mln "
    },
    {
        "content": "July 17 Canadian drugmaker Valeant Pharmaceuticals International Inc  said it would buy Egypt's largest drugmaker  Amoun Pharmaceutical  for about $800 million.",
        "date": "07172015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to buy Egyptian drugmaker Amoun for about $800 mln "
    },
    {
        "content": "OTTAWA  July 2 Canada's main stock index rose on Thursday as market choppiness due to uncertainty in Greece sent investors looking for safety in healthcare shares and other defensive sectors  offsetting weakness in commodity-sensitive stocks.",
        "date": "07022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX climbs as investors seek safety in defensive shares "
    },
    {
        "content": "OTTAWA  July 2 Canada's main stock index rose modestly on Thursday as investors pushed into healthcare shares and other defensive sectors  offsetting weakness in commodity-sensitive stocks.",
        "date": "07022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX rises as investors buy up defensive shares "
    },
    {
        "content": "Canada-based drugmaker Valeant Pharmaceuticals International Inc   has approached to buy Zoetis Inc   an animal-health company  the Wall Street Journal reported.",
        "date": "06252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Canada's Valeant approaches to buy Zoetis: WSJ "
    },
    {
        "content": "June 25 Canada-based drugmaker Valeant Pharmaceuticals International Inc  has approached to buy Zoetis Inc  an animal-health company  the Wall Street Journal reported.",
        "date": "06252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Canada's Valeant approaches to buy Zoetis - WSJ "
    },
    {
        "content": "June 25 Canada-based drugmaker Valeant Pharmaceuticals International Inc  has approached to buy Zoetis Inc  an animal-health company  the Wall Street Journal reported.",
        "date": "06252015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant offers to buy Zoetis - WSJ "
    },
    {
        "content": "June 11 Valeant Pharmaceuticals International Inc has again reached into the ranks of business advisory firm McKinsey & Co to hire a senior executive  naming Robert Rosiello as its next chief financial officer on Thursday.",
        "date": "06112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant names McKinsey merger expert as its next CFO "
    },
    {
        "content": "WASHINGTON  May 27 U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc  and Valeant Pharmaceuticals International Inc   on Wednesday  validating big investments both companies made to acquire the products.",
        "date": "05272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "FDA approves Actavis  Valeant drugs for irritable bowel syndrome "
    },
    {
        "content": "WASHINGTON  May 27 U.S. health regulators approved new irritable bowel syndrome drugs from Actavis Plc  and Valeant Pharmaceuticals International Inc   on Wednesday  validating big investments both companies made to acquire the products.",
        "date": "05272015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-FDA approves Actavis  Valeant drugs for irritable bowel syndrome "
    },
    {
        "content": "May 28 The U.S. Food and Drug Administration has asked manufacturers of dermal fillers to update their labeling to reflect the possible risk of serious injuries caused by unintentional injection of the fillers into the blood vessels in the face.",
        "date": "05282015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CORRECTED-UPDATE 1-FDA asks dermal filler makers to indicate risk of serious injury "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio  Bloomberg reported  citing people familiar with the matter.",
        "date": "05202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant in talks to buy Egyptian drugmaker Amoun Pharma: Bloomberg "
    },
    {
        "content": "MONTREAL  May 19 Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020  Chief Executive Michael Pearson said on Tuesday.",
        "date": "05192015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant CEO expects sharp rise in Asia revenue by 2020 "
    },
    {
        "content": "May 20 Valeant Pharmaceuticals International Inc   is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio  Bloomberg reported  citing people familiar with the matter.",
        "date": "05202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to buy Egyptian drugmaker Amoun Pharma-Bloomberg "
    },
    {
        "content": "* Enters into cooperation with Bausch & Lomb Nordic AB  a subsidiary of Valeant Pharmaceuticals Inc",
        "date": "05112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "BRIEF-Medica Nord signs distribution agreement with Bausch & Lomb Nordic AB "
    },
    {
        "content": "Drugmaker Valeant Pharmaceuticals International Inc   raised its earnings and sales forecasts for the year on Wednesday and said its chief financial officer will step down.",
        "date": "04292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Drugmaker Valeant raises forecasts  says CFO to leave "
    },
    {
        "content": "TORONTO  May 1 Canada's main stock index advanced on Friday to recoup most of the previous session's losses  led by broad gains in financials and mining firms as well as some positive earnings reports.",
        "date": "05012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX climbs  led by Valeant  materials and banks "
    },
    {
        "content": "April 29 Canadian drugmaker Valeant Pharmaceuticals International Inc  reported a quarterly profit  compared with a year-ago loss  driven by higher demand in the United States.",
        "date": "04292015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant Pharma posts profit  says CFO to step down "
    },
    {
        "content": "Canada's Valeant Pharmaceuticals International Inc  completed its $10.96 billion purchase of Salix Pharmaceuticals Ltd   the acquisitive company said on Wednesday.",
        "date": "04012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Drugmaker Valeant completes $11 billion purchase of Salix "
    },
    {
        "content": "April 1 Canada's Valeant Pharmaceuticals International Inc completed its $10.96 billion purchase of Salix Pharmaceuticals Ltd  the acquisitive company said on Wednesday.",
        "date": "04012015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-Drugmaker Valeant completes $11 billion purchase of Salix "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  increased its offer for Salix Pharmaceuticals Inc  to $10.96 billion in cash on Monday  eclipsing Endo International Plc   the only other bidder.",
        "date": "03172015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant trumps Endo with $10.96 billion bid for Salix Pharma "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc  increased its offer for Salix Pharmaceuticals Inc to $10.96 billion in cash on Monday  eclipsing Endo International Plc  the only other bidder.",
        "date": "03172015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 5-Valeant trumps Endo with $10.96 billion bid for Salix Pharma "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  increased its takeover offer for Salix Pharmaceuticals Inc  to $10.96 billion in cash on Monday  eliminating Endo International Plc   the only other bidder for the maker of gastrointestinal drugs.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant trumps Endo with $10.96 billion bid for Salix Pharma "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  plans to raise its bid for Salix Pharmaceuticals Ltd  close to $170 per share  a person familiar with matter told Reuters.",
        "date": "03142015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant plans to raise offer for Salix close to $170/share: source "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc  increased its takeover offer for Salix Pharmaceuticals Inc to $10.96 billion in cash on Monday  eliminating Endo International Plc  the only other bidder for the maker of gastrointestinal drugs.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Valeant trumps Endo with $10.96 billion bid for Salix Pharma "
    },
    {
        "content": "March 13 Valeant Pharmaceuticals International Inc plans to raise its bid for Salix Pharmaceuticals Ltd close to $170 per share  a person familiar with matter told Reuters.",
        "date": "03142015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant plans to raise offer for Salix close to $170/shr -source "
    },
    {
        "content": "TORONTO  March 16 Canada's main stock index rose on Monday as most major sectors benefited from bullish global equity market sentiment ahead of a crucial U.S. Federal Reserve policy meeting later this week.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX climbs on upbeat sentiment ahead of Fed meeting "
    },
    {
        "content": "TORONTO  March 16 Canada's main stock index rose on Monday as most major sectors benefited from bullish global equity market sentiment  while a gain in Valeant Pharmaceuticals International Inc provided further support.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends higher on Valeant  brighter sentiment "
    },
    {
        "content": "TORONTO  March 16 Canada's main stock index jumped on Monday as a gain in Valeant Pharmaceuticals International Inc helped overcome a drop in oil and gas shares spurred by lower crude prices.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-Valeant helps push TSX higher despite drop in oil shares "
    },
    {
        "content": "March 16 Endo International Plc said it would withdraw its cash-and-stock offer to acquire Salix Pharmaceuticals Ltd after Valeant Pharmaceuticals International Inc increased its bid for the bowel drug maker.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Endo withdraws offer for Salix "
    },
    {
        "content": "March 16 Valeant Pharmaceuticals International Inc said it increased its offer for Salix Pharmaceuticals Inc to $173 per share  hoping to end a bidding war with Endo International Plc for the bowel drug maker.",
        "date": "03162015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant raises offer for Salix Pharma to $173 per share "
    },
    {
        "content": "March 13 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Friday:",
        "date": "03132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Endo International Plc offered to buy Salix Pharmaceuticals Ltd for about $11 billion in cash and stock  trumping an agreed bid by Canada's Valeant Pharmaceuticals International Inc.",
        "date": "03112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Endo offers about $11 bln for Salix  trumping Valeant "
    },
    {
        "content": "March 15 Endo International Plc  which is in a bidding war with Valeant Pharmaceuticals International Inc for Salix Pharmaceuticals Ltd  believes it could close a takeover within as little as five weeks of a negotiated deal  according to an email obtained by Reuters.",
        "date": "03152015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Endo claims it could close Salix deal swiftly - email "
    },
    {
        "content": "NEW YORK  March 13 (IFR) - Pharmaceuticals firm Endo stunned the market with a last-minute bid for Salix last Wednesday  but the surprise turn of events did little to dent demand for a multi-billion dollar junk bond issue backing rival Valeant's bid.",
        "date": "03132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-Valeant deal survives Endo surprise "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  plans to raise its bid for Salix Pharmaceuticals Ltd  to above $160 per share  a source familiar with matter told Reuters  hoping to end a bidding war with Endo International Plc.",
        "date": "03132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant plans to raise offer for Salix: source "
    },
    {
        "content": "* Endo falls 1 pct  Salix up 7 pct  Valeant closes down 3 pct   (Adds Valeant comment  updates shares)",
        "date": "03112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 4-Endo offers about $11 bln for Salix  trumping Valeant "
    },
    {
        "content": "March 13 Valeant Pharmaceuticals International Inc plans to raise its bid for Salix Pharmaceuticals Ltd to above $160 per share  a source familiar with matter told Reuters  hoping to end a bidding war with Endo International Plc.",
        "date": "03132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant plans to raise offer for Salix - source "
    },
    {
        "content": "March 11 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Wednesday:",
        "date": "03112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "March 9 The following bids  mergers  acquisitions and disposals were reported by 2000 GMT on Monday:",
        "date": "03092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": " ",
        "date": "03092015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "BRIEF-Pershing Square Holdings announces new position in Valeant Pharmaceuticals International "
    },
    {
        "content": "TORONTO  March 3 Canada's main stock exchange fell shortly after the open on Tuesday in a broad decline led in part by the Bank of Nova Scotia  which reported a lower-than-expected quarterly profit  and a sell off in Valeant Pharmaceuticals International Inc shares.",
        "date": "03032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX falls as Scotiabank  Valeant lead declines "
    },
    {
        "content": "TORONTO  March 2 Canada's main stock index rose on Monday as a jump in Valeant Pharmaceuticals International Inc  helped offset weakness in the energy sector after the price of Brent crude oil dropped.",
        "date": "03022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX advances as Valeant climbs  offsets weaker oil shares "
    },
    {
        "content": "TORONTO  March 2 Canada's main stock index rose on Monday as a jump in Valeant Pharmaceuticals International Inc  helped offset weakness in the energy sector after the price of Brent crude oil dropped.",
        "date": "03022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX ends higher as Valeant offsets energy fall "
    },
    {
        "content": "TORONTO  March 2 Canada's main stock index was steady on Monday as weakness in shares of energy producers on lower oil prices was offset by a gain in Valeant Pharmaceuticals International Inc.",
        "date": "03022015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX steady as Valeant's climb helps offset oil-share drop "
    },
    {
        "content": "NEW YORK  Feb 24 (IFR) - High-yield investors clamoring for chunky-sized trades with ratings closer to investment grade will get another stab at picking up paper when pharma giant Valeant launches a US$9.6bn bond to finance its acquisition of Salix Pharmaceuticals.",
        "date": "02242015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant's jumbo bond to quench thirst for large liquid issues "
    },
    {
        "content": "TORONTO  Feb 23 Canada's main stock index edged higher on Monday as weakness in shares of banks and insurers was offset by a surge in Valeant Pharmaceuticals after the drugmaker announced a major acquisition.",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX gains on Valeant news; financial stocks weigh "
    },
    {
        "content": "NEW YORK  Feb 22 Canada's Valeant Pharmaceuticals International Inc  agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd  in an all-cash deal valued at about $10.1 billion  the two companies said on Sunday.",
        "date": "02222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "RPT-UPDATE 2-Canada's Valeant to acquire Salix in $10.1 billion deal "
    },
    {
        "content": "* Dow down 0.1 pct  S&P down 0.03 pct  Nasdaq up 0.1 pct   (Updates to close)",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Nasdaq ends up 9th session; S&P 500  Dow dip with energy "
    },
    {
        "content": "TORONTO  Feb 23 Canada's main stock index ended slightly higher on Monday  as broad weakness in financial and some energy stocks was offset by a surge in shares of Valeant Pharmaceuticals after the drugmaker announced a major acquisition.",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX edges higher on Valeant surge; financials weigh "
    },
    {
        "content": "NEW YORK Canada's Valeant Pharmaceuticals International Inc   agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd  in an all-cash deal valued at about $10.1 billion  the two companies said on Sunday.",
        "date": "02222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Canada's Valeant to acquire Salix in $10.1 billion deal "
    },
    {
        "content": "NEW YORK  Feb 22 Canada's Valeant Pharmaceuticals International Inc  agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd  in an all-cash deal valued at about $10.1 billion  the two companies said on Sunday.",
        "date": "02222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Canada's Valeant to acquire Salix in $10.1 billion deal "
    },
    {
        "content": "NEW YORK Canada's Valeant Pharmaceuticals International Inc agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion  the two companies said on Sunday. |\u00a0Video ",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Canada's Valeant to buy Salix in $10.1 billion deal "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc plans to strike smaller deals to build on its acquisitions of Salix Pharmaceuticals Ltd and assets of Dendreon Corp  its chief executive said on Monday.",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant eyes smaller deals to build on Salix  Dendreon purchases "
    },
    {
        "content": "NEW YORK  Feb 22 Valeant Pharmaceuticals International Inc. agreed to acquire Salix Pharmaceuticals Ltd. for $158.00 per share  or a total enterprise value of $14.5 billion  the two companies said on Sunday.",
        "date": "02222015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to acquire Salix in $14.5 bln deal "
    },
    {
        "content": "Feb 23 Valeant Pharmaceuticals International Inc   plans to strike smaller deals to build on its acquisitions of Salix Pharmaceuticals Ltd and assets of Dendreon Corp  its chief executive said on Monday.",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 3-Valeant eyes smaller deals to build on Salix  Dendreon purchases "
    },
    {
        "content": "* Indexes off: Dow 0.27 pct  S&P 0.22 pct  Nasdaq 0.06 pct   (Updates to midday)",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St eases after Dow  S&P records as energy declines "
    },
    {
        "content": "TORONTO  Feb 20 Canada's main stock index ended little changed on Friday as a drop in bank shares ahead of their earnings season helped offset a gain in shares of Valeant Pharmaceuticals International Inc.",
        "date": "02202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX steady as bank shares offset Valeant gain "
    },
    {
        "content": "* Indexes off: Dow 0.24 pct  S&P 0.16 pct  Nasdaq 0.16 pct   (Adds data  updates prices)",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall Street slips off Dow  S&P records as oil price drops "
    },
    {
        "content": "TORONTO  Feb 23 Canada's main stock index slipped on Monday as shares of energy companies were pulled lower by weakness in oil prices  offsetting a surge in Valeant Pharmaceuticals International Inc after the drugmaker announced a major acquisition.",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX edges lower as energy  bank shares drag "
    },
    {
        "content": "TORONTO  Feb 20 Canada's main stock index ended little changed on Friday as a decline in the energy sector  following weakness in the price of oil  helped offset a gain in shares of Valeant Pharmaceuticals International Inc.",
        "date": "02202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX little changed as energy weakness offsets Valeant gain "
    },
    {
        "content": "NEW YORK Valeant Pharmaceuticals International Inc is close to a $10.2 billion deal to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd  according to a person directly familiar with the matter.",
        "date": "02202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant close to buying Salix - source "
    },
    {
        "content": "Feb 13 The following corporate finance-related stories were reported by media:",
        "date": "02132015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Market Chatter- Corporate finance press digest "
    },
    {
        "content": "* Indexes off: Dow 0.39 pct  S&P 0.25 pct  Nasdaq 0.05 pct   (Updates to market open)",
        "date": "02232015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "US STOCKS-Wall St dips after Dow  S&P touch records; energy drags "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc   has arranged financing for a potential bid for bowel-drug maker Salix Pharmaceuticals Ltd   Bloomberg reported  citing people familiar with the matter.",
        "date": "02122015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Valeant secures financing for potential Salix bid:  Bloomberg "
    },
    {
        "content": "NEW YORK  Feb 20 Valeant Pharmaceuticals International Inc is close to a $10.2 billion deal to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd   according to a person directly familiar with the matter.",
        "date": "02202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 2-Drugmaker Valeant close to buying Salix - source "
    },
    {
        "content": "TORONTO  Feb 20 Canada's main stock index slipped on Friday as grim domestic economic news and prospects for another interest rate cut weighed on financials  offsetting strength in gold stocks and a surge in drugmaker Valeant  as it closes in on a deal to buy Salix.",
        "date": "02202015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX lower as weak financials offset gold strength "
    },
    {
        "content": "* Adds Expedia  Valeant  Enel  Sumitomo Mitsui  Centrica  BT  Fininvest",
        "date": "02122015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Feb 12 Canada's Valeant Pharmaceuticals International Inc  has arranged financing for a potential takeover bid for  bowel-drug maker Salix Pharmaceuticals Ltd  Bloomberg reported  citing people familiar with the matter.",
        "date": "02122015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant secures financing for potential Salix bid - Bloomberg "
    },
    {
        "content": "Valeant Pharmaceuticals International Inc  will scoop up bankrupt cancer vaccine maker Dendreon Corp   after no additional qualified bids came forward by Tuesday's deadline  Valeant said.",
        "date": "02112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to buy bankrupt vaccine maker Dendreon "
    },
    {
        "content": "Feb 10 Valeant Pharmaceuticals International Inc  will scoop up bankrupt cancer vaccine maker Dendreon Corp  after no additional qualified bids came forward by Tuesday's deadline  Valeant said.",
        "date": "02102015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon "
    },
    {
        "content": "Feb 10 Valeant Pharmaceuticals International Inc  appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process  three sources close to the sale told Reuters.",
        "date": "02102015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant appears poised to buy bankrupt vaccine maker Dendreon -sources "
    },
    {
        "content": "Feb 10 Valeant Pharmaceuticals International Inc  will scoop up bankrupt cancer vaccine maker Dendreon Corp  after no additional qualified bids came forward by Tuesday's deadline  Valeant said.",
        "date": "02112015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "REFILE-UPDATE 2-Valeant to buy bankrupt vaccine maker Dendreon "
    },
    {
        "content": "Feb 3 The following bids  mergers  acquisitions and disposals were reported by 2100 GMT on Tuesday:",
        "date": "02032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "Deals of the day- Mergers and acquisitions "
    },
    {
        "content": "Feb 5 Valeant Pharmaceuticals International Inc   said on Thursday it has raised its bid for worldwide rights to a prostate cancer vaccine owned by bankrupt drugmaker Dendreon Corp.",
        "date": "02052015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Drugmaker Valeant raises bid for Dendreon cancer vaccine "
    },
    {
        "content": "Canadian drugmaker Valeant Pharmaceuticals International Inc  is in talks to buy Salix Pharmaceuticals Ltd   Bloomberg reported  citing people with knowledge of the matter.",
        "date": "02032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to buy Salix Pharma: Bloomberg "
    },
    {
        "content": "Feb 3 Canadian drugmaker Valeant Pharmaceuticals International Inc is in talks to buy Salix Pharmaceuticals Ltd  Bloomberg reported  citing people with knowledge of the matter.",
        "date": "02032015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant in talks to buy Salix Pharma - Bloomberg "
    },
    {
        "content": "Jan 29 Bankrupt drugmaker Dendreon Corp  has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine  Provenge  and certain assets for $296 million.",
        "date": "01302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant to buy Dendreon's prostate cancer vaccine Provenge "
    },
    {
        "content": "Jan 29 Valeant Pharmaceuticals International Inc  said it would buy the worldwide rights of Dendreon Corp's Provenge drug and certain other assets through a \"stalking horse\" deal for $296 million.",
        "date": "01302015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to buy worldwide rights to Dendreon's Provenge "
    },
    {
        "content": "TORONTO  Jan 8 Canada's main stock index rose 1.2 percent on Thursday as positive U.S. data reinforced the Federal Reserve's confidence in the economy and the energy sector climbed with the price of U.S. crude oil.",
        "date": "01082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "topStory",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX jumps on U.S. data  energy shares "
    },
    {
        "content": "TORONTO  Jan 8 Canada's main stock index strengthened on Thursday as solid U.S. economic data boosted sentiment and recent comments from the Federal Reserve signaled that the U.S. central bank was in no hurry to raise interest rates.",
        "date": "01082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "CANADA STOCKS-TSX advances on positive U.S. data  Fed signals "
    },
    {
        "content": "Jan 8 Valeant Pharmaceuticals International Inc  will focus its acquisition strategy on smaller  private companies in 2015  Chief Executive Michael Pearson said on Thursday.",
        "date": "01082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant to focus on smaller  private deals in 2015 -CEO "
    },
    {
        "content": "(Adds comments on acquisitions  CEO contract  Q4 outlook and share activity)",
        "date": "01082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "UPDATE 1-Valeant raises 2015 adjusted profit outlook more than expected "
    },
    {
        "content": "Jan 8 Valeant Pharmaceuticals International Inc  said on Thursday that it expected in 2015 to reap revenue of $9.2 billion to $9.3 billion and cash earnings of $10.10 to $10.40 per share  exceeding last year's results.",
        "date": "01082015",
        "name": "Valeant Pharmaceuticals International Inc",
        "news_type": "normal",
        "symbol": "VRX",
        "title": "Valeant raises 2015 adjusted profit outlook more than expected "
    }
]